



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Board Meeting

February 21, 2018

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Table of Contents

1 – A.	Table of Contents	002
1 – B.	Meeting Notice & Arrangements	004
1 – C.	Acronyms	005
1 – D.	Agenda	009
2.	Invocation & Pledge of Allegiance	
3.	Quorum Call	
4.	Call for Additional Agenda Items & Adoption of Agenda	
5.	Consideration of Minutes from Previous Meetings ~ November 15, 2017	011
6.	Report on Action Items	036
7.	Confirmation of Acts	
8.	Opportunity for Public Comment	
*	Statement of Purpose & Mission of Board	
9.	Special Orders of the Day	039
	A. Presentation of Pharmacists Gold Certificates	
10.	Committee Reports	
	A. Finance – Mr. Pitre	040
	• Review of Interim Report for Fiscal Year 2017-2018	041
	B. Application Review – Mr. Soileau	051
	• Consideration of Committee Recommendations Re Applications	
	C. Reciprocity – Ms. Hall	052
	• Consideration of Committee Recommendations Re Applications	
	D. Violations – Mr. Bond	053
	• Consideration of Proposed Voluntary Consent Agreements	054
	E. Impairment – Mr. Rabb	085
	• Consideration of Committee Recommendations re Applications	
	F. Reinstatement – Ms. Melancon	086
	• Consideration of Committee Recommendations re Applications	
	G. Tripartite	087
	H. Regulation Revision – Mr. McKay	088
	• Consideration of Legislative Proposal 2018-A ~ CDS Update (Draft #1)	089
	• Consideration of Legislative Proposal 2018-C ~ Foreign Pharmacy Schools (Draft #1)	091
	• Consideration of Legislative Proposal 2018-E ~ Partial Fills for Schedule II (Draft #1)	092
	• Consideration of Legislative Proposal 2018-F ~ PMP – Medicaid Audit Trail (Draft #3)	094
	• Consideration of Legislative Proposal 2018+H ~ PMP – Drugs of Concern (Draft #2)	096
	• Consideration of Legislative Proposal 2018-J ~ Pharmacist Licensing Law (Draft #1)	098
	• Consideration of Legislative Proposal 2018-K ~ PMP – Epidemiologist Access (Draft #3)	104
	• Consideration of Regulatory Proposal 2018-F ~ Pharmacy Benefit Managers (Draft #2)	106

(cont.)

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

10.	Committee Reports (<i>cont.</i>)	
	I. Executive Committee – Mr. Aron	109
	• Annual Review of Contracts & Agreements	110
	• Request for Approval of Pharmacy Technician Training Program (MedCerts)	111
11.	Staff Reports	
	J. Assistant Executive Director – Mr. Fontenot	125
	• Quarterly Report from Prescription Monitoring Program (PMP)	126
	• Consideration of Requests for Waivers from PMP Reporting Rule	143
	K. General Counsel – Mr. Finalet	163
	• Consideration of Proposed Voluntary Consent Agreements	164
	L. Executive Director – Mr. Broussard	178
	• Narrative Report	179
	• Internal Reports	
	➤ Census – Compliance Division	184
	➤ Census – Credentials Division	185
	➤ Credentials Div. – Licensure Activity Report	190
	➤ Credentials Div. – Application Activity Report	191
	➤ Credentials Div. – Exceptions Report	192
	• Examinations Report – MPJE	193
	• Examinations Report – NAPLEX	213
	• Initial Legislative Report	235
	• NABP Annual Meeting – Proposed Resolutions	237
12.	Announcements	243
13.	Recess	

Documents Added via Committee Deliberations

10.	Committee Reports	
	E. Impairment – Mr. Rabb	
	> Proposed Addition to Board’s Roster of Approved Addictionists	247
	I. Executive – Mr. Aron	
	> Resolution for Professional Legal Services – Celia R. Cangelosi	251
	> Resolution for Professional Legal Services – Shows Cali & Walsh	252
	> Proposed Revision to LPM.II.A ~ Authorized Drivers	253
	> Proposed Revision to LPM.II.B ~ Initial Authorization Process	255
	> Proposed Revision to LPM.II.C ~ Annual Re-Authorization Process	256
	> Proposed Revision to LPM.II.D ~ Supervisor’s Responsibility	257
	> Proposed Revision to LPM.II.E ~ Employee’s Responsibility	258
	> Proposed Revision to LPM.II.F ~ Accident Reporting	259
	> Proposed Revision to LPM.II.H ~ Safety Audits & Recordkeeping	261
	> Proposed Revision to PPM.II.E.6 ~ Corporate Travel Card	262
	> Proposed Revision to PPM.IV.B.6 ~ Application for New Pharmacy Permit	281
	> Proposed Revision to PPM.IV.B.7 ~ Application for New Nonresident Pharmacy Permit	284
11.	Staff Reports	
	L. Executive Director – Mr. Broussard	
	> Examinations Report – PTCB	288

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



MEMORANDUM

To: Board Members & Staff
From: Malcolm Broussard
Date: February 7, 2018
Re: Board Meeting Schedule & Arrangements

.....

The next quarterly meeting of the Board and certain of its committees will be held at the Board office on February 20-22, 2018. The schedule of events is as follows:

Tuesday, February 20, 2018

0900	Reinstatement Committee	<i>Boardroom</i>
1030	Impairment Committee	<i>Boardroom</i>
1200	Committee Luncheon	<i>Boardroom</i>
1530	Application Review Committee	<i>Boardroom</i>
1600	Executive Committee	<i>Boardroom</i>

Wednesday, February 21, 2018

0800	Reciprocity Committee	<i>Boardroom</i>
0900	Board Meeting	<i>Boardroom</i>

Thursday, February 22, 2018

0830	Administrative Hearing	<i>Boardroom</i>
1000	Special Board Meeting	<i>Boardroom</i>

You will receive your hotel reservations from Ms. Kelley Villeneuve via email within the next few days. If you have any questions about those arrangements, please contact her directly at kvilleneuve@pharmacy.la.gov or 225.925.6498.

Some of your meeting materials have been posted in the *Boardroom Library*. You may access the library by visiting our website at www.pharmacy.la.gov, selecting the *Login* link at the right-sided margin of the horizontal menu bar, and entering your log-in and password information. At the *Boardroom Library Lobby*, select the link for the *Main Reading Room*, and then the 02-21-2018 link for the board meeting. I anticipate completion of all the committee and board meeting materials by the Sunday before the meeting; we will advise you when all of the materials have been posted.

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals

DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners

LSBN	Louisiana State Board of Nursing
LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America

PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 9:00 a.m. on Wednesday, February 21, 2018 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-14-2018

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Minutes from Previous Meetings – November 15, 2017
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Special Orders of the Day
 - A. Presentation of Pharmacist Gold Certificates
PST.009331 – James Benedict Collins (issued 11-29-1967)
10. Committee Reports
 - A. Finance – Mr. Pitre
 - Review of Interim Report for Fiscal Year 2017-2018
 - B. Application Review – Mr. Soileau
 - Consideration of Committee Recommendations re Applications
 - C. Reciprocity – Ms. Hall
 - Consideration of Committee Recommendations re Applications
 - D. Violations – Mr. Bond
 - Consideration of Proposed Voluntary Consent Agreements
 - E. Impairment – Mr. Rabb
 - Consideration of Committee Recommendations re Applications
 - F. Reinstatement – Ms. Melancon
 - Consideration of Committee Recommendations re Applications
 - G. Tripartite – Mr. Moore
 - H. Regulation Revision – Mr. McKay
 - Consideration of Legislative Proposal 2018-A ~ CDS Update (Draft #1)
 - Consideration of Legislative Proposal 2018-C ~ Foreign Pharmacy Schools (Draft #1)
 - Consideration of Legislative Proposal 2018-E ~ Partial Fills for Schedule II (Draft #1)
 - Consideration of Legislative Proposal 2018-F ~ PMP – Medicaid Audit Trail (Draft #3)
 - Consideration of Legislative Proposal 2018-H ~ PMP – Drugs of Concern (Draft #2)
 - Consideration of Legislative Proposal 2018-J ~ Pharmacist Licensing Law (Draft #1)
 - Consideration of Legislative Proposal 2018-K ~ PMP – Epidemiologist Access (Draft #3)
 - Consideration of Regulatory Proposal 2018-F ~ Pharmacy Benefit Managers (Draft #2)
 - I. Executive – Mr. Aron
 - Consideration of Approval of Pharmacy Technician Training Program – MedCerts® [Livonia, MI]
 - Consideration of Committee Recommendations

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

11. Staff Reports
 - J. Assistant Executive Director – Mr. Fontenot
 - Quarterly Report from Prescription Monitoring Program (PMP)
 - Consideration of Requests for Waivers from PMP Reporting Requirement
 - K. General Counsel – Mr. Finalet
 - Consideration of Proposed Voluntary Consent Agreements
 - L. Executive Director – Mr. Broussard
12. Announcements
13. Recess



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Consideration of Minutes from Previous Meetings

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Meeting

&

Administrative Hearing

Wednesday, November 15, 2017 at 9:00 a.m.

Thursday, November 16, 2017 at 8:30 a.m.

Location:

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Table of Contents

Wednesday, November 15, 2017 – Board Meeting

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	04
2.	Invocation & Pledge of Allegiance	04
3.	Quorum Call	04
4.	Call for Additional Agenda Items & Adoption of Agenda	06
5.	Consideration of Minutes from Previous Meetings	06
6.	Report on Action Items	06
7.	Confirmation of Acts	06
8.	Opportunity for Public Comment	06
*	Statement of Purpose	07
9.	Special Orders of the Day	07
10.	Committee Reports	
	A. Finance	07
	B. Application Review	08
	C. Reciprocity	08
	D. Violations	09
	E. Impairment	10
	F. Reinstatement	11
	G. Tripartite	12
	H. Regulation Revision	12
	I. Executive	12
11.	Staff Reports	
	J. Assistant Executive Director	16
	K. General Counsel	18
	L. Executive Director	19
12.	Review of La. Attorney General Opinion No. 17-0076	15
13.	Discussion of Letter to La. Attorney General & La. Dept. of Insurance re Pharmacy Benefit Managers	15
14.	Request for Waiver of Licensure Renewal Fee For Military Spouse	20
15.	Petition for Additional Testing Opportunity by Applicant for Pharmacist Licensure	20
	<i>Items Added to the Agenda</i>	
15-A.	<i>Electronic Transmission of Chart Orders to Pharmacies</i>	21
15-B.	<i>Request for PMP Reporting Waiver for Chateau Drugs</i>	17
16.	Announcements	21
17.	Recess	21

Table of Contents

Thursday, November 16, 2017 – Administrative Hearing

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
A.	Call to Order	21
B.	Invocation & Pledge of Allegiance	21
C.	Quorum Call	22
D.	Call for Additional Agenda Items & Adoption of Agenda	22
E.	Opportunity for Public Comment	22
*	Appearances	22
F.	Formal Hearings	22
G.	Adjourn	24

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, November 15, 2017 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 9:10 a.m.

2. Invocation & Pledge

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Ms. Jacqueline Hall then led the group in the Pledge of Allegiance.

3. Quorum Call

Mr. Aron called upon the Secretary, Mr. Bond, to call the roll to establish a quorum.

Members Present:

Mr. Carl W. Aron
Mr. Brian A. Bond
Mr. Allen W. Cassidy, Jr.
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina, Jr.
Mr. Richard Mannino
Mr. Marty R. McKay
Ms. Chris B. Melancon
Ms. Diane G. Milano
Mr. Blake P. Pitre
Mr. T. Morris Rabb
Mr. Don L. Resweber
Mr. Douglas E. Robichaux
Mr. Richard A. Soileau
Dr. Raymond J. Strong
Mr. Rhonny K. Valentine

Members Absent:

Mr. Ronald E. Moore

Staff Present:

Mr. Malcolm J. Broussard, Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. M. Joseph Fontenot, Assistant Executive Director

Guests:

Mr. Robert Rock – Haydel's Drug Store
Mr. Carl Savoie – Carl's Thrifty Way Pharmacy
Mr. Minh Nguyen – Willow Bark Pharmacy
Mr. Ken Savoie – Ken's Thrifty Way Pharmacy
Mr. Chris Dupre – Ralph's Pharmacy

Mr. David Bares – Farmer’s Drugs
Mr. Bruce Soileau – New Perrino Drug Store
Mr. David Darce – Thrifty Way Pharmacy of St. Martinville
Mr. Errol Duplantis – Lloyd’s Remedies
Ms. Nikki Hollier – Hollier’s Family Pharmacy
Mr. Robert Hollier – Hollier’s Family Pharmacy
Mr. Michael Simmons – Lloyd’s Remedies
Mr. Greg Poret – Poret’s Thrifty Way Pharmacy
Ms. Kimberly Wixson – Cottonport Corner Drug
Mr. Peter Wolfe – Wolfe’s Pharmacy
Mr. J. Scott Black – GPS Pharmacy
Mr. Mark Mula – Mula Family Pharmacy
Mr. Don Couvillon – La. Wholesale Drug Co.
Mr. Robert Launey – Launey’s Thrifty Way Pharmacy
Mr. Ben J. Sims – Brookshire Grocery Co.
Mr. Neil Ducote – Brookshire Grocery Co.
Mr. T. J. Woodard – Prescriptions to Geaux
Ms. Jennifer O’Grady – Veterinary Pharmacies of America
Mr. Steve Rome – Veterinary Pharmacies of America
Mr. Brendan Buras – La. Legislative Auditor’s office
Mr. Randal Johnson – La. Independent Pharmacies Association
Mr. Russell Caffery – La. Independent Pharmacies Association
Mr. David Osborn – Schilling Pharmacy
Ms. Deborah Duvic – The Picard Group
Mr. Perry Catching – Wal-Mart Stores
Ms. Angelle Huff – The Wellness Corner
Ms. Nhung Nguyen – The Wellness Corner
Mr. Max Huff – The Wellness Corner
Mr. Leo LeBlanc – The Wellness Corner
Ms. Linda Spradley – Spradley & Spradley
Mr. Robert Lancon – Adams & Reese
Mr. Derrell Cohoon – Capitol Partners
Dr. Glenn Anderson – ULM College of Pharmacy
Mr. Aurdie Bellard – Bellard’s Pharmacy
Mr. Don Caffery – La. Independent Pharmacies Association
Rep. Bernard LeBas
Mr. Rock LeBas – Glenn’s Pharmacy
Ms. Lyndsey McDonald – National Healthcareer Association
Mr. Michael Tinnerello, Jr. – Channell Drugs
Ms. Connie Tinnerello – Channell Drugs
Mr. Jerrett Richter – Jerrett Richter, CPA
Ms. M. J. Terrebonne – M. J. Terrebonne, LLC

Mr. Bond certified 16 of the 17 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items & Adoption of Agenda

Mr. Aron asked if there were any additional agenda items. Mr. Robichaux moved to add a discussion of the regulation of electronic transmission of chart orders to pharmacies serving long-term care facilities. With no public comment or objections from the members, Mr. Aron indicated he would add that item following the final discussion item on the agenda just prior to the announcements. Ms. Milano moved to add a request for an exemption to the requirement for reporting to the PMP for Chateau Drugs / Lake Pines Hospital. With no public comment or objections from the members, Mr. Aron indicated he would add that item following the just previously added discussion. With no further requests for amendment, and with no objection, the Board adopted the posted agenda dated November 13, 2017 as amended. Mr. Aron then requested authority from the members to reorder the agenda as necessary for the purpose of accommodating certain guests and/or reports. There were no objections to that request.

5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting and the Administrative Hearing on August 23, 2017 held in Baton Rouge, Louisiana. With no objections, he waived the reading of the draft minutes. With no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

6. Report on Action Items

Mr. Aron called on Mr. Broussard for the report. Mr. Broussard directed the members to a copy of the report in their meeting binder. There were no questions from the members.

7. Confirmation of Acts

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Mr. Rabb moved,

Resolved, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since August 23, 2017 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative.

8. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and one guest requested the opportunity to ask a question.

Mr. Errol Duplantis recalled Mr. Aron's announcement at the Board's previous meeting of his intent to appoint a stakeholder committee to work with the Board's Regulation Revision Committee relative to the requirements of the impending USP

Chapter <800> Hazardous Drugs. He wanted to know whether that committee had been appointed. Mr. Aron replied with information that USP had recently announced a significant delay in the implementation of that chapter of federal standards (more than one year); therefore, the Regulation Revision Committee had downgraded the priority of that topic. Mr. Aron replied the stakeholder committee had not yet been appointed.

* *Statement of Purpose*

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

9. *Special Orders of the Day*

A. *Presentation of Pharmacist Gold Certificate*

Mr. Aron announced the pharmacist identified on the agenda to receive his Gold Certificate had just notified the Board office of his inability to attend the meeting that day. Before moving to the scheduled election of officers, he informed the members the recently-appointed dean of pharmacy school in Monroe was in attendance and had requested an opportunity to give the members some information about the pharmacy school. Mr. Aron introduced Dr. Glenn Anderson, Dean of the ULM College of Pharmacy. Dr. Anderson shared an update on some recent faculty appointments as well as the school's response to the recent probation decision from the ACPE.

B. *Annual Election of Board Officers*

Mr. Aron conducted the annual election of officers. Mr. Valentine moved, **Resolved**, to nominate and re-elect by acclamation all of the current officers in their same positions for Calendar Year 2018. The motion was adopted after a unanimous vote in the affirmative. Mr. Aron expressed his appreciation to the members and congratulated the other members of the committee on their re-election:

Mr. Morris Rabb, from Monroe, as First Vice President;
Mr. Marty McKay, from Woodworth, as Second Vice President;
Ms. Chris Melancon, from Carencro, as Third Vice President; and
Mr. Brian Bond, from Jena, as Secretary.

10. *Committee Reports*

A. *Finance Committee*

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre reported the committee had met the previous day to review two documents prepared by the staff. He directed the members to the interim report for the current fiscal year in their meeting binder, reviewed the highlights, and answered questions from the members. He indicated the report was presented for information only and required no action by the Board. He then directed the members to the *Proposed Budget for Fiscal Year 2018-2019*. He reported the committee members had reviewed the proposal and voted to recommend the adoption of the proposed budget as presented. He then moved,

Resolved, to approve and adopt the Proposed Budget for Fiscal Year 2018-2019.

The motion was adopted after a unanimous vote in the affirmative.

Finally, he expressed his appreciation to the other committee members for their efforts the previous day.

B. Application Review Committee

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee had met the previous day to consider two referrals from the staff – two applicants for a pharmacy technician candidate registration. Following their interviews and deliberations, the committee voted to recommend the denial of both applications. Mr. Soileau informed the members they would consider one of those cases at their subsequent meeting in February 2018. He then presented the following files to the members for their consideration.

Markesha LaShun Bailey – Applicant for PTC Registration: Mr. Soileau informed the members the committee had considered this applicant during their August 2017 meeting and had voted to recommend the denial of her application. Ms. Bailey has recently confirmed her intent not to dispute the recommendation. Mr. Soileau then moved,

Resolved, to deny the application for pharmacy technician candidate registration and refuse to issue the credential.

The motion was adopted after a unanimous vote in the affirmative.

Yashcia Sherell Hamilton – Applicant for PTC Registration: Mr. Soileau reported the committee interviewed the applicant to discuss her criminal history. He then moved,

Resolved, to approve the application for pharmacy technician candidate registration, to immediately suspend the registration for eighteen months and stay the execution of the suspension, then place the registration on probation for eighteen months, effective November 16, 2017, subject to certain terms enumerated in the consent agreement.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Soileau expressed his appreciation to the other members of the committee for their work the previous day.

C. Reciprocity Committee

Mr. Aron called upon Ms. Hall for the committee report. She reported the staff had evaluated 40 applications for pharmacist licensure by reciprocity since the last Board meeting and that none of them contained information that warranted a committee level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials.

Finally, she closed the report with appreciation to the other committee

members for their ongoing efforts.

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held preliminary hearings on September 6, 2017 to consider their posted agenda which included 16 cases: 5 pharmacists, 4 pharmacy technicians, 6 pharmacy permits, and one applicant for a pharmacy permit. Prior to the meeting, the committee authorized continuances for 3 of the respondents. After interviews and deliberations, the committee took no action on 6 of the respondents. The committee referred one respondent to the Board's Impairment Committee, and also deferred further consideration for one respondent upon his execution of a private no-practice agreement. The committee offered proposed voluntary consent agreements to the remaining 5 respondents, all of whom have accepted their proposed consent agreements. Mr. Bond then presented the following proposals to the members for their consideration.

Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 04998 [Shreveport, LA] (PHY.004176): Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board ordered the pharmacy to perform an inventory reconciliation audit for all controlled substances for a one year period of time beginning June 9, 2016 (performance of which was acknowledged in the agreement); and further, the Board assessed a fine of \$5,000 plus administrative and investigative costs.

Gregory Tyrome Sweet (PST.019579): Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board ordered the pharmacist to acquire 6 hours of ACPE-accredited pharmacist-specific continuing education relative to the proper dispensing of controlled substance prescriptions; and further, the Board issued a Letter of Reprimand and directed its publication in the Board's quarterly newsletter; and further, assessed administrative costs.

Laura Kaye Brantley (CPT.004700): Mr. Bond moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the certificate for an indefinite period of time, effective June 16, 2017.

Louisiana Medical Center & Heart Hospital, LLC d/b/a Louisiana Medical Center & Heart Hospital [Lacombe, LA] (PHY.006464): Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the permit, and further, assessed administrative and investigative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 17562 [Kenner,

LAJ (PHY.007268): Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$10,000 plus administrative and investigative costs.

Mr. Bond reported the committee was scheduled to meet on December 6-7 to consider that docket, which included 11 pharmacists, 5 pharmacy technicians, 8 pharmacy permits, and one applicant for a pharmacy permit.

Finally, Mr. Bond concluded his report with appreciation to the other committee members for their ongoing efforts.

E. Impairment Committee

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to consider 13 referrals from the staff – 2 applications for reinstatement of pharmacist licenses, 2 applications for probation modification from pharmacists, one application for a pharmacist license, 6 appearances for informal conference (three pharmacists and three technicians), and 2 appearances for guidance (both pharmacists). They also considered professional credentials and letters of interest from three addiction medicine specialists for approval and placement on the Board's Roster of Approved Addictionists. Following their interviews of the applicants and subsequent deliberations, the committee took no action on three technicians and one pharmacist, authorized the issuance of the new pharmacist license without restriction, removed restrictions from one pharmacist license, issued a non-disciplinary Letter of Noncompliance to one pharmacist, and deferred further consideration of the pending matter against one pharmacist. Mr. Rabb then presented the following files to the members for their consideration.

Danny Roy Myers (PST.018776) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously relinquished license, suspended it for nine years plus two days and stayed the execution of the suspension, then placed the license on probation for nine years plus two days, effective November 15, 2017, subject to certain terms enumerated in the consent agreement; the Board noted the probationary period was to run concurrently with the probationary period ordered by the Mississippi Board of Pharmacy on his Mississippi pharmacist license.

Charles Paul Guidry (PST.020067) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and stayed the execution of the suspension, then placed the license on probation for five years, effective November 15, 2017, subject to certain

terms enumerated in the consent agreement.

Kevin Trenouth Kellow (PST.019095) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board denied his request for modification of previous orders.

Kerry Michael Finney (PST.013535) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board removed Article 2-e from his March 2013 probationary board order, which had restricted him from accepting an appointment as the pharmacist-in-charge of a pharmacy; however, all other probationary terms remain effective.

Amanda Shubert Balli (PST.019454) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for five years and stayed the execution of the suspension, then placed the license on probation for five years, effective November 15, 2017, subject to certain terms enumerated in the consent agreement.

Mr. Rabb reported the committee had received letters of interest from two addiction medicine specialists seeking enrollment on the Board's Roster of Approved Addictionists. Following the committee's review of their professional credentials, the committee voted to recommend the addition of both physicians to the Board's roster. Mr. Rabb then moved,

Resolved, to approve the November 15, 2017 edition of the Board's Roster of Approved Addictionists for the remainder of Fiscal Year 2017-2018.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day and for the ongoing staff support.

F. Reinstatement Committee

Mr. Aron called upon Ms. Melancon for the committee report. Ms. Melancon reported the committee met the previous day to consider one referral from the staff, a petition from a pharmacist to return her voluntary inactive license to active status. Ms. Melancon then presented the following file to the members for their consideration.

Sumitra B. Patel (PST.010943) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board denied respondent's request for the return of her voluntary inactive license to active status, and further, conditioned the future acceptance of any similar application upon the satisfaction of certain requirements identified in the consent agreement.

Ms. Melancon closed her report with appreciation to the other committee members for their work the previous day.

G. Tripartite Committee

Mr. Aron noted Mr. Moore's absence as well as the absence of a committee meeting since the previous Board meeting.

H. Regulation Revision Committee

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reported the committee met on September 28. He reported the committee had 12 topics previously assigned and received 5 new topics that day. The committee discussed six of those topics and voted to recommend the approval of a legislative proposal relative to CDS licenses for third-party logistics (3PL) providers. He then moved,

Resolved, to approve Legislative Proposal 2018-B ~ Controlled Dangerous Substance License for Third-Party Logistics Provider, and further, to authorize the filing of same upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the legislative process.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. McKay announced the next committee meeting was scheduled for December 6, 2017. He then expressed his appreciation to the other committee members for their ongoing efforts and for the staff support.

I. Executive Committee

Mr. Aron reported the committee had met the previous day to consider the items on their posted agenda. The committee reviewed several documents prepared by staff, including some policies and procedures, a management letter for the pending annual financial audit, proposed pharmacy inspection blueprints, a request to change the Board's contracted CPA firm, an additional pharmacy technician examination provider, and other requests. He indicated Mr. Rabb was prepared to offer motions on behalf of the committee.

- The committee reviewed two new policy and procedure documents for the Board's Credentials Division, relating to the processing of applications for new pharmacy permits, both in-state as well as non-resident applicants. The proposed revisions were intended to reduce the amount of information required to be submitted by persons owning small percentages of companies applying for pharmacy permits, as well as to remove the requirement for criminal background checks for those persons. Mr. Rabb then moved,

Resolved, to approve *Board Policy PPM.IV.B.06 ~ Application for New Louisiana Pharmacy Permit*.

The motion was adopted after a majority vote in the affirmative; Mr. Mannino objected. Mr. Rabb then moved,

Resolved, to approve *Board Policy PPM.IV.B.07 ~ Application for New Nonresident Pharmacy Permit.*

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed proposed revisions of several staff-related policies and procedures, made necessary by changes made by several state agencies. Mr. Rabb then moved,

Resolved, to rescind *Board Policy PPM.II.A.6 ~ Special Entrance Rates for Salaries.*

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to approve *Board Policy PPM.II.A.7 ~ Extraordinary Qualifications / Credentials.*

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to approve the proposed revision of *Board Policy LPM.I.P ~ Worker's Compensation Post-Accident Drug Testing.*

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to approve the proposed revision of *Board Policy PPM.II.E.1 ~ Purchases.*

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to approve the proposed revision of *Board Policy PPM.II.E.2 ~ Invoices & Receipts.*

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed a request from the Accreditation Council for Pharmacy Education (ACPE) to recognize its Joint Accreditation program for interprofessional continuing education and to approve programs accredited by Joint Accreditation for licensure renewal purposes. Mr. Rabb then moved,

Resolved, to recognize Joint Accreditation program for interprofessional continuing education, to approve programs accredited by Joint Accreditation for licensure purposes, and to request the Regulation Revision Committee to consider whether the Board's rules for continuing education should be amended.

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed the pharmacy inspection blueprint documents prepared by the staff, reflecting the NABP Pharmacy Inspection Blueprint program documents. Mr. Rabb moved,

Resolved, to approve the Pharmacy Inspection Blueprints, more specifically – *Module I re Basic Pharmacy Services*, *Module II re Compounding of Nonsterile Preparations*, and *Module III re Compounding of Sterile Preparations*.

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed a communication from the current firm contracted with the Board to provide professional accounting services indicating a pending split in the firm, as well as the intent from the current

CPA to establish a separate firm. Mr. Rabb then moved,

Resolved, to authorize the executive director to prepare, sign, and deliver formal notice of its intent to terminate the existing contract with *Kolder, Champagne, Slaven & Co., LLC* effective December 18, 2017.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to authorize the executive director to prepare and sign a contract for professional accounting services with *Russell F. Champagne, CPA, A Professional Corporation*, effective December 18, 2017, and further, to secure the state's approval of that contract.

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed recent information concerning an evaluation of the *Examination for Certification of Pharmacy Technicians (ExCPT)* administered by the National Healthcareer Association (NHA). The evaluation included an analysis of the psychometric validity of the test as well as a comparison of that examination's blueprint with the blueprint of the other technician examination approved by the Board, the *Pharmacy Technician Certification Examination (PTCE)* administered by the Pharmacy Technician Certification Board (PTCB). Mr. Rabb then moved, **Resolved**, to approve the *Examination for Certification of Pharmacy Technicians (ExCPT)* administered by the National Healthcareer Association (NHA) effective January 1, 2018, for the remainder of Fiscal Year 2017-2018.

The motion was adopted after a unanimous vote in the affirmative.

- The committee reviewed a request from the Pharmacist-in-Charge at Elayn Hunt Correctional Center, requesting the Board's assistance in facilitating the use of automated medication systems (AMS) at correctional facilities owned and operated by the La. Dept. of Corrections. The committee voted to recommend the authorization of a pilot program while the Regulation Revision Committee considers the appropriate revisions to the rules for AMS devices. Mr. Rabb then moved, **Resolved**, to approve the request from the Dept. of Corrections to implement a pilot program for the placement and operation of automated medication systems at correctional facilities owned and operated by the department, and further, the pilot program shall terminate no later than December 31, 2018 unless extended further by the Board, and further, to request the Regulation Revision Committee to develop a regulatory proposal authorizing the operation of automated medication systems at correctional facilities owned and operated by the Dept. of Corrections.

The motion was adopted after a majority vote in the affirmative; Mr. Soileau objected.

- The committee reviewed a request from several members to approve the presentations at the MALTAGON Conference for live continuing education credit. Mr. Rabb then moved,

Resolved, to approve up to ten hours of live continuing education earned by participants at the recent MALTAGON conference held in Charleston, SC on October 22-25-, 2017.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Aron closed his report with appreciation for the other committee members and their work the previous day.

At this point, Mr. Aron declared a luncheon recess. It was noted the members recessed at 11:45 a.m. and then reconvened at 12:45 p.m. Mr. Aron then re-ordered the sequence of the agenda, moving to Agenda Item 12.

12. Review of La. Attorney General Opinion 17-0076

Mr. Aron recognized Mr. Randal Johnson with the La. Independent Pharmacies Association (LIPA), who requested the Board's review. He requested the Board determine a pathway to regulate those activities of pharmacy benefit managers (PBMs) which fall within the practice of pharmacy. Following a brief discussion of the potential impact of the North Carolina Dental Board case [*North Carolina State Board of Dental Examiners v. Federal Trade Commission*, 135 S. Ct. 1101 (2015)], Mr. Pitre moved,

Resolved, to request the Regulation Revision Committee to review, study and develop a rule for the licensure and regulation of pharmacy benefit managers.

Following additional discussion on how the Board should approach the desired objective of the motion, Mr. Pitre called the question. That motion failed following a majority roll call vote in the negative; Mr. Pitre and Ms. Milano voted in the affirmative. Following additional discussion by members and guests, Mr. Aron called the question. The motion was adopted after a unanimous vote in the affirmative. Mr. Aron directed the topic be referred to the Regulation Revision Committee and noted the committee's next meeting had already been scheduled for December 6, 2017. He reminded the guests the committee meeting was open to the public. He reminded Mr. Johnson of the members' (LIPA members present and board members) request for LIPA to present at the December 6 meeting their specific examples of PBM activities which should be regulated by the Board.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 2:30 p.m. and then reconvened at 3:00 p.m. Mr. Aron called for Agenda Item 13.

13. Discussion of Letter of La. Attorney General & La. Dept. of Insurance re Pharmacy Benefit Managers

Mr. Aron recognized Mr. Mannino, who requested the agenda item. Mr. Mannino directed the members to a suggested letter he wanted to send to the state attorney general and to the state commissioner of insurance. The letter questioned whether the attorney general or commissioner of insurance was responsible for enforcement of La. R.S. 22:1060.6, and if not, which agency was responsible for enforcement of that law. In addition, the letter questioned what protections the agency was prepared to provide pharmacists who would submit written evidence of violations of that law in the event such pharmacists had reasonable expectations of retribution from pharmacy benefit

managers. Following a short discussion, Mr. Mannino moved,

Resolved, to direct staff to send the requested letter to the state attorney general and the state commissioner of insurance.

The motion was adopted after a majority vote in the affirmative; Mr. Cassidy objected.

At this point, Mr. Aron reordered the sequence of the agenda, returning to the posted agenda and moving to the staff reports in Agenda Item 11.

11. Staff Reports

J. Report of Assistant Executive Director

Mr. Aron noted Mr. Fontenot's absence and called upon Mr. Broussard for the report. Mr. Broussard explained the reason for Mr. Fontenot's absence. He informed the members Mr. Fontenot had recently been appointed to a three-year term on ACPE's CPE Commission. That organization meets twice per year and he was attending a commission meeting at that time. Mr. Broussard also informed the members Mr. Fontenot had recently been elected Vice President of the National Association of State Controlled Substance Authorities (NASCSA) and that he was on a leadership track for that organization. Mr. Aron noted those accomplishments recognized not only Mr. Fontenot personally and also the Louisiana Board.

Mr. Broussard reviewed the quarterly report of the prescription monitoring program, detailing the prescription transaction counts as well as queries from prescribers, dispensers, and law enforcement agencies. There were no questions from the members. He then directed the members to the requests from pharmacies seeking a waiver from the duty to report zero prescription transaction reports to the prescription monitoring program. Mr. Cassidy then moved,

Resolved, to authorize the issuance of full PMP reporting waivers to:

- > PHY.006870-NR – allMedRx Specialty Pharmacy (FL);
- > PHY.007526-HOS – Avoyelles Hospital Pharmacy (LA);
- > PHY.007534-IN – BAART Program, Breaux Bridge (LA);
- > PHY.006102-CH – Beauregard Agape Clinic (LA);
- > PHY.007528-NR – Cardinal Health Pharmacy Services (NC);
- > PHY.004741-NR – Caremark (AZ);
- > PHY.006592-NR – CHD Pharmacy (OH);
- > PHY.005460-HOS – Christus Coushatta Healthcare Center Pharmacy (LA);
- > PHY.005667-CH – CMAP Express Pharmacy (LA);
- > PHY.005556-CH – Community Health Worx (LA);
- > PHY.005242-NR – CVS Caremark (FL);
- > PHY.005448-NR – Dohmen Life Science Services (MO);
- > PHY.007060-NR – ESI Mail Order Processing (OH);
- > PHY.004459-NR – Express Scripts (NM);
- > PHY.004570-NR – Express Scripts (NY);
- > PHY.006987-NR – Express Scripts (OH);
- > PHY.006990-NR – Express Scripts (FL);

- > PHY.007052-NR – Express Scripts (MO);
 - > PHY.007053-NR – Express Scripts (MO);
 - > PHY.007058-NR – Express Scripts (AZ);
 - > PHY.006986-NR – Express Scripts (OH);
 - > PHY.006991-NR – Express Scripts (PA);
 - > PHY.007529-NR – Factor One Source Pharmacy (MD);
 - > PHY.007442-IR – FAST Access Specialty Therapeutics (LA);
 - > PHY.007523-NR – Fertility Pharmacy of America (TN);
 - > PHY.007010-NR – Gentry Health Services (OH);
 - > PHY.005542-HOS – Greenbrier Hospital Pharmacy (LA);
 - > PHY.007299-NR – ImprimisRx TX (TX);
 - > PHY.007218-NR – Lumicer Health Services (WI);
 - > PHY.007512-NR – Marley Drug (NC);
 - > PHY.007505-NR – Matlock Specialty Pharmacy (TX);
 - > PHY.004745-NR – Med 4 Home Pharmacy (MO);
 - > PHY.005919-HOS – Northern Louisiana Medical Center (LA);
 - > PHY.007527-HOS – Oakdale Community Hospital (LA);
 - > PHY.006094-HOS – Ochsner Medical Center – West Bank (LA);
 - > PHY.007111-NR – OptiMed Specialty Pharmacy (MI);
 - > PHY.004466-NR – PharMerica (IN);
 - > PHY.007508-NR – Prime Therapeutics (TX);
 - > PHY.005956-NR – Ridgeway Pharmacy (MT);
 - > PHY.002651-HOS – River Oaks Hospital (LA);
 - > PHY.005478-NR – Rx.com Community Pharmacy (TX);
 - > PHY.006738-NR – SimfaRose Pharmacy (FL);
 - > PHY.001021-HOS – Slidell Memorial Hosp Pharmacy (LA);
 - > PHY.007483-NR – Starcare Pharmacy (TX);
 - > PHY.001103-HOS – Thibodaux Reg Med Ctr Pharmacy (LA);
 - > PHY.007520-NR – U.S. PharmaMed (NC);
 - > PHY.006792-HOS – University Hospital & Clinics (LA);
 - > PHY.007506-IR – Vital Rx of Louisiana (LA);
 - > PHY.007521-NR – Walgreens Pharmacy #1109-2 (AL);
 - > PHY.001196-HOS – West Calcasieu Cameron Hospital Pharmacy (LA);
 - > PHY.007525-HOS – Winn Parish Medical Center Pharmacy (LA);
- and
- > PHY.006583-HOS – Woman’s Hospital Pharmacy (LA),
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative. Mr. Broussard indicated the completion of that report.

Mr. Aron noted the item added to the agenda relative to Chateau Drugs was similar to the report just concluded, so he adjusted the agenda sequence to Agenda Item 15-B.

Item Added to Agenda

15-B. Waiver from PMP Reporting for Chateau Drugs / Lake Pines Hospital

Mr. Aron recognized Ms. Milano, who requested the agenda item. Ms. Milano reported she had submitted a request for a waiver on behalf of Chateau Drugs and noted her pharmacy was not on the list of pharmacies just approved for the waiver. Mr. Finalet noted her request was in the list of communications from the pharmacies, but it was a request for a partial exemption, not a full exemption. He noted it would have been inappropriate to place her pharmacy in the list just approved, but a separate motion should have been prepared. Mr. Broussard noted the staff recommendation for the approval of that partial exemption request contingent upon execution of the standard consent agreement for that purpose. Ms. Milano then moved,

Resolved, to grant a partial exemption to the reporting of eligible transactions originating from Lake Pines Hospital by Chateau Drugs, contingent upon the execution of the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Aron then returned the agenda sequence to the staff reports.

11. *Staff Reports*

K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet then presented the following files to the members for their consideration.

Christina Marshall Buhrman (PST.017495) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for one month plus thirteen days and stayed the execution of the suspension, then placed the license on probation for one month plus thirteen days, effective November 15, 2017, subject to certain terms enumerated in the consent agreement, noting the probationary period was to run concurrently with the probationary period ordered by the Maryland Board of Pharmacy on her Maryland pharmacist license, and further, assessed administrative costs.

Marley Drug, Inc. d/b/a Marley Drug [Winston-Salem, NC] (PHY.007512) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed a fine of \$15,000 plus administrative costs.

McKesson Corporation d/b/a McKesson [Washington Court House, OH] (CDS.023883-DIS) Ms. Hall moved to approve the proposed voluntary consent agreement. The motion was approved after a unanimous vote in the affirmative. The Board ordered the suspension of the license from January 18, 2019 to January 18, 2021, noting the suspension was to run concurrently with the period of suspension of their federal registration ordered by the U. S. Drug Enforcement Administration, and further, assessed administrative costs.

McKesson Corporation d/b/a McKesson [Livonia, MI] (CDS.031429-DIS)

Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license from June 29, 2017 to January 17, 2019, noting the suspension was to run concurrently with the period of suspension of their federal registration ordered by the U.S. Drug Enforcement Administration, and further, assessed administrative costs.

Hailey Chyene Pate (PTC.025001) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the registration for an indefinite period of time, effective August 28, 2017.

Gina Maria Picone (PST.016021) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the license for an indefinite period of time, effective October 26, 2017.

Finally, Mr. Finalet indicated the completion of his report.

L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
 - Internal Reports
 - Census Reports – Credentials & Compliance Divisions
 - Production Reports – Credentials Division
 - Exceptions Report
 - External Reports
 - Administrative and Legislative Agency Reports
- Examinations
 - MPJE
 - NAPLEX
 - PARE
 - PTCB
- Operations
 - Credentials Division
 - Compliance Division
 - Administrative Division
- State Activities
 - La. Dept. of Health – Bureau of Health Services Financing
 - La. State Board of Dentistry
 - La. State Board of Medical Examiners

- Regional & National Activities
 - National Association of Boards of Pharmacy (NABP)
 - NABP-AACP District 6
 - MALTAGON
 - U.S. Congress
 - U.S. Dept. of Labor
 - Federal Trade Commission
- International Activities
 - International Pharmaceutical Federation (FIP)
 - .Pharmacy Verified Websites Program

Mr. Aron asked Mr. Broussard to review the schedule for the Application Review Committee's consideration of the applicants for the marijuana pharmacy permits. The committee members determined their meeting dates for the last two weeks in January 2018. Mr. Aron indicated he would defer until a later date the determination of the meeting dates for the subsequent special meeting of the full Board to consider the committee recommendations.

Finally, Mr. Broussard indicated the completion of his report.

14. *Request for Waiver of Licensure Renewal Fee for Military Spouse*

Mr. Aron requested Mr. Broussard review the request from Lt. Col. Charlton J. Meginley. Mr. Broussard directed the members to the information in their meeting packet. Mr. Broussard reminded the members the current pharmacy law allowed the Board to grant waivers to renewal requirements to active duty military pharmacists and technicians, but the law did not address spouses of active duty military pharmacists and technicians. Mr. Broussard presented a draft of potential legislation that could be filed in the event the members were supportive of the request. After a brief discussion, Mr. McKay moved,

Resolved, to approve *Legislative Proposal 2018-D ~ Renewal Fee for Military Spouse (Draft #1)*, and further, to authorize the filing of same in the Regular Session of the 2018 Legislature upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the legislative process.

The motion was adopted after a unanimous vote in the affirmative.

15. *Petition for Additional Testing Opportunity by Applicant for Pharmacist Licensure*

Mr. Aron requested Mr. Broussard review the petition. Mr. Broussard directed the members to the information in their meeting packet, which included an excerpt from the *NABP 2017 Candidate Registration Bulletin*, a publication intended for candidates of the NAPLEX and MPJE tests. He directed the members to the provisions of the Retake Policy described on pages 35-36 of the bulletin. NABP limits the total number of attempts of the NAPLEX test to five. With respect to the MPJE, NABP limits the number of attempts to five for a given state; e.g., five attempts of the MPJE for one state and five attempts for another state. Mr. Broussard reminded the members NABP had adopted this policy in 2013. He informed the members an applicant for pharmacist

licensure had passed the NAPLEX on his fourth attempt but had failed the MPJE for Louisiana five times. Given the confidential nature of examination scores, he declined to name the pharmacist, but he related the pharmacist had submitted a request for an additional testing opportunity. Mr. Broussard indicated this was the first case of a Louisiana applicant failing all five attempts since the 2013 policy was implemented. He requested guidance from the Board as to whether the Board supported the limit or whether they wanted to grant an exception. Several members suggested that five attempts of a licensure examination was a generous limit and they did not believe an exception was appropriate. No motion for an exception was offered. Mr. Aron directed staff to inform the applicant the Board supported the NABP examination retake policy and declined to authorize an exception.

Item Added to Agenda

15-A. Transmission of Electronic Chart Orders to Pharmacies

Mr. Aron recognized Mr. Robichaux, who requested the agenda item. Mr. Robichaux requested the Board review its rules on pharmacy recordkeeping with respect to electronic transmission of chart orders to pharmacies serving long term care patients. Pharmacies serving long term care patients are seeking guidance whether commercially-available information system applications used in long term care facilities are compliant with the Board's rules.

Mr. Aron referred the topic to the Regulation Revision Committee for their consideration of the issue and development of a regulatory proposal for the Board's consideration.

16. Announcements

Mr. Aron directed the members to the announcements in their meeting binder.

17. Recess

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron recessed the meeting at 5:05 p.m.

* * * * *

An Administrative Hearing was convened on Thursday, November 16, 2017 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and public notice was properly posted.

A. Call to Order

Mr. Aron called the hearing to order at 8:25 a.m.

B. Invocation & Pledge

Mr. Aron called upon Mr. Valentine, and he delivered the invocation. Mr. Allen Cassidy

then led the group in the Pledge of Allegiance.

C. Quorum Call

Mr. Aron called upon Secretary Bond and he called the roll. After doing so, he certified Mr. Moore and Mr. Soileau were absent; however, the remaining 15 members were present, constituting a quorum for the conduct of official business.

D. Call for Additional Agenda Items & Adoption of Agenda

Mr. Aron asked if there were any additional agenda items, and none were requested. With no objection, the Board adopted the posted agenda, dated November 10, 2017. He then requested authority to re-order the agenda as may become necessary, and there were no objections to that request.

E. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited comments from the guests, but none were offered.

Appearances

Mr. Aron indicated he would serve as the Hearing Officer. Mr. Carlos Finalet served as the Prosecuting Attorney. Mr. Mark LaCour served as the Official Recorder, and Mr. Malcolm Broussard as the Hearing Clerk. Without objection, Mr. Aron waived the reading of the posted agenda and instead directed the insertion thereof into these minutes. The posted agenda is re-created here.

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.
Revised 11-10-2017

- A. Call to Order
- B. Invocation & Pledge of Allegiance
- C. Quorum Call
- D. Call for Additional Agenda Items & Adoption of Agenda
- E. Opportunity for Public Comment
- F. Formal Hearing
 - 01. Samantha Lee Landry ~ Applicant for PTC Registration Case No. 17-0149
- G. Adjourn

F. Formal Hearing

Samantha Lee Landry (Applicant for PTC Registration) Mr. Finalet appeared

for the Board. The respondent, Ms. Samantha Lee Landry, appeared without counsel. Mr. Finalet offered an opening statement during which he reported the respondent had met with him just prior to the hearing and agreed to the admission of Board Exhibits 1 through 9 as well as the proposed Findings of Fact which he presented to the members of the hearing panel. Ms. Landry then responded to questions from several members. Mr. Finalet offered the proposed Findings of Fact to which the respondent had stipulated but deferred to the Board for its Conclusions of Law and Board Order. Mr. Finalet then tendered the matter to the hearing panel for its consideration. Mr. Cassidy moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency and fitness for practice. The motion for executive session was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 9:15 a.m. and then reconvened in open session at 9:50 a.m. Mr. Aron reported no decision was made during the executive session.

Mr. Cassidy then moved,

Resolved, that the hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Mr. Cassidy then moved,

Resolved, that the hearing panel find the respondent in violation of the following statutes:

La. R.S. 37:1241(A)(1): Practiced or assisted in the practice of pharmacy, or knowingly permitted or has permitted anyone in his employ or under his supervision to practice or assist in the practice of pharmacy, in violation of the provisions of this Chapter and any rules and regulations promulgated thereto in accordance with the Administrative Procedure Act.

La. R.S. 37:1241(A)(2): Has attempted to or obtained a license by misrepresentation.

La. R.S. 37:1241(A)(22): Has failed to furnish to the board or representatives any information legally requested by the board.

The motion was adopted after a unanimous vote in the affirmative. Mr. Cassidy then moved,

Resolved, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that the board authorize the issuance of a pharmacy technician candidate registration to Samantha Lee Landry, to suspend the registration for an indefinite period of time and stay the

execution of the suspension, then place the registration on probation for the life of the registration.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Finalet indicated completion of the cases scheduled for that day. Mr. Aron expressed his appreciation to Mr. LaCour for his recording services that day.

G. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the hearing at 9:55 a.m.

Respectfully submitted,

Brian A. Bond
Secretary



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report on Action Items

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 21, 2018

Agenda Item 6: Report on Action Items

During the report from the Finance Committee at your last meeting, you approved the Proposed Budget for Fiscal Year 2018-2019. We filed that report on December 1 with the Joint Legislative Oversight Committee on Health & Welfare as well as the Legislative Fiscal Office and the Legislative Auditor.

During the report from the Regulation Revision Committee at your last meeting, you approved a legislative proposal relative to CDS licenses for 3PL companies. We submitted the proposal to the House legislative staff for their preparation of a bill. HB 45 has been pre-filed and is sponsored by Rep. Patrick Connick.

During the report from the Executive Committee at your last meeting:

- You approved two new policies relative to the processing of applications for new pharmacy permits. We applied the new policies to existing applications for pharmacy permits to clear some of the backlog of pharmacy permit applications awaiting your decision.
- You rescinded one policy relative to special entrance rates for salaries and approved a new policy relative to extraordinary qualifications or credentials to justify salaries for new hires higher than the beginning of the pay range for the position. We forwarded the new policy to the Civil Service Commission and they approved it effective January 15, 2018.
- You approved the revision of existing policies for purchases and invoices as recommended by the legislative auditor, and you also approved the revision of the post-accident drug testing policy in your Loss Prevention Manual. We have updated your Policies & Procedures Manuals to reflect your decisions, and we have implemented the new procedures.
- You approved the new Joint Accreditation program for those pharmacists completing interprofessional continuing education programs from providers accredited by that program. We informed Joint Accreditation of your approval. We also referred the continuing education rules for pharmacists and technicians to the Regulation Revision Committee for their consideration of any potential amendment to those rules to accommodate the Joint Accreditation program.
- You approved three modules of the Pharmacy Inspection Blueprints. We developed a new page on your website, a Pharmacy Resource Center. We posted several items on that page, including the blueprint documents. We notified pharmacies of that new webpage via a Pharmacy Alert on February 3.
- You voted to terminate your contract for professional accounting services from the current firm (*Kolder, Champagne, & Slaven, LLC*) and to seek a new contract for those services for the remainder of this fiscal year from a new firm (*Russell F. Champagne, CPA, A Professional Corporation*). We mailed the required contract termination letter on November 17; on that same day, we initiated the process to secure state approval of the new contract. The state approved that contract on December 13, 2018.
- You approved a second pharmacy technician certification examination (ExCPT), administered by National Healthcareer Association (NHA). The NHA representative was present for your decision at that meeting, so formal notification was not necessary. We have established the communication procedure to receive their quarterly data report and additional analytical data. We have also updated the guidance documents and application forms for pharmacy technicians and pharmacy technician candidates to recognize both certification examinations (PTCB and ExCPT). We also included an article in the January 2018 edition of the Board's newsletter, informing all of your licensees of the changes in the licensing requirements for pharmacy technicians.
- You approved the implementation of a pilot program at the pharmacies operated by the La. Dept. of Corrections to authorize the use of automated medication systems in state owned and operated correctional facilities. We notified the Pharmacist-in-Charge at Elayn Hunt Correctional Center of your decision and encouraged them to work with the Board to determine the parameters for the

project. We also referred the topic to the Regulation Revision Committee for their development of a regulatory proposal.

During your discussion of a suggested communication to the Attorney General and Commissioner of Insurance relative to pharmacy benefit managers, you voted to send the suggested letters. We mailed those letters the following day. We have received responses from both entities:

- The Commissioner of Insurance will be meeting with the Board on Thursday, Feb. 22, 2018; and
- The Attorney General has deemed your letter as a request for an opinion; the request has been titled Opinion 18-0012 and assigned to their staff.

During your discussion of a request to waive licensure renewal fees for spouses of military pharmacists, you approved a legislative proposal to authorize such fee waivers. We submitted the proposal to the House legislative staff for their preparation of a pre-filed bill for consideration in the Regular Session of the 2018 legislature.

Finally, you determined it appropriate to support the lifetime testing limit policy previously adopted by the National Association of Boards of Pharmacy (NABP) with respect to their NAPLEX and MPJE tests. We communicated your decision to the person who sought an exception to that policy.

Respectfully submitted,
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Special Order of the Day

Presentation of Pharmacist Gold Certificate

PST.009331 – James Benedict Collins, issued 11-29-1967

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

Interim Report Fiscal Year 2017-2018

February 21, 2018

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
 FY 2017-2018
 Statement of Assets, Liabilities, Equity

	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017
ASSETS		
> Current Assets		
* Cash		
General Operations		
Whitney Bank	160,985.43	245,158.00
Iberia Bank	648,018.98	1,031,830.00
Hurricane Relief Fund - Whitney Bank	83,389.04	0.00
Reserve Funds		
General Account	1,235,544.47	1,228,822.00
OPEB Account	1,198,137.48	1,191,981.00
Pension Account	<u>1,760,670.05</u>	<u>1,745,516.00</u>
* <i>Total Cash</i>	5,086,745.45	5,443,307.00
* <i>Prepaid Expenses</i>	6,600.00	7,031.00
* <i>Accounts Receivable</i>	14,593.74	4,000.00
* <i>Accrued Interest Receivable</i>	0.00	11,516.00
<i>Total Current Assets</i>	5,107,939.19	5,465,854.00
> Fixed Assets		
Land: Lot 5-A, Towne Center Business Park	709,079.90	709,079.90
Land: Lot 1-A-2, Leonard Place Subdivision	295,860.00	295,860.00
Office Building - 3388 Brentwood Drive	1,057,861.29	1,057,861.29
> Construction in Progress	0.00	11,056.00
Office Equipment	224,348.23	227,265.00
Furniture	157,808.58	163,127.00
Software: Licensure & Website	408,560.00	408,560.00
Accumulated Depreciation	<u>(887,718.31)</u>	<u>(916,035.00)</u>
<i>Total Fixed Assets</i>	1,965,799.69	1,956,774.19
TOTAL ASSETS	7,073,738.88	7,422,628.00
DEFERRED OUTFLOWS OF RESOURCES	1,215,759.00	1,215,759.00
<u>TOTAL ASSETS & DEFERRED OUTFLOWS</u>	<u>8,289,497.88</u>	<u>8,638,387.00</u>
LIABILITIES		
> Current Liabilities		
Accounts payable	4,975.76	0.00
Accrued salaries and benefits	41,249.33	0.00
Unemployment taxes payable	73.35	63.00
State taxes withheld	3,772.92	3,733.00
Deferred compensation withheld	50.00	0.00
Compensated absences (ST)	56,822.31	56,822.00
PES fee payable	<u>400.00</u>	<u>114,400.00</u>
<i>Total Current Liabilities</i>	107,343.67	175,018.00

Louisiana Board of Pharmacy
 FY 2017-2018
 Statement of Assets, Liabilities, Equity

	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017
LIABILITIES (cont.)		
> Long Term Liabilities		
Compensated absences (LT)	64,263.96	64,263.96
Other Post Employment Benefits (OPEB) Payable	1,209,508.00	1,209,508.00
Net Pension Liability	<u>5,336,594.00</u>	<u>5,336,594.00</u>
<i>Total Long Term Liabilities</i>	<i>6,610,365.96</i>	<i>6,610,365.96</i>
TOTAL LIABILITIES	6,717,709.63	6,785,384.00
DEFERRED INFLOWS OF RESOURCES	78,386.00	78,386.00
EQUITY		
Fund Balance at End of Prior Fiscal Year	(881,161.96)	(672,443.17)
Fund Balance - designated	209,220.00	209,220.00
Invested in Fixed Assets	1,965,799.69	1,956,625.42
Net Income/Loss	<u>199,544.52</u>	<u>281,215.00</u>
TOTAL EQUITY	1,493,402.25	1,774,617.25
<u>TOTAL LIABILITIES, DEFERRED INFLOWS, & EQUITY</u>	<u>8,289,497.88</u>	<u>8,638,387.00</u>

Louisiana Board of Pharmacy
FY 2017-2018
Statement of Revenue, Expenses, and Budget Performance

	Revenue		
	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017	FY 17-18 Budget (A#1)
Licensing Fees			
Pharmacist License Application Fee	178,800.00	51,900.00	180,000.00
Pharmacist License Reciprocity Application Fee	50,850.00	21,000.00	50,000.00
Pharmacist License Renewal Fee	831,200.00	781,050.00	830,000.00
Pharmacy Intern Registration Application Fee	3,030.00	2,040.00	3,000.00
Pharmacy Technician Candidate Registration Fee	42,975.00	19,050.00	40,000.00
Pharmacy Technician Certificate Application Fee	54,800.00	27,200.00	55,000.00
Pharmacy Technician Certificate Renewal Fee	339,350.00	8,800.00	335,000.00
Pharmacy Permit Application & Renewal Fee	281,325.00	249,575.00	290,000.00
AMS (Automated Medication System) Registration Fee	19,950.00	2,250.00	20,000.00
DME (Durable Medical Equipment) Permit Fee	86,700.00	79,425.00	85,000.00
EDK (Emergency Drug Kit) Permit Fee	12,025.00	2,000.00	12,000.00
CDS (Controlled Dangerous Substance) License Fee	472,545.00	208,225.00	470,000.00
Credential Reinstatement Fee	28,400.00	11,390.00	30,000.00
Delinquent Renewal Fee for Licenses (people)	19,105.00	6,417.00	9,000.00
Delinquent Renewal Fee for Permits (places)	3,462.50	5,487.00	12,000.00
Sales of Goods & Services			
Product Charge for Duplicate Credentials	4,420.00	1,670.00	4,400.00
Product Charge for Pharmacist Original Certificate	6,300.00	3,920.00	6,300.00
Product Charge for Pharmacist Silver Certificate	300.00	500.00	300.00
Product Charge for Law Book & Supplement	255.00	165.00	2,500.00
Product Charge for Official List of Licensees	18,150.00	10,050.00	15,000.00
Product Charge for Document Copies	289.50	367.00	200.00
Service Charge for Document Certification	4,200.00	2,140.00	4,600.00
Service Charge for Inspection Services for U.S. CPSC	2,400.00	0.00	2,000.00
Service Charge for PNT Practical Experience	0.00	160.00	0.00
Disposal of Assets	0.00	0.00	0.00
Administrative Fees			
Administrative Fee for NSF Items	425.00	200.00	500.00
Administrative Fee for Handling & Mailing	169.00	225.00	200.00
Enforcement Activities			
Administrative Hearing Fee	20,950.00	19,800.00	22,000.00
Fines	211,750.00	87,750.00	200,000.00
Cost Recoveries	9,805.28	7,816.00	10,000.00
Prescription Monitoring Program (PMP)			
PMP Assessments	519,100.00	224,905.00	520,000.00
Miscellaneous			
Miscellaneous Revenue	5,047.50	809.00	1,000.00
TOTAL REVENUE	3,228,078.78	1,836,286.00	3,210,000.00

Louisiana Board of Pharmacy
FY 2017-2018
Statement of Revenue, Expenses, and Budget Performance

Expenses

	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017	FY 17-18 Budget (A#1)
Operations			
Equipment Rentals	15,169.70	6,268.00	16,500.00
Equipment Maintenance	2,793.92	2,163.00	3,000.00
Telephone	16,410.53	8,350.00	15,000.00
Printing	26,962.56	19,107.00	28,000.00
Postage	50,033.28	40,021.00	53,000.00
Dues & Subscriptions	11,871.81	10,141.00	12,500.00
Financial Service Charges	59,196.40	45,815.00	60,000.00
Office Meeting Expenses	608.55	1,285.00	1,000.00
Office Supply Expenses	21,596.15	12,990.00	22,000.00
Utilities	9,402.63	4,489.00	9,700.00
Civil Service Assessments (DSCS)	5,805.00	6,663.00	6,700.00
Office Insurance (ORM)	10,595.00	11,546.00	11,600.00
Depreciation of Fixed Assets	60,720.98	28,317.00	60,000.00
Acquisitions	4,543.62	3,049.00	20,000.00
Miscellaneous Expenses	0.00	0.00	0.00
Personal Services			
Salaries for Employees	1,337,023.83	726,564.00	1,480,000.00
Wages for Temporary Labor	5,782.52	9,385.00	40,000.00
Payroll Taxes (FICA & FUTA)	22,260.29	12,212.00	30,000.00
Health Insurance Premiums (SEGBP)	158,756.68	81,382.00	178,000.00
Pension Plan Premiums (LASERS)	663,901.70	266,509.00	568,500.00
Other Post-Employment Benefits (OPEB)	37,479.00	0.00	40,000.00
Board Member Per Diem	29,175.00	12,225.00	30,000.00
Professional Services			
Accounting & Expense Reimbursement	24,315.10	17,784.00	30,000.00
Legal & Expense Reimbursement	63,491.30	7,160.00	60,000.00
Information Systems	113,146.50	96,194.00	132,000.00
Prescription Monitoring Program	82,400.00	31,000.00	100,000.00
Property Management	28,130.25	11,423.00	393,500.00
Staff Expenses			
Executive Director	4,838.79	3,546.00	10,000.00
Assistant Executive Director	5,782.27	2,831.00	10,000.00
General Counsel	8,595.85	7,706.00	10,000.00
Compliance Officer - Travel	5,074.12	1,917.00	6,000.00
Compliance Officer - Rental Cars	12,602.75	5,343.00	13,000.00
Compliance Officer - Fuel for Rental Cars	3,835.70	1,340.00	4,000.00
Compliance Officer - Conference Travel Expenses	6,001.16	5,036.00	12,000.00
House Staff Travel & Education	0.00	0.00	1,000.00
Mileage	19,092.87	11,032.00	20,000.00
Board Expenses			
Board Meetings	16,543.17	7,824.00	17,000.00
Committee Meetings	3,853.40	2,519.00	8,000.00
Conference Travel Expenses	22,563.37	9,248.00	23,000.00
Mileage - Members & President	13,528.71	6,215.00	17,000.00
President's Expenses	8,322.79	2,211.00	8,000.00
TOTAL EXPENSES	2,992,207.25	1,538,810.00	3,560,000.00

Louisiana Board of Pharmacy
 FY 2017-2018
 Summary of Income Fund Balance Changes

Summary

	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017	FY 17-18 Budget (A#1)
Income Statement			
Total Revenue	3,228,078.78	1,836,286.00	3,210,000.00
Total Expenses	2,992,207.25	1,538,810.00	3,560,000.00
Net Ordinary Income	235,871.53	297,476.00	(350,000.00)
Other Income & Expenses			
Investment	(36,327.01)	(16,261.00)	0.00
Reserve Accounts	0.00	0.00	350,000.00
Net Income	199,544.52	281,215.00	0.00

	FY 16-17 Q4 06/30/2017	FY 17-18 Q2 12/31/2017	FY 17-18 Budget (A#1)
Fund Balance			
Beginning Fund Balance	1,293,857.73	1,493,402.25	1,493,402.25
Total Income	3,191,751.77	1,820,025.00	3,210,000.00
Total Expenses	2,992,207.25	1,538,810.00	3,560,000.00
Ending Fund Balance	1,493,402.25	1,774,617.25	1,143,402.25
Reservations of Fund Balance	1,750,000.00	1,750,000.00	1,750,000.00
Unreserved Fund Balance	(256,597.75)	24,617.25	(606,597.75)

Notes on Reservation of Fund Balance

Net Pension Liability	1,000,000.00	1,000,000.00	1,000,000.00
Other Post Employment Benefits	500,000.00	500,000.00	500,000.00
Continuing Payroll Obligations	150,000.00	200,000.00	200,000.00
Land & Building Maintenance	<u>100,000.00</u>	<u>50,000.00</u>	<u>50,000.00</u>
<i>Total</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>

Louisiana Board of Pharmacy
 FY 2017-2018
 Schedule A - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity	FY 16-17	FY 17-18
	Q4 06/30/2017	Q2 12/31/2017
ASSETS		
Current Assets		
Hancock Bank - Checking Account	83,389	0
<u>TOTAL ASSETS</u>	<u>83,389</u>	<u>0</u>
LIABILITIES		
Current Liabilities	0	0
EQUITY		
Retained Earnings	83,389	0
Net Income	<u>0</u>	<u>0</u>
<u>TOTAL LIABILITIES & EQUITY</u>	<u>83,389</u>	<u>0</u>
Statement of Receipts & Disbursements		
	FY 16-17	FY 17-18
	Q4 06/30/2017	Q2 12/31/2017
RECEIPTS		
FEMA - Funds for payment of claims	8,920,812	0
FEMA - Administrative allowance	81,103	0
Pharmacies - reversal of claims	430,138	0
Interest income	<u>22,314</u>	<u>0</u>
<u>TOTAL RECEIPTS</u>	<u>9,454,367</u>	<u>0</u>
DISBURSEMENTS		
Claims paid to pharmacies	8,920,812	0
Reversed claim funds returned	430,138	0
Reversed administrative allowance returned	7,338	0
Interest earned on reversed admin. allowance returned	<u>12,690</u>	<u>0</u>
<u>TOTAL DISBURSEMENTS</u>	<u>9,370,978</u>	<u>0</u>
FUND BALANCE	<u>83,389</u>	<u>0</u>

Note: These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

> FEMA confirmed closure of audit period; funds transferred to general fund prior to 12/31/2017

Holdings by Investor



LA Board of Pharmacy
3388 Brentwood Dr
Baton Rouge, LA 70809

JOSEPH BARRECA, JR.
2900 Ridgelake Dr
Metairie, LA 70002
504-310-7346

H5E-049797
Date: 12/31/2017
Created: 01/23/2018

LA Board of Pharmacy

Acct Name: Louisiana Board of Pharmacy

Acct No: H5E049797

Acct Type: Non-Profit Organization

Asset Name	Ticker	Investment Objective	Mgt. Name	Quantity	Price (\$)	Value (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	25,641.07	1.00	25,641.07
US TREAS INFLAT PROT	912828N M8	LONG-TERM BOND		25,000.00	1.17	29,341.99
US TREASU NT 1.625% UST NOTE DUE 06/30/20	TSRYS44 944	NON-CLASSIFIED		145,000.00	0.99	143,929.90
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44 942	NON-CLASSIFIED		457,000.00	0.98	447,160.49
US TREASURY SENIOR NOTE	TSRYS44 942	NON-CLASSIFIED		593,000.00	0.99	587,084.22
Account Total						\$1,233,157.66
Investor Total						\$1,233,157.66

Holdings by Investor



LA Board of Pharmacy
3388 Brentwood Dr
Baton Rouge, LA 70809

JOSEPH BARRECA, JR.
2900 Ridgelake Dr
Metairie, LA 70002
504-310-7346

H5E-077160
Date: 12/31/2017
Created: 01/23/2018

LA Board of Pharmacy

Acct Name: OPEB Reserve account

Acct No: H5E077160

Acct Type: Non-Profit Organization

Asset Name	Ticker	Investment Objective	Mgt. Name	Quantity	Price (\$)	Value (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	23,260.63	1.00	23,260.63
UNITED STATES TREAS NTS 1.250% 12/31/18 B/EDTD 12/31/16	TSRYS44 943	NON-CLASSIFIED		99,000.00	0.99	98,450.55
US TREASU NT 1.625% UST NOTE DUE 06/30/20	TSRYS44 944	NON-CLASSIFIED		61,000.00	0.99	60,549.82
US TREASUR NT 1% UST NOTE DUE 06/30/19	TSRYS44 943	INTERMEDIATE GOVERNMENT		63,000.00	0.99	62,215.02
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44 942	NON-CLASSIFIED		728,000.00	0.98	712,325.68
US TREASURY SENIOR NOTE	TSRYS44 942	NON-CLASSIFIED		241,000.00	0.99	238,595.78
Account Total						\$1,195,397.48
Investor Total						\$1,195,397.48

Holdings by Investor



LA Board of Pharmacy
3388 Brentwood Dr
Baton Rouge, LA 70809

JOSEPH BARRECA, JR.
2900 Ridgelake Dr
Metairie, LA 70002
504-310-7348

H5E-102679
Date: 12/31/2017
Created: 01/23/2018

LA Board of Pharmacy

Acct Name: Pension Reserve account

Acct No: H5E102679

Acct Type: Non-Profit Organization

Asset Name	Ticker	Investment Objective	Mgt. Name	Quantity	Price (\$)	Value (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	28,296.59	1.00	28,296.59
UNITED STATES TREAS NTS NOTE 1.37500% 01/31/2021	TSRYS44 942	NON-CLASSIFIED		297,000.00	0.98	293,037.04
UNITED STATES TREAS NTS NOTE 2.00000% 12/31/2021	TSRYS44 943	NON-CLASSIFIED		769,000.00	0.99	765,093.48
US TREASU NT 1.625% UST NOTE DUE 06/30/20	TSRYS44 944	NON-CLASSIFIED		29,000.00	0.99	28,785.98
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44 942	NON-CLASSIFIED		648,000.00	0.98	634,048.13
Account Total						\$1,749,261.23
Investor Total						\$1,749,261.23



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Application Review Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reciprocity Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Violations Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Impairment Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reinstatement Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Tripartite Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Regulation Revision Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

1 HLS 18-
2 Regular Session, 2018
3 House Bill No. _____
4 By Representative

5
6 CONTROLLED SUBSTANCES: Adds cyclopropylfentanyl and deschloroketamine to Schedule
7 I and removes naldemedine from Schedule II.

8
9 AN ACT

10
11 To amend and reenact R.S. 40:964, relative to the composition of various schedules of controlled
12 substances.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:

15 §964. Composition of schedules

16 * * *

17 Schedule I

18 A. Opiates.

19 Unless specifically excepted or unless listed in another schedule,
20 any of the following opiates, including their isomers, esters, ethers, salts, or
21 salts of isomers, esters, and ethers, whenever the existence of such isomers,
22 esters, ethers, or salts is possible within the specific chemical designation:

23 * * *

24 *(61) Cyclopropylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-

25 phenylcyclopropanecarboxamide)

26 * * *

27 C. Hallucinogenic Substances.

28 Unless specifically excepted or unless listed in another schedule, any
29 material, compound, mixture, or preparation which contains any quantity of
30 the following hallucinogenic substances, or which contains any of their salts,
31 isomers, or salts of isomers, whenever the existence of such salts, isomers, or
32 salts of isomers is possible within the specific chemical designation; for
33 purposes of this Paragraph only, the term "isomer" includes the optical,
34 position, and geometric isomers:

35 * * *

36 (64) Deschloroketamine (2-phenyl-2(methylamino) cyclohexanone)

37 * * *

38 Schedule II

39 A. Substances of vegetable origin or chemical synthesis

40 * * *

41 (1) Opium and opiate, and any salt, compound, isomer, derivative, or
42 preparation of opium or opiate, excluding apomorphine, thebaine-derived
43 butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol,
44 naloxone, and naltrexone, and their respective salts, but including the
45 following:

46 * * *

47

1 HLS 18-
2 Regular Session, 2018
3 House Bill No. _____
4 By Representative

5

6 BOARD OF PHARMACY: Amends the definition of approved college of pharmacy.

7

8 AN ACT

9

10 To amend and reenact R.S. 37:1164(2), relative to the definition of approved college of
11 pharmacy.

12 Be it enacted by the Legislature of Louisiana:

13 Section 1. R.S. 37:1164(2) is hereby amended and reenacted to read as follows:

14 §1164. Definitions

15 * * *

16 (2) "*Approved college of pharmacy*" means an educational institution approved
17 by the board which meets one of the following additional criteria:

18 * * *

19 (b) A foreign college or school of pharmacy ~~which is listed in the World~~
20 ~~Health Organization's "World Directory of Schools of Pharmacy" and~~
21 whose graduate has attained educational equivalency status through a
22 mechanism established by the board.

23 * * *

1 HLS 18-
2 Regular Session, 2018
3 House Bill No. _____
4 By Representative

5

6 CONTROLLED SUBSTANCES: Authorizes the dispensing of partial fills of prescriptions for
7 Schedule II substances.

8

9 AN ACT

10

11 To amend and reenact R.S. 40:978(A), relative to prescriptions.

12

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:978(A) is hereby amended and reenacted to read as follows:

15 §978. Prescriptions

16 A. Except when dispensed or administered directly by a medical practitioner
17 or administered by a person authorized to administer by such practitioner,
18 other than a pharmacist, to an ultimate user, no controlled dangerous
19 substance included in Schedule II, which is a prescription drug as
20 determined under the Louisiana Revised Statutes of 1950, may be
21 dispensed or administered without either the written prescription of a
22 practitioner, or an electronic prescription order as provided by federal law
23 or regulation, except that in emergency situations, as prescribed by the
24 ~~department~~board by regulation, such drug may be dispensed or

25 administered upon oral prescription reduced promptly to writing and filed
26 by the pharmacist. Prescriptions shall be retained in conformity with the
27 requirements of R.S. 40:976. No prescription for a Schedule II substance
28 may be refilled nor may such prescription be filled more than ninety days
29 after the date of the prescription. The pharmacist filling a prescription for
30 a Schedule II substance may, upon request of the patient, dispense the
31 prescribed substance in an amount less than the full quantity prescribed in
32 accordance with 21 U.S.C. 829.

DRAFT

1 SLS 18RS-
2 Regular Session, 2018
3 Senate Bill No. _____
4 By Senator

5
6 CONTROLLED SUBSTANCES: Authorizes designated representatives of Medicaid to access
7 certain audit trail information in the prescription monitoring program.

8
9 AN ACT

10
11 To amend and reenact R.S. 40:1007(J), relative to audit trail information in the prescription
12 monitoring program.

13
14 Be it enacted by the Legislature of Louisiana:

15 Section 1. R.S. 40:1007(J) is hereby amended and reenacted to read as follows:

16 §1007. Access to prescription monitoring information and audit trail information

17 * * *

18 J. The board may disclose or provide access to audit trail information to the
19 following:

- 20 (1) Individuals identified in Paragraphs (E)(2) and Subsections F and I
21 of this Section for use in an active investigation of an individual
22 who submitted requests for prescription monitoring information.

1 SLS 18RS-
2 Regular Session, 2018
3 Senate Bill No. _____
4 By Senator

5

6 CONTROLLED SUBSTANCES: Amends the definitions of “dispenser” and “drugs of concern”
7 in the state prescription monitoring program.

8

9 AN ACT

10

11 To amend and reenact R.S. 40:1003(9), relative to dispensers and drugs of concern in the state
12 prescription monitoring program.

13

14 Be it enacted by the Legislature of Louisiana:

15 Section 1. R.S. 40:1003(9) is hereby amended and reenacted to read as follows:

16 §1003. Definitions

17 (6) “Dispenser” means a person authorized by this state to dispense or
18 distribute to the ultimate user any controlled substance or drug monitored
19 by the program, but shall not include any of the following:

20 (a) – (c) ...

21 (d) A wholesale distributor of such controlled substance or drug that is
22 credentialed by the Louisiana ~~State~~ Board of ~~Wholesale Drug~~ and
23 Device Distributors.

24

*

*

*

25 (9) “Drugs of concern” mean drugs other than controlled substances as
26 defined by rule which demonstrates a potential for abuse or whose use
27 requires tracking for public health purposes.

28 * * *

29

DRAFT

1 SLS 18RS-
2 Regular Session, 2018
3 Senate Bill No. _____
4 By Senator

5
6 PHARMACISTS: Amends the licensing requirements for pharmacists.

7
8 AN ACT
9 To amend and reenact R.S. 37:1202 relative to pharmacist licensure by examination and R.S.
10 37:1203 relative to pharmacist licensure by reciprocity.

11
12 Be it enacted by the Legislature of Louisiana:

13
14 Section 1. R.S. 37:1202 and R.S. 37:1203 are hereby amended and reenacted to read as
15 follows.

16 §1202. Qualifications for licensure by examination

17 A. To obtain a license to engage in the practice of pharmacy, an applicant for
18 licensure by examination shall:

19 (1) Be at least twenty-one years of age.

20 ~~(2) Be of good moral character and temperate habits.~~

21 ~~(3)~~ (2) Meet one of the following educational requirements:

22 (a) Have graduated and received a professional degree from an

23 approved college of pharmacy; or
24 (b) Have graduated from a foreign college of pharmacy,
25 completed a transcript verification program, taken and passed
26 a college of pharmacy equivalency examination program, and
27 completed a process of communication ability testing as
28 defined by the board in order to assure that the applicant meets
29 the standards necessary to protect public health, safety, and
30 welfare.

31 ~~(4)~~ (3) Meet the following experiential requirement:

32 Supply proof, substantiated by proper affidavits, of a Complete a
33 minimum of one year of ~~service and~~ professional experience through
34 an internship or other program that has been approved by the board
35 under the supervision of a licensed pharmacist, which service shall be
36 predominantly related to the provision of pharmacy primary care and
37 the dispensing of drugs and medical supplies, the compounding of
38 prescriptions, and the keeping of records and the making of reports as
39 required under state and federal law.

40 ~~(5)~~ (4) Have submitted to the board an application, in the time frame and
41 form prescribed by the board, by regulation. Have passed all
42 examinations required by the board.

43 ~~(6)~~ (5) Have paid fees specified by the board for the examination, and
44 issuance of the license, certificate, or registration and any related

45 materials.

46 ~~(7) (6) Have passed an examination or examinations required by the board.~~

47 Have submitted to the board a completed application form supplied by
48 the board.

49 ~~(7) Complete a criminal history record check as authorized by R.S.~~
50 ~~37:1216.~~

51 B. Examinations.

52 (1) Due notice of all meetings for examination of applicants shall be
53 given to all approved colleges of pharmacy in the state.

54 (2) The board shall determine the content and subject matter of each
55 examination and approve the site and date of the administration of the
56 examination.

57 (3) The examination shall be prepared to measure the knowledge of the
58 applicant to engage in the practice of pharmacy. The board may
59 employ, cooperate, and contract with any organization or consultant in
60 the preparation and grading of an examination, but shall retain the
61 sole discretion and responsibility for determining which applicants
62 have passed such an examination.

63 ~~(4) An applicant who takes and satisfactorily completes any board~~
64 ~~required examinations shall become licensed within one year of the~~
65 ~~examination dates or the results of the examinations shall become~~
66 ~~invalid. Examination scores shall expire one year after the date of the~~

67 examination, and expired scores are not valid for licensure.

68 (5) An applicant, who takes any board required examinations and is
69 unsuccessful, may repeat the examinations as administratively
70 defined.

71 (6) An applicant who takes any board required examinations or any
72 examination or examinations in other jurisdictions and is unsuccessful
73 for the third time shall not thereafter be eligible to take the board
74 examination without satisfying the requirements of the board as
75 administratively defined.

76 (a) An individual who has taken and failed the examinations more
77 than three times may not practice as a pharmacy intern, as
78 administratively defined.

79 (b) An individual who has taken and failed for the third time a
80 comparable examination to the board's examination within
81 another jurisdiction shall not be eligible to take the
82 examination of the board without satisfying the requirements
83 of the board as administratively defined.

84 C. Internship and other training programs.

85 (1) All applicants for licensure by examination shall obtain ~~practical~~
86 professional experience in the practice of pharmacy concurrent with
87 attending or after graduation from an approved college of pharmacy,
88 or both, under such terms and conditions as determined by regulation.

89 (2) The board shall establish such licensure requirements for pharmacy
90 interns and standards for internship, or any other experiential program
91 necessary to qualify an applicant for the licensure examination, and
92 shall also determine the qualifications of ~~preceptors~~ pharmacists or
93 other practitioners used in ~~practical~~ professional experience programs
94 as determined by regulation.

95 D. Upon successful completion of the requirements of Subsections A, B, and C,
96 the board shall license the pharmacist within fourteen working days.

97 §1203. Qualifications for licensure by reciprocity

98 A. In order for a pharmacist currently licensed in another jurisdiction to obtain a
99 license as a pharmacist by reciprocity in this state, an applicant shall:

100 (1) Have attained the age of twenty-one years.

101 ~~(2) Have good moral character and be of temperate habits.~~

102 ~~(3)~~ (2) Have possessed at the time of initial licensure as a pharmacist all
103 qualifications necessary to have been eligible for licensure at that time
104 in this state.

105 ~~(4) Have engaged in the practice of pharmacy for a period of at least one~~
106 ~~year or have met the internship requirements of this state within the~~
107 ~~one year period immediately previous to the date of such application.~~

108 ~~(5) Have submitted an application in the form prescribed by the board.~~

109 ~~(6)~~ (3) Have presented to the board evidence of initial licensure by
110 examination and evidence that such license is in ~~good standing~~ active

111 status.

112 ~~(7)~~ (4) Have presented to the board evidence of any disciplinary, criminal, or
113 other adverse action, including arrests, taken against him by another
114 licensing jurisdiction, government agency, law enforcement agency,
115 or court. Such action may serve as grounds for the denial of
116 reciprocity to an applicant.

117 ~~(5)~~ Have passed all examinations required by the board.

118 ~~(8)~~ (6) Have paid the fees specified by the board to defray the expenses of
119 making an investigation of his ~~character, general reputation, and~~
120 licensure the status of his original and all subsequently acquired
121 pharmacist licenses in the state in which he has resided.

122 ~~(9)~~ (7) ~~Have passed all examinations required by the board.~~ Have submitted a
123 completed application form supplied by the board.

124 B. No applicant shall be eligible for licensure by reciprocity unless the state or
125 jurisdiction in which the applicant was initially licensed as a pharmacist also
126 grants reciprocity to a pharmacist duly licensed by examination in this state,
127 under comparable circumstances and conditions.

128 C. Upon successful completion of the requirements of Subsections A and B, the
129 board shall license the pharmacist within fourteen working days.

130

1 SLS 18RS-
2 Regular Session, 2018
3 Senate Bill No. _____
4 By Senator

5

6 CONTROLLED SUBSTANCES: Authorizes access to state prescription monitoring program
7 information by epidemiologist with Dept. of Health pursuant to an agreement with the Board of
8 Pharmacy.

9

10 AN ACT

11

12 To enact R.S. 40:1007(E)(8), relative to access to prescription monitoring information and audit
13 trail information in the state prescription monitoring program.

14

15 Be it enacted by the Legislature of Louisiana:

16 Section 1. R.S. 40:1007(E)(8) is hereby enacted to read as follows:

17 §1007. Access to prescription monitoring information and audit trail information

18 * * *

19 E. The following persons may access prescription monitoring information at
20 no cost and in the same or similar manner, and for the same or similar
21 purposes, as those persons are authorized to access similar protected
22 health information under federal and state law and regulation:

23 * * *

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 24. Limited Service Providers

Subchapter F. Pharmacy Benefit Managers

§2471. Definitions

- A. The following terms shall have the meaning ascribed to them in this Section:
1. “Health insurance plan” means an individual or group plan or program, whether commercial, self-insured, or mandated or sponsored by any federal, state, or local government, which is established by contract, certificate, law, plan, policy, subscriber agreement, or by any other method and which is entered into, issued, or offered for the purpose of arranging for, delivering, paying for, providing, or reimbursing any of the costs of health or medical care, including pharmacy services, drugs, or devices.
 2. “Pharmacy benefit management plan” or “pharmacy benefits program” means a plan or program that pays for, reimburses, covers the cost of, or otherwise provides for pharmacist services or drugs or devices to individuals who reside in or are employed in Louisiana.
 3. “Pharmacy benefit manager” or “PBM” means any person or other entity who administers the prescription drug or device program of one or more health insurance plans on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager, hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

§2473. Pharmacy Benefit Manager Permit; Activities; Prohibitions

- A. Any pharmacy benefit manager who, pursuant to a contract or under an employment relationship with a carrier, health benefit plan sponsor, or other third-party payer, either directly or through an intermediary, manages the drug or device coverage or other pharmacy benefits provided by the carrier, plan sponsor, or other third-party payer, shall be permitted by the board.
- B. A pharmacy benefit manager permit shall authorize the permit holder to administer pharmacy benefit management services.
- C. Pharmacy benefit management services include, but are not limited to:
 1. Development, maintenance, and/or administration of drug formularies;
 2. Development, maintenance, and/or administration of step therapy procedures;
 3. Development, maintenance, and/or administration of utilization management and utilization reviews;
 4. Development, maintenance, and/or administration of drug regimen reviews;
 5. Development, maintenance, and/or administration of quality care dosing services;
 6. Development, maintenance, and/or administration of prescription drug management programs and the contracting with pharmacies for same;
 7. Development, maintenance, and/or administration of disease management programs;
 8. Administration, processing, and/or payment of claims for prescription drugs;
 9. Processing of prior authorization requests;
 10. Adjudication of appeals and/or grievances related to prescription drug coverage; and

- 53 11. Any other act, service, operation, or transaction incidental to or forming a part of the
54 compounding, filling, dispensing, exchanging, giving, offering for sale, or selling drugs,
55 medicines, poisons or devices in this state by pharmacists or pharmacies, pursuant to a
56 prescription or an order of physicians, dentists, veterinarians, or other licensed practitioners,
57 requiring, involving, or employing the science or art of any branch of the pharmacy profession,
58 study, or training.
- 59 D. The provisions of R.S. 37:1232(A) and Section 2303 of this Part notwithstanding, the pharmacy
60 benefit manager need not hold a resident pharmacy permit in the state in which it is located prior to
61 applying for a pharmacy benefit manager permit. However, should the pharmacy benefit manager not
62 hold a resident pharmacy permit in the state in which it is located, the pharmacy benefit manager shall
63 be subject to an inspection by the board or its designated agent, in compliance with the provisions of
64 R.S. 37:1232(C).
- 65 E. The board shall not issue a pharmacy benefit manager permit to any person or other entity which has
66 not yet registered with the Louisiana Secretary of State to conduct business within the state.
- 67 F. When the pharmacy benefit manager permit is issued, it shall be valid only for the owner and specific
68 location noted on the application and recorded on the permit, and the permit shall not be valid for any
69 premises other than the physical location to which it was issued.
- 70 G. A pharmacy benefit manager permit is not transferable from the original owner. The permit shall not
71 be subject to sale, assignment or other transfer, voluntary or involuntary. Moreover, in the event the
72 ownership of the pharmacy benefit manager changes by 50 percent or more after the initial issuance of
73 the permit, the ownership will be deemed sufficiently different as to require a new pharmacy benefit
74 manager permit. The continued operation of a pharmacy benefit manager permit after its ownership
75 has changed by more than 50 percent shall constitute sufficient basis for the board to issue a finding for
76 the operation of a pharmacy benefit manager without a valid permit, in violation of R.S. 37:1241
77 (A)(12).
- 78 H. Any pharmacy benefit manager may request an exemption from the requirement of this Section.

79
80 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

81 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

82
83 **§2475. Licensing Procedures**

- 84 A. Application for Initial Issuance of Permit
- 85 1. The board shall develop an application form suitable for the pharmacy benefit manager permit.
86 The board may revise that application form on its own initiative in order to collect the information
87 it deems necessary to properly evaluate an applicant.
- 88 2. The board shall not process applications received by facsimile, or that are incomplete, or
89 submitted with the incorrect fee.
- 90 3. Once received by the board, an application for the permit shall expire one year thereafter. Fees
91 attached to an expired application shall be forfeited by the applicant and deposited by the board.
- 92 4. In the event any information contained in the application or accompanying documents changes
93 after being submitted to the board and before the issuance of the permit, the applicant shall
94 immediately notify the board in writing and provide corrected information.
- 95 5. The applicant may be required to personally appear before the board or one of its committees prior
96 to any decision on the permit application.
- 97 6. Upon approval of the application, the board shall issue the pharmacy benefit manager permit to the
98 applicant.
- 99 B. Application for Renewal of Permit
- 100 1. All pharmacy benefit manager permits shall expire at midnight on August 31 of every year,
101 regardless of the date of its initial issuance.
- 102 2. The board shall not process applications received by facsimile, or that are incomplete, or
103 submitted with the incorrect fee.
- 104 3. In the event the pharmacy benefit manager does not submit a properly completed renewal
105 application and fee to the board prior to the expiration of the permit, the permit shall be rendered
106 null and void. A pharmacy benefit manager shall not operate with an expired permit. The

- 107 continued operation of a pharmacy benefit manager with an expired permit shall constitute
108 sufficient basis for the board to issue a finding for the operation of a pharmacy benefit manager
109 without a valid permit, in violation of R.S. 37:1241(A)(12).
110 4. An application for the late renewal of an expired pharmacy benefit manager permit that is received
111 in the board office no later than 30 days after the expiration date of the permit may be processed
112 by the board office provided the appropriate delinquent fee authorized in R.S. 37:1184 is included
113 with the application.
114 5. A pharmacy benefit manager permit not renewed by 30 days after the expiration date shall be
115 automatically terminated by the board.
116 6. An application for the reinstatement of a terminated pharmacy benefit manager permit shall be
117 referred to the board's reinstatement committee for its consideration.
118 C. Application for Reinstatement of Lapsed, Suspended, or Revoked Permit
119 1. The applicant shall complete the application form for this specific purpose supplied by the board
120 2. The application shall be accompanied by the payment of the permit fee, delinquent renewal fee,
121 and reinstatement fees authorized in R.S. 37:1184.
122 3. Upon the receipt of a properly completed application form and fee, the board staff shall refer the
123 application to the board's reinstatement committee for its consideration and shall notify the
124 applicant of the time and place for the committee meeting.
125 D. Maintenance of Permit
126 1. A pharmacy benefit manager permit shall be valid for the entity to whom it is issued and shall not
127 be subject to sale, assignment or other transfer, voluntary or involuntary, nor shall the permit be
128 valid for any premises other than the business location recorded on the permit.
129 2. Upon receipt of a written request and payment of the fee authorized in R.S. 37:1184, the board
130 shall issue a duplicate or replacement permit to the applicant; however, such duplicate or
131 replacement permit shall not serve or be used as an additional or second permit.
132 3. Prior to any change in the location of a pharmacy benefit manager, the owner of the permit shall
133 submit an application form for that purpose supplied by the board and pay the appropriate fee
134 authorized in R.S. 37:1184. The board may require an inspection of the new location prior to the
135 issuance of the permit for the new location. The operation of a pharmacy benefit manager in a
136 new location not approved by the board shall constitute sufficient basis for the board to issue a
137 finding for the operation of a pharmacy benefit manager without a valid permit, in violation of
138 R.S. 37:1241(A)(12).
139 4. In the event the pharmacy benefit manager contemplates permanent closure of the pharmacy
140 benefit manager business, the owner of the permit shall notify the board, in writing, 10 days prior
141 to the anticipated date of closure and surrender its permit.
142

143 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

144 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

145 §2477. Applicable Laws and Regulations; Sanctions

- 146 A. Any pharmacy benefit management service of a pharmacy benefit manager that adversely affects or
147 impairs the health, safety, and welfare of a person who is a beneficiary of the pharmacy benefit
148 program administered by the pharmacy benefit manager and who resides or works in this state or
149 directly impairs the ability of a pharmacist or pharmacy to compound, fill, dispense, exchange, give,
150 offer for sale, or sell drugs, medicines, poisons or devices to any such person shall be deemed a
151 violation of R.S. 37:1241(A)(1), as well as a violation of any other applicable provisions of R.S.
152 37:1241(A), providing cause for the board to take any of the actions permitted in R.S. 37:1241.
153 Further, Louisiana pharmacy laws shall be applicable to regulation of the practice of pharmacy for that
154 portion of the permitted pharmacy benefit manager's Louisiana pharmacy practice or operation.
155

156 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

157 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR
158



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Executive Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

PROPOSED CONTRACTS / AGREEMENTS

Fiscal Year 2018-2019

Contractor	Service	2014/2015 Terms	2015/2016 Terms	2016/2017 Terms	2017/2018 Terms	2018/2019	Changes to prior FY	Contract Received
Celia Cangelosi	Legal	\$195/hr maximum \$80,000	\$225/hr maximum \$80,000	\$225/hr maximum \$80,000	\$225/hr maximum \$100,000	\$225/hr maximum \$100,000	No	
Shows, Cali & Walsh	Legal	\$175/hr maximum \$40,000	\$225/hr maximum \$40,000	\$225/hr maximum \$40,000	\$225/hr maximum \$50,000	\$225/hr maximum \$50,000	No	
Champagne & Co., LLC	CPA	\$75/hr - prepare bank reconciliations, journal entries, financial statements	\$75/hr - prepare bank reconciliations, journal entries, financial statements	\$75/hr - prepare bank reconciliations, journal entries, financial statements	\$80/hr - prepare bank reconciliations, journal entries, financial statements	\$80/hr - prepare bank reconciliations, journal entries, financial statements	No	
		\$145/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$160/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$160/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$165/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$160/hr - review bank reconciliations, adjusting journal entries, and financial statements	Yes	
		\$180/hr - oversight and final approval of accounting work	\$180/hr - oversight and final approval of accounting work	\$180/hr - oversight and final approval of accounting work	\$200/hr - oversight and final approval of accounting work	\$200/hr - oversight and final approval of accounting work	No	
				\$40/hr - travel to annual meeting	\$50/hr - travel to annual meeting	\$50/hr - travel to annual meeting	No	
		maximum \$22,500	maximum \$22,500	maximum \$22,500	maximum \$30,000	maximum \$30,000	No	
Appriss (05/18/15 - present) (07/01/10 - 02/28/14: HID) (03/01/14 - 05/17/15: Optimum)	PMP (Rx Hosting)		\$76,100	\$74,900	\$73,700	Must be re-bid	Yes	
Essential Solutions	IT Support	\$2,500/mo (July -June)	No					
MicroPact (CAVU/Iron Data)	Database	\$57,600 (plus additional for software upgrade)	\$60,600 (plus additional for software upgrade)	\$63,600 (plus additional for software upgrade)	\$66,600 (plus additional for software upgrade)	\$69,600 (plus additional for software upgrade)	Yes	

To be sent to DHH / Contracts & Procurement Department

New proposed contract terms



13955 Farmington Road • Livonia • MI 48154 • Tel. (800)734-1175

January 16, 2018

Louisiana Board of Pharmacy
1516 Jefferson Highway
New Orleans, LA 70121

Dear, Louisiana Board of Pharmacy,

The purpose of this letter is to request Board approval for our ASHP Accredited Pharmacy Technician Training Program.

About MedCerts:

MedCerts provides instructor/mentor supported self-paced online education to students around the globe. With a focus on healthcare and IT certification training, MedCerts delivers world-class programs with engaging videos that bring the instructor to the student's desktop in a self-paced, yet structured delivery format. These comprehensive video-based training programs provide students with the knowledge and skills required to obtain nationally and internationally recognized certifications in growing healthcare and IT fields.

Sincerely,

Domenic Policicchio III
Director of Corporate Development



June 26, 2017

Michael Colvin
President
MedCerts
13955 Farmington Road
Livonia, MI 48154

Dear Mr. Colvin:

It is a pleasure to inform you of the following action taken at the Pharmacy Technician Accreditation Commission meeting on May 9, 2017

VOTED

To approve for accreditation the pharmacy technician training program at MedCerts, Livonia, Michigan; further,

To grant accreditation for three years (2020), at which time a progress report will be requested to determine continued accreditation.

(Note: The Commission identified that areas of partial compliance 2, 3, 4, 7, 9, 10, 14, and 15 have been resolved to its satisfaction and no further information needs to be provided in these areas on the progress report; all other areas of partial compliance should be addressed.)

The Commission arrived at its decision based on a thorough review of the report of the survey conducted on January 4, 2017, and your facility's response to the survey findings.

The ASHP and ACPE Board of Directors reviewed and accepted the Pharmacy Technician Accreditation Commission on June 3, 2017 and June 21, 2017.

Accreditation is granted subject to the provisions set forth in the *ASHP/ACPE Regulations on Accreditation of Pharmacy Technician Training Programs*. A Certificate of Accreditation from our Executive Vice President's office on behalf of the Society's Board of Directors has been forwarded to Keith M. Binion, BS, CPhT, Director, Pharmacy Technician Education and Training Program.

Michael Colvin
June 26, 2017
Page 2

We congratulate you and the members of your staff on receiving accreditation for your pharmacy technician accreditation program.

Sincerely,



Janet A. Silvester, Pharm. D., MBA, FASHP
Vice President, Accreditation Services Office
American Society of Health-System Pharmacists



Peter H. Vlasses, Pharm. D., DSC(HON), BCPS, FCCP
Executive Director
Accreditation Council for Pharmacy Education

ASO/MI-11

cc: Keith M. Binion, BS, CPhT, Director, Pharmacy Technician Education and Training Program



**APPLICATION FOR ACCREDITATION OR REACCREDITATION
OF A PHARMACY TECHNICIAN EDUCATION AND TRAINING PROGRAM**

Please check one: Initial Application Reaccreditation

This form must be completed and submitted to ASHP-ACPE's Accreditation Services Division at the time of application for accreditation or reaccreditation of a pharmacy technician education and training program.

Name of Organization: MED CERTS
 Address: 13955 FARMINGTON ROAD
 City/State/Zip: LIVONIA, MI 48154
 Phone: (800) 734-1175 Fax: _____

TERMS AND INFORMATIONAL REQUIREMENTS

1. The above organization is applying for ASHP-ACPE accreditation/reaccreditation of a pharmacy technician education and training program. This application form must be completed in full; signed by the director of the pharmacy technician education and training program, the senior administrator or manager to whom the program director reports, and the dean or chief executive officer; and accepted by the ASHP-ACPE Accreditation Services Division before any further actions will occur on the application.
2. The organization named above accepts and understands the sole basis for accreditation/reaccreditation is the requirements in the regulations (see: <http://www.ashp.org/DocLibrary/Accreditation/Regulations-on-Accreditation-of-Pharmacy-Technician-Education.pdf>) and standards as follows: Effective for existing programs until January 15, 2015 ASHP-ACPE Accreditation Standard for Pharmacy Technician Training Programs. (See: <http://www.ashp.org/DocLibrary/Accreditation/RTP-TechStandards.aspx>). Existing programs may also use the new standard, ASHP-ACPE Accreditation Standard for Pharmacy Technician Education and Training Programs, effective January 1, 2014. All new programs must use the new standard: (See: <http://www.ashp.org/DocLibrary/Accreditation/Regulations-Standards/Pharmacy-Technician-Education-and-Training-Programs.pdf>). All of these Regulations and Standards are incorporated by reference into this application form.
3. To the best of our knowledge, the pharmacy technician education and training program of this organization for which accreditation/reaccreditation is being sought meets the requirements of the accreditation Regulations and Standards by which the pharmacy technician education and training program will be reviewed.
4. The organization agrees and accepts that any and all decisions to award accreditation/reaccreditation to the pharmacy technician education and training program of the organization is contingent upon the pharmacy technician education and training program being in compliance with the relevant accreditation Regulations and Standards, as determined by the official ASHP-ACPE survey and review process.
5. All decisions to accredit or reaccredit a pharmacy technician education training program are determined solely through the ASHP-ACPE-ACPE Pharmacy Technician Accreditation Commission as authorized by the ASHP-ACPE Board of Directors and the ACPE Board of Directors.
6. The pharmacy technician education and training program for which accreditation is being sought has been in existence for 4.5 years.
7. This organization conducts other ASHP-ACPE-accredited or candidate status pharmacy technician education and training programs. Yes No
 If yes, please list other programs: _____

8. If application is for initial accreditation, the following are highly recommended prior to application or prior to the start of the first class of pharmacy technician students:
- The program director for this pharmacy technician education and training program attended an ASHP-ACPE "New and Prospective Pharmacy Technician Educational and Training Program Directors and Preceptors" session at the ASHP Midyear Clinical Meeting held each December and the Pharmacy Technician Educators Council meeting in July.
 - The program director conducted an evaluation of this program using the "Pre-survey Questionnaire and Self-Assessment Checklist for the Accreditation of a Pharmacy Technician Education and Training Program" to see that the program meets the accreditation Standard and ASHP Best Practices in (month/year) 1/2016. (Submission of this document is not required until 45 days prior to the on-site accreditation survey visit.)
 - The Program Director has completed the R U Ready tool (month/year) 1/13/2016
9. The last pharmacy technician student to complete this residency graduated (mo/yr) 6/2016 projected
10. The current pharmacy technician students began this program in (month/year): 8/2015.
How many students currently? 444

Having read and understood the above application form, the Terms and Required Information, and the Regulations and applicable Standard for accreditation, the Organization agrees to the requirements outlined, and certifies that the responses provided in the application are correct and accurate.

Pharmacy Technician Education and Training Program

Director's Information:

Name: KEITH M. BINION

Title: PROGRAM DIRECTOR

Phone: (734) 743-1983 x142
(800) 734-1175

Fax: _____

E-Mail: kbinion@medcerts.com

Keith M. Binion

Signature, Pharmacy Technician Education and Training Program Director

Chief Executive Officer's Information:

(if College sponsored, Dean or President of College):

Name: MICHAEL COLVIN

Title: PRESIDENT

Phone: 734-418-6227

E-Mail: MCOLVIN@MEDCERTS.COM

Michael Colvin

Signature, Chief Executive Officer
(If CEO's or Dean's address is different from the Organization's please supply.)

DATE SUBMITTED: _____

Senior Administrator's or Manager's Information:

(if College sponsored, individual to whom the Program Director reports):

Name: Dana Janssen

Title: Director

Phone: 734-437-5450

Fax: _____

E-Mail: djanssen@medcerts.com

Dana Janssen

Signature, Senior Administrator or Manager

ASHP-ACPE Use Only:

Program Code: _____

ID Number: _____

Date Received: _____



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Assistant Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.




LOUISIANA
BOARD *of*
PHARMACY

PRESCRIPTION MONITORING PROGRAM (PMP)

BOARD MEETING – FEBRUARY 21, 2018

NUMBER OF ELIGIBLE PRESCRIPTION TRANSACTIONS REPORTED TO THE PMP

Total Reported: 117,504,704
(06/01/2008 through 12/31/2017)



Rx DISPENSING ACTIVITY



Yrly Prescriptions / Capita
2.633

Quick Slicers:



2013

2014

2015

2016

2017

2018



Prescriptions
11,934,319



Quantity
658,231,157




Days Supply
278,212,391



Total Opioid MME
3,412,425,529
*Excluding Buprenorphine

YoY Prescriptions (#)




YoY Prescriptions (#) by Drug Schedule

Schedule	Year	Quantity
Schedule 2	2017	5,475,198
Schedule 3	2017	737,400
Schedule 4	2017	4,812,289
Schedule 5	2017	590,428
Unspecified	2017	319,004


YoY Prescriptions (#) by Drug Classes

Drug Class	Year	Quantity
Opioid	2017	4,972,776
Other	2017	3,529,837
Benzo	2017	2,591,713
Anxiolytic, Hypnotics, Se..	2017	839,993


% Prescriptions > 90 MME vs. All




Patient Demographic Environment



New vs. Refill Prescriptions (%)



Opioids vs. Non Opioids (%)



Rx DISPENSING ACTIVITY



Yrly Prescriptions / Capita
2.668

Quick Slicers:



2013 2014 2015 **2016** 2017 2018



Prescriptions
24,183,450



Quantity
1,344,599,935




Days Supply
562,702,171



Total Opioid MME
7,308,650,335
*Excluding Buprenorphine

YoY Prescriptions (#)




YoY Prescriptions (#) by Drug Schedule

Schedule	2016	2017
Schedule 2	5,661,992	5,475,621
Schedule 3	735,235	737,547
Schedule 4	4,994,311	4,812,926
Schedule 5	574,131	590,504
Unspecified	282,127	319,056


YoY Prescriptions (#) by Drug Classes

Class	2016	2017
Opioid	5,321,232	4,973,084
Other	3,392,794	3,530,387
Benzo	2,666,644	2,592,072
Anxiolytic, Hypnotics, Sedatives	867,126	840,111


% Prescriptions > 90 MME vs. All




Patient Demographic Environment



New vs. Refill Prescriptions (%)



Opioids vs. Non Opioids (%)



Rx VOLUME BY GENERIC NAME

Prescriptions **11,934,319**
 Opioids **41.67%** Non-Opioids **58.33%**



Quick Filters:

Year

Month



Drug Schedule

Drug Class (AHFS)

Top Ranking **CDS** for 2017 by the **Number of Prescriptions**, Generic Name



EACH (TABLETS, KITS, ETC.)
92.63%

MILLILITERS (LIQUIDS)
6.24%

GRAMS (SOLIDS)
0.77%

Unspecified
0.37%

Measure

Listing by Drug Generic Name (#)

Drug Generic Name	Drug AHFS Class Desc	Prescriptions (#)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	OPIATE AGONISTS	2,187,230
ALPRAZOLAM	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	1,044,946
DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-AS..	AMPHETAMINES	991,238
TRAMADOL HCL	OPIATE AGONISTS	941,210
OXYCODONE HCL/ACETAMINOPHEN	OPIATE AGONISTS	692,401
ZOLPIDEM TARTRATE	ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC.	680,059
CLONAZEPAM	BENZODIAZEPINES (ANTICONVULSANTS)	625,787
LISDEXAMFETAMINE DIMESYLATE	AMPHETAMINES	465,168
LORAZEPAM	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	350,311
METHYLPHENIDATE HCL	RESPIRATORY AND CNS STIMULANTS	302,935
DIAZEPAM	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	291,197
PHENTERMINE HCL	AMPHETAMINE DERIVATIVES	238,594
OXYCODONE HCL	OPIATE AGONISTS	233,479

Rx VOLUME BY GENERIC NAME

Quick Filters:



Prescriptions
11,934,319

Opioids
41.67%

Non-Opioids
58.33%



Year

Month



Drug Schedule

Drug Class (AHFS)

Top Ranking **CDS** for 2017 by the **Number of Dosage Units**, Generic Name



EACH (TABLETS, KITS, ETC.)

84.53%

MILLILITERS (LIQUIDS)

14.57%

GRAMS (SOLIDS)

0.65%

Unspecified

0.25%

Measure

Listing by Drug Generic Name (#)

Drug Generic Name	Drug AHFS Class Desc	Quantity (#)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	OPIATE AGONISTS	126,080,836
TRAMADOL HCL	OPIATE AGONISTS	60,908,937
ALPRAZOLAM	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	58,293,828
DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-AS..	AMPHETAMINES	44,893,873
OXYCODONE HCL/ACETAMINOPHEN	OPIATE AGONISTS	43,400,015
CLONAZEPAM	BENZODIAZEPINES (ANTICONVULSANTS)	33,758,714
CODEINE PHOSPHATE/GUAIFENESIN	ANTITUSSIVES	22,186,869
OXYCODONE HCL	OPIATE AGONISTS	21,686,481
ZOLPIDEM TARTRATE	ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC.	21,513,960
PROMETHAZINE HCL/CODEINE	ANTITUSSIVES	18,158,937
LORAZEPAM	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	16,291,795
PREGABALIN	ANTICONVULSANTS, MISCELLANEOUS	15,174,217

Rx VOLUME BY GENERIC NAME

Quick Filters:

Year

Month



Prescriptions
4,972,776

Opioids
100.00%



Drug Schedule

Drug Class (AHFS)

Top Ranking Opioids for 2017 by the Number of Prescriptions, Generic Name



EACH (TABLETS, KITS, ETC.)

97.39%

MILLILITERS (LIQUIDS)

2.47%

GRAMS (SOLIDS)

0.14%

Measure

Listing by Drug Generic Name (#)

Drug Generic Name	Drug AHFS Class Desc	Prescriptions (#)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	OPIATE AGONISTS	2,187,230
TRAMADOL HCL	OPIATE AGONISTS	941,210
OXYCODONE HCL/ACETAMINOPHEN	OPIATE AGONISTS	692,401
OXYCODONE HCL	OPIATE AGONISTS	233,479
BUPRENORPHINE HCL/NALOXONE HCL	OPIATE PARTIAL AGONISTS	213,916
ACETAMINOPHEN WITH CODEINE PHOSPHATE	OPIATE AGONISTS	202,944
MORPHINE SULFATE	OPIATE AGONISTS	151,200
FENTANYL	OPIATE AGONISTS	74,613
BUPRENORPHINE HCL	OPIATE PARTIAL AGONISTS	63,154
METHADONE HCL	OPIATE AGONISTS	33,995
HYDROMORPHONE HCL	OPIATE AGONISTS	31,577
TRAMADOL HCL/ACETAMINOPHEN	OPIATE AGONISTS	30,576
OXYMORPHONE HCL	OPIATE AGONISTS	22,089

Rx VOLUME BY GENERIC NAME



Prescriptions
4,972,776

Opioids
100.00%



Quick Filters:

Year:

Month:



Drug Schedule

Drug Class (AHFS)

Top Ranking Opioids for 2017 by the Number of Dosage Units, Generic Name



EACH (TABLETS, KITS, ETC.)
94.37%

MILLILITERS (LIQUIDS)
5.57%

GRAMS (SOLIDS)
0.06%

Measure

Listing by Drug Generic Name (#)

Drug Generic Name	Drug AHFS Class Desc	Quantity (#)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	OPIATE AGONISTS	126,080,836
TRAMADOL HCL	OPIATE AGONISTS	60,908,937
OXYCODONE HCL/ACETAMINOPHEN	OPIATE AGONISTS	43,400,015
OXYCODONE HCL	OPIATE AGONISTS	21,686,481
ACETAMINOPHEN WITH CODEINE PHOSPHATE	OPIATE AGONISTS	10,004,308
MORPHINE SULFATE	OPIATE AGONISTS	8,596,300
BUPRENORPHINE HCL/NALOXONE HCL	OPIATE PARTIAL AGONISTS	7,725,901
METHADONE HCL	OPIATE AGONISTS	4,076,625
BUPRENORPHINE HCL	OPIATE PARTIAL AGONISTS	2,211,271
HYDROMORPHONE HCL	OPIATE AGONISTS	2,076,794
TRAMADOL HCL/ACETAMINOPHEN	OPIATE AGONISTS	1,820,560
OXYMORPHONE HCL	OPIATE AGONISTS	1,463,531
FENTANYL	OPIATE AGONISTS	777,158

Rx VOLUME BY LABEL NAME

Quick Filters:

Year

Month



Prescriptions
11,934,319

Opioids
41.67%

Non-Opioids
58.33%

Drug Schedule

Drug Class (AHFS)

Top Ranking **CDS** for 2017 by the
Number of Prescriptions, Label Name



EACH (TABLETS, KITS, ETC.)
92.63%

MILLILITERS (LIQUIDS)
6.24%

GRAMS (SOLIDS)
0.77%

Unspecified
0.37%

Measure

Click to filter the data set

Drug Label Name	Drug AHFS Class Desc	Prescriptions (#)
TRAMADOL HCL 50 MG TABLET	OPIATE AGONISTS	928,214
HYDROCODONE-ACETAMINOPHEN 10-325 TABLET	OPIATE AGONISTS	739,458
ZOLPIDEM TARTRATE 10 MG TABLET	ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC.	490,715
ALPRAZOLAM 0.5 MG TABLET	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	429,159
OXYCODONE-ACETAMINOPHEN 10-325 MG TAB	OPIATE AGONISTS	373,913
HYDROCODONE-ACETAMINOPHEN 7.5-325 TAB	OPIATE AGONISTS	365,071
HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET	OPIATE AGONISTS	331,584
ALPRAZOLAM 1 MG TABLET	BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP)	311,734
HYDROCODONE-ACETAMINOPHEN 10-325 MG TABLET	OPIATE AGONISTS	299,374
CLONAZEPAM 0.5 MG TABLET	BENZODIAZEPINES (ANTICONVULSANTS)	280,334
CLONAZEPAM 1 MG TABLET	BENZODIAZEPINES (ANTICONVULSANTS)	274,657
DEXTROAMP-AMPHETAMIN 20 MG TAB	AMPHETAMINES	229,489
DEXTROAMP-AMPHETAMIN 30 MG TAB	AMPHETAMINES	222,790

Rx YoY PRESCRIPTIONS BY COUNTY

Quick Slicers:



Year

Month



Prescriptions
27,149,515

Opioids
100.00%



Drug Schedule

Drug Class (AHFS)


Number of Opioid Prescriptions by Parish

County Listing by Prescription Count (#)

	2013	2014	2015	2016	2017
LA East Baton Rouge Parish	738,580	707,138	689,105	684,531	644,526
Jefferson Parish	672,039	676,685	665,600	660,542	611,879
Caddo Parish	458,122	476,627	480,669	466,530	441,569
Lafayette Parish	426,604	419,433	400,201	389,058	360,112
Orleans Parish	412,045	389,974	383,703	379,771	323,258
St. Tammany Parish	400,654	382,071	364,235	358,110	342,348
Rapides Parish	280,149	287,036	287,625	274,759	262,130
Calcasieu Parish	244,522	254,473	233,801	228,094	206,059
Ouachita Parish	215,000	220,139	208,841	207,692	205,381
Terrebonne Parish	159,190	143,787	137,086	138,123	128,771
St. Landry Parish	112,756	110,815	104,644	109,402	108,664
Tangipahoa Parish	92,225	100,470	105,045	113,377	109,145
Bossier Parish	89,743	97,029	100,256	108,388	114,872
Lafourche Parish	90,773	94,849	84,954	82,021	78,465
Ascension Parish	72,412	74,162	68,953	71,275	68,602
Iberia Parish	81,226	77,215	65,063	65,833	63,525
Evangeline Parish	59,089	57,539	56,108	54,433	49,808
Lincoln Parish	42,605	42,526	42,793	42,802	35,223
St. Mary Parish	38,907	39,863	35,564	33,739	30,622
St. John the Baptist Parish	30,704	29,361	34,740	39,787	40,048

PRESCRIBER & PHARMACIST SEARCHES (INCLUDES DELEGATES) - 2017


Total for 2017: 3,512,840



PRESCRIBER & PHARMACIST SEARCHES

(01/01/2009 THROUGH 12/31/2017)

Overall Search Total: 13,891,743



PMP User Statistics for 2017Q4 (10/01/2017 through 12/31/2017)

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 12/31/2017)	Number of Providers <u>Approved</u> for PMP Access (as of 12/31/2017)	Number of PMP Searches by Approved Providers During 2017Q4 (Percentage of Total)
Physician (MD, DO)	12,581	6,107	312,551 (34.92%)
Nurse Practitioner (APRN)	2,816	1,774	54,515 (6.09%)
Dentist (DDS)	2,144	1,088	2,534 (0.28%)
Physician Assistant (PA)	736	336	13,288 (1.48%)
Optometrist (OD)	344	22	1
Podiatrist (DPM)	154	56	172 (0.01%)
Medical Psychologist (MP)	91	67	4,571 (0.51%)
Prescriber's Delegate	NA	1,695	181,871 (20.32%)
Pharmacist (PST)	8,809	3,922	289,498 (32.35%)
Pharmacist's Delegate	NA	617	35,922 (4.01%)
Totals	27,675	15,684	894,923

PMP User Statistics for 2017Q3 (07/01/2017 through 09/30/2017)

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 09/30/2017)	Number of Providers <u>Approved</u> for PMP Access (as of 09/30/2017)	Number of PMP Searches by Approved Providers During 2017Q3 (Percentage of Total)
Physician (MD, DO)	12,485	4,584	323,080 (35.30%)
Nurse Practitioner (APRN)	2,745	1,392	53,668 (5.86%)
Dentist (DDS)	2,120	565	1,718 (0.19%)
Physician Assistant (PA)	728	305	12,856 (1.40%)
Optometrist (OD)	345	12	0
Podiatrist (DPM)	153	34	108 (0.01%)
Medical Psychologist (MP)	89	67	4,825 (0.53%)
Prescriber's Delegate	NA	1,505	174,228 (19.04%)
Pharmacist (PST)	8,778	3,835	305,662 (33.40%)
Pharmacist's Delegate	NA	571	38,992 (4.26%)
Totals	27,443	12,870	915,137

PMP User Statistics for 2017Q2 (04/01/2017 through 06/30/2017)

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 06/30/2017)	Number of Providers <u>Approved</u> for PMP Access (as of 06/30/2017)	Number of PMP Searches by Approved Providers During 2017Q2 (Percentage of Total)
Physician (MD, DO)	12,482	4,528	308,932 (35.27%)
Nurse Practitioner (APRN)	2,595	1,326	48,838 (5.58%)
Dentist (DDS)	2,119	557	1,770 (0.20%)
Physician Assistant (PA)	721	287	11,913 (1.36%)
Optometrist (OD)	338	13	0
Podiatrist (DPM)	151	34	118 (0.01%)
Medical Psychologist (MP)	87	65	3,022 (0.34%)
Prescriber's Delegate	NA	1,284	160,675 (18.34%)
Pharmacist (PST)	8,577	3,721	302,883 (34.58%)
Pharmacist's Delegate	NA	484	37,841 (4.32%)
Totals	27,070	12,299	875,992

PMP User Statistics for 2017Q1 (01/01/2017 through 03/31/2017)

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 03/31/2017)	Number of Providers <u>Approved</u> for PMP Access (as of 03/31/2017)	Number of PMP Searches by Approved Providers During 2017Q1 (Percentage of Total)
Physician (MD, DO)	12,436	4,438	292,292 (35.35%)
Nurse Practitioner (APRN)	2,532	1,263	46,864 (5.67%)
Dentist (DDS)	2,116	541	1,598 (0.19%)
Physician Assistant (PA)	705	270	12,357 (1.49%)
Optometrist (OD)	339	13	0
Podiatrist (DPM)	150	34	175 (0.02%)
Medical Psychologist (MP)	85	59	2,490 (0.30%)
Prescriber's Delegate	NA	1,590	156,137 (18.88%)
Pharmacist (PST)	8,499	3,666	288,130 (34.85%)
Pharmacist's Delegate	NA	560	26,745 (3.23%)
Totals	26,862	12,434	826,788


LAW ENFORCEMENT REQUESTS

Total Number of Law Enforcement
Requests Processed: 8,695
01/01/2009 through 12/31/2017



Total PMPi Requests for 2017 = 829,412

PMP Interconnect Requests from Louisiana





Time Period

Last 6 months



Disclosing State: Louisiana PDMP Integration Request/Responses by Licensee

Licensee	August 2017	September 2017	October 2017	November 2017	December 2017
Kroger	9,556	9,076	9,812	9,827	10,192
Ochsner Health System			176,780	279,014	260,523
Total	9,556	9,076	186,592	288,841	270,715

Kroger Total Requests for 2017 = 111,628

Ochsner Health System Request for 2017 = 716,317

Originating State

Louisiana

Role Group

(All)

Request Type

(Multiple values)

Response Type

(All)

Requests for Full Exemption from PMP Reporting

February 21, 2018

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
4	HOS	Acadia St. Landry Hospital Pharmacy	In-Patient Hospital Pharmacy	Yes	Church Point	LA
6234	NR	Central Avenue Pharmacy	Non-Sterile Compounding	Yes	Pacific Grove	CA
7544	HOS	CHRISTUS Lake Area Hospital	In-Patient Hospital Pharmacy	Yes	Lake Charles	LA
6719	NR	Coastal Meds	Outsourcing Facility	Yes	Biloxi	MS
5327	NR	CVS Caremark #1638	Non-Resident Pharmacy	No	Pittsburg	PA
7364	NR	CVS/Specialty	Non-Resident Pharmacy	No	Chandler	AZ
7517	NR	Edgepark Medical Supplies	Medical Supplies	Yes	Twinsburg	OH
7553	NR	Humana Pharmacy, Inc.	Specialty Pharmacy	Yes	Miramar	FL
7369	NR	Imperial Beach Pharmacy	Specialty Pharmacy	Yes	Imperial Beach	CA
7571	NR	Janus Rx	Remote Data Entry	Yes	Virginia Beach	VA
7546	IR	JenCare Senior Pharmacy - Metairie	Retail Pharmacy	No	Metairie	LA
5829	NR	Kroger Specialty Pharmacy FL	Non-Resident Pharmacy	Yes	Lake Mary	FL
5747	NR	Kroger Specialty Pharmacy, Inc.	Non-Resident Pharmacy	Yes	Vicksburg	MS
7564	IR	Midcity Pharmacy	Non control drugs	Yes	Baton Rouge	LA
7549	NR	Mint Pharmacy and Skin Clinic	Specialty Pharmacy	Yes	Spring	TX
7567	NR	Soleo Health	Non-Resident Pharmacy	Yes	Mobile	AL
7569	NR	Stellar Rx	Specialty Pharmacy	Yes	Avondale	PA
7572	NRN	Triad Isotopes	Nuclear Pharmacy	No	Hattiesburg	MS

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS
CONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy's request for an exemption to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of a hospital pharmacy permit's inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this exemption and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of General Counsel

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 21, 2018

Agenda Item 11-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. Regional & National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

Dec. 7	Inaugural Meeting – Advisory Council on Heroin & Opioid Prevention and Education (HOPE)
Dec. 18	Accreditation Committee – Center for Pharmacy Practice Accreditation (CPPA) [via webinar]
Jan. 10	NABP Workgroup on International Membership – Mt Prospect, IL
Jan. 18	.Pharmacy Executive Board [via webinar]

2. **Reports**

A. Internal Reports (posted in Boardroom Library)

1. Census – Compliance Division – Practitioner Recovery Program & Discipline
2. Census – Credentials Division – CDS & Pharmacy Programs
3. Credentials Division – Licensure Activity Report
4. Credentials Division – Application Activity Report
5. Credentials Division – Exceptions Report

B. External Reports

Since the last Board meeting, we have filed the following reports on your behalf:

1. La. Div. of Administration – Boards & Commissions
 - a. Monthly Report of Member Per Diem
 - b. Quarterly Report of Member Expense Reimbursements
2. La. Div. of Administration – Property Assistance Agency
 - a. Monthly Agency Fleet Mileage Report
3. La. Div. of Administration – Office of Risk Management
 - a. Monthly Loss Claims Report
 - b. Monthly Report re Transitional Return to Work
 - c. Quarterly Risk Exposure Report
 - d. Quarterly Property Safety & Maintenance Inspections
4. La. Div. of Administration – Office of Statewide Reporting & Accounting Policy
 - a. Quarterly Report of Accounts Receivable
5. La. Dept. of Health – Bureau of Health Services Financing
 - a. Monthly Report of Pharmacy Openings & Closures

6. La. Dept. of Justice – Office of the Attorney General
 - a. Quarterly Report of Private Legal Fees Paid
7. La. Dept. of Revenue
 - a. Quarterly Employer’s Return of State Withholding Tax
8. La. Dept. of Civil Service
 - a. Payroll Comparison Report
9. La. Dept. of Treasury – Cash Management Review Board
 - a. Quarterly Report of Agency Bank Accounts
10. La. State Employees Retirement System
 - a. Monthly Report of Employer & Employee Contributions
11. La. Workforce Commission
 - a. Quarterly Report of Employer’s Unemployment Tax
12. La. Legislative Auditor
 - a. Comprehensive Budget for FY 18-19
13. La. House of Representatives
 - a. Cmte on Commerce – Act 262 Report for Calendar Year 2017
 - b. Cmte on Health & Welfare – Comprehensive Budget for FY 18-19
 - c. Cmte on Health & Welfare – Annual Report on Rulemaking Activities
14. La. Senate
 - a. Cmte on Health & Welfare – Comprehensive Budget for FY 18-19
 - b. Cmte on Health & Welfare – Annual Report on Rulemaking Activities
 - c. Cmte on Senate & Governmental Affairs – Annual Boards & Commissions Update
15. Joint Legislative Committee on the Budget
 - a. Comprehensive Budget for FY 18-19
16. Legislative Fiscal Office
 - a. Comprehensive Budget for FY 18-19
17. U.S. Dept. of Health & Human Services – Office of Public Health
 - a. Quarterly Report to ESAR-VHP
18. U.S. Dept. of Labor – Bureau of Labor Statistics
 - a. Monthly Survey of Current Employment Statistics
19. U. S. Dept. of Treasury – Internal Revenue Service
 - a. Quarterly Employer’s Federal Tax Return

3. Examinations

- A. MPJE – the results for the third trimester of 2017 are available.
- B. NAPLEX – the results for the third trimester of 2017 are available.
- C. PARE – discontinued by NABP 01-31-2018.
- D. PTCB – the results for the second half of 2017 are not yet available.

4. Operations

A. Credentials Division

As of February 12, we had 48,028 active credentials under management by the Board. That number reflects a 6.8% increase from the beginning of the fiscal year on July 1, 2017. Just over half of the credentials (25,618) reside in the Pharmacy Program with the balance in the CDS Program.

We opened the renewal cycle on November 1 for pharmacist licenses, pharmacy permits, and CDS licenses for pharmacies. We mailed reminder notices on October 31 to 8,875 pharmacists, 1,872 pharmacy permit holders, and 1,359 pharmacies with CDS licenses. We held back one notice for a pharmacist due to a defaulted student loan. In addition, we held back notices for 124 pharmacy permit holders; of that number, 12 were due to the absence of a pharmacist-in-charge, 5 were due to the combination of the absence of a pharmacist-in-charge and no inspection within the prior two years, and 107 were due to the absence of an inspection within the prior two years.

- Pharmacists: 8,446 renewed timely, and of that number, 93.9% did so online. We mailed 303 license expiration notices on February 1.
- Pharmacies: 1,904 renewed timely, and of that number, 88.1% did so online. We mailed 59 permit expiration notices on February 1.
- CDS licenses for pharmacies: 1,344 renewed timely, and of that number, 94.3% did so online. We mailed 7 license expiration notices on February 1.

B. Compliance Division

Our 6 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,464 pharmacies within the state, as well as approximately 515 various types of facilities and persons for CDS visits, including hospitals, animal control shelters, researchers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 147 cases pending from the prior fiscal year. We have entered 305 new cases and closed 276, leaving 176 cases still open for the fiscal year. Of the 276 cases closed this fiscal year, 71% were disposed of through staff activities and the balance through committee and Board action.

C. Administrative Division

The Legislative Auditor is still engaged in their performance audit of the Board and the Prescription Monitoring Program.

The office building renovation project is in the early stage. The bidders' conference is scheduled for March 13. They will tour the office building to see the current condition and review the requested renovations prior to submitting their project bids to the state.

5. State Activities

A. La. Legislature

The First Extraordinary Session of the 2018 Legislature convened on February 19 and is scheduled to adjourn no later than March 7. The Governor's Call for the Special Session included 19 items, with a primary focus on fiscal matters.

The Regular Session of the 2018 Legislature is scheduled to convene on March 12 and to adjourn no later than June 4. A copy of the initial legislative report was posted in the Boardroom Library.

B. La. State Board of Medical Examiners

The agency published a *Notice of Intent* in the December 2017 edition of the Louisiana Register, amending their rules on continuing medical education for renewal of licensure for all of their licensees with statutory authority to prescribe controlled dangerous substances. The amended rule will require the licensee to acquire three hours of CME during Calendar Year 2018 relative to drug diversion training, best practices for prescribing of controlled substances, appropriate treatment for addiction, and for physicians, the treatment of chronic pain. The deadline for comments was January 24, 2018. We will advise you of the status of that regulatory project.

6. Regional & National Activities

A. National Association of Boards of Pharmacy (NABP)

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

NABP will hold its 114th Annual Meeting on May 5-8, 2018 at the Hyatt Regency Denver at Colorado Convention Center in Denver, CO. Online registration is now available at www.NABPAnnualMeeting.pharmacy. The registration fee is \$450; however, a \$25 discount is available for registrations completed by **Friday, March 30, 2018**.

For your travel planning purposes, the first CE session is scheduled for 1:30 pm on Saturday, May 5, and the last event is the Awards Dinner which concludes at 9:00 pm on Tuesday, May 8. For those of you intending to travel by air, please remember your tickets must be purchased from the state-contracted travel agent at www.ShortzTravel.com/LA. NABP has secured a conference rate at the Hyatt Regency Denver at Colorado Convention Center of \$119 + 15.75% tax per night, for double or single occupancy. To ensure the conference rate, reservations must be completed by **Wednesday, April 4, 2018**. You may secure your hotel reservation by telephone at 1.800.233.1234 and identifying yourself as a participant at NABP's 114th Annual Meeting, or in the alternative, by accessing the online portal available for this conference at <https://aws.passkey.com/event/49114906/owner/21829/home>.

NABP has distributed the preliminary report of resolutions received from the district meetings last fall. These resolutions will be reviewed by the Resolutions Committee during the Annual Meeting in Denver, and will then be considered by the delegates voting during that meeting. We encourage your review of these items so that you can inform your delegate how the Louisiana Board should vote. A copy of the report was posted in the Boardroom Library.

B. NABP-AACP District 6

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49. For your planning purposes, the 2018 meeting will be held October 14-17 at the Westin Crown Center in Kansas City, MO. Districts 7 and 8 will be joining District 6 for that meeting.

C. MALTAGON

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

For your planning purposes, the 2018 conference will be held October 11-14 at the Westin Crown Center in Kansas City, MO.

7. ***International Activities***

A. International Pharmaceutical Federation (FIP)

For your planning purposes, the 2018 congress will be held Sep. 2-6 in Glasgow, Scotland. Online registration is now available at <https://www.fip.org/glasgow2018>. Registration fees are discounted for registrations completed prior to May 15.

The educational offerings include plenary sessions, platform presentations and poster sessions, all within the four primary topics for the congress:

Topic A – From bench to bedside – advancing pharmaceutical care

This topic focuses on new technologies and approaches to achieve individualized therapy, including emerging ethical dimensions associated with their implementation.

Advancements in drug discovery, formulation, compounding, delivery systems and mathematical modeling can be used to translate such innovations into better outcomes in populations and individual patients.

Topic B – Partners in health

This topic recognizes that pharmacists and pharmaceutical scientists cannot operate in a vacuum if the goal is to transform patient outcomes. New collaborative practices, research and educational models are needed among traditional health care professionals, but also must be expanded to include members.

Topic C – Empowered for health

The main emphasis of this topic is training and leadership development of the current and next generation of pharmacy and pharmaceutical science practitioners. Efforts under this topic include innovations in disseminating new knowledge through the identification of key competencies or skill sets, along with outstanding approaches to effective and ethical communication, to enable life-long learning. The transformation of patient outcomes can

only be achieved with a strong pharmaceutical care workforce empowered to develop and implement the latest advancements in *pharmacy and pharmaceutical sciences*.

Topic D – Targeting special interests

This topic will target special interests in the different fields of pharmacy and pharmaceutical sciences.

B. .Pharmacy Verified Websites Program

.Pharmacy is a generic top level domain (gTLD) on the Internet. Although it is owned by NABP, the .Pharmacy domain is governed by a global collaboration including the International Pharmaceutical Federation (FIP) and the National Association of Pharmacy Regulatory Authorities (NAPRA – Canada) and endorsed by multiple global partners, including the World Health Organization (WHO), Interpol, and the Pharmaceutical Group of the European Union (PGEU). .Pharmacy is different from most TLDs in that authority to host a website on .Pharmacy is restricted to applicants whose legitimacy has been verified by NABP or one of its global partners. The vision for .Pharmacy is to create an online pharmacy community where patients can go to safely order prescription drugs, knowing the sites have already been verified as legitimate pharmacies, licensed by the appropriate pharmacy regulatory authority. In addition to pharmacies, the plan is to create a presence for a number of related organizations, including professional membership organizations, colleges of pharmacy, boards of pharmacy, drug manufacturers, and consumer-oriented drug information organizations. .Pharmacy began accepting applications for website registrations in June 2015.

By January 2018, there were 505 registered domains, 389 of which were held by pharmacy organizations representing approximately 49% of the physical pharmacy locations in the U.S. Although most of the domains are based in the U.S., 35 domains are based in Canada, 2 from the Netherlands, and one each from Germany, Japan, and the United Kingdom. More information, including a list of registered domains, is available at www.safe.pharmacy.

C. World Health Professions Alliance (WHPA)

The alliance will convene its 5th International Conference on the Regulation of Health Professions on May 19-20 in Geneva, Switzerland. This conference will immediately precede the World Health Organization's (WHO) World Health Assembly in Geneva. Online registration is now available at www.whpa.org/whpcr2018/registration. The deadline for a discounted registration fee has passed, and online registrations will close on May 15.

With the overall theme of *Facing Challenges to Acting in the Public Interest*, presentations will address three primary topics: (1) a call to set the right standards in regulation, (2) safety, quality and compliance – benefiting patients, communities, and populations, and (3) supporting the quality of lifelong learning.

Respectfully submitted,
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Compliance Division Census Report

February 21, 2018

Practitioner Recovery Program

- Probation Completion Report

(None since last Board meeting)

- Active Probation 44 Pharmacist
 1 Pharmacy intern
 6 Technician
- Active Suspension 38 Pharmacist
 2 Pharmacy intern
 16 Technician
 4 Technician candidate

Disciplinary Restrictions

- Probation Completion Report

12-14-2017	DME.000217	Orthofix
12-28-2017	PST.017495	Christina Marshall Buhrman
01-25-2018	PHY.004944	Sterling Pharmacy
02-25-2018	PST.019770	Mehrdad Hariri

- Active Probation 11 Pharmacist
 1 Pharmacy intern
 5 Technician
 2 Technician candidate
 5 Pharmacy permit
 1 CDS-PHY license
- Active Suspension 54 Pharmacist
 1 Pharmacy intern
 78 Technician
 19 Technician candidate
 12 Pharmacy permit
 4 CDS-PHY license
 81 CDS license for practitioners

Louisiana Board of Pharmacy
 Credentials Division
 Pharmacy Program

		06/30/08	06/30/09	06/30/10	06/30/11	06/30/12	06/30/13	06/30/14	06/30/15	06/30/16	06/30/17	02/12/18
PST-VI	LA	0	0	0	12	10	9	9	13	16	18	14
	NR	0	0	0	9	10	15	14	15	16	24	20
	Total	0	0	0	21	20	24	23	28	32	42	34
PST-GVI	LA	0	0	0	0	6	13	13	12	15	26	23
	NR	0	0	0	0	0	3	5	5	5	10	7
	Total	0	0	0	0	6	16	18	17	20	36	30
PST-M	LA	0	0	0	3	5	3	1	2	1	0	0
	NR	0	0	0	11	11	11	13	10	10	9	8
	Total	0	0	0	14	16	14	14	12	11	9	8
PST-G	LA	0	0	0	158	157	164	166	186	204	216	185
	NR	0	0	0	30	35	32	31	31	35	30	25
	Total	0	0	0	188	192	196	197	217	239	246	210
PST	LA	4,612	4,750	4,860	4,654	4,933	4,981	5,140	5,408	5,304	5,372	5,477
	NR	1,964	2,029	2,098	2,079	2,212	2,527	2,479	2,471	2,835	2,950	2,911
	Total	6,576	6,779	6,958	6,733	7,145	7,508	7,619	7,879	8,139	8,322	8,388
	PST	6,576	6,779	6,958	6,935	7,353	7,758	7,871	8,108	8,441	8,655	8,670
PNT	LA	1,074	1,035	965	907	938	942	948	952	957	946	958
	NR	67	84	153	137	128	128	127	143	127	145	147
	Total	1,141	1,119	1,118	1,044	1,066	1,070	1,075	1,095	1,084	1,091	1,105
PNT-FPG	Total	0	0	0	5	0	3	6	2	4	3	5
PNT	1,141	1,119	1,118	1,049	1,066	1,073	1,081	1,097	1,088	1,094	1,110	
CPT	LA	4,780	4,733	5,363	5,720	5,509	5,751	6,463	6,584	6,815	6,418	6,889
	NR	144	109	144	145	120	112	138	141	152	141	170
	Total	4,924	4,842	5,507	5,865	5,629	5,863	6,601	6,725	6,967	6,559	7,059
CPT-M	Total	0	0	0	1	0	1	2	1	2	2	2
CPT	4,924	4,842	5,507	5,866	5,629	5,864	6,603	6,726	6,969	6,561	7,061	
PTC	LA	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,929	1,813	1,971	2,030
	NR	23	32	35	35	39	37	37	52	48	54	71
	PTC	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,981	1,861	2,025	2,101
PHY	CH	11	12	14	12	12	12	12	12	12	11	10
	HOS	167	167	165	151	154	158	164	163	160	163	162
	HOX	0	0	0	19	18	14	11	8	7	6	6
	IN	37	37	27	14	10	12	12	11	11	12	12
	INX	0	0	0	11	14	13	11	10	10	11	12
	IR	588	592	587	570	568	558	583	588	576	577	584
	IRX	0	0	0	21	19	17	10	10	7	6	6
	NR	250	256	286	318	361	387	422	473	513	515	494
	NRN	0	0	0	0	0	0	9	9	8	7	8
	NRP	0	0	0	0	0	0	1	2	2	2	2
	NU	16	16	16	15	15	15	15	14	15	14	13
	PEN	0	0	0	0	0	0	0	0	0	0	0
	PEX	0	0	0	0	0	1	2	2	2	2	2
	SAT	0	0	0	0	0	0	1	3	6	6	6
	RC	534	545	562	576	587	597	619	649	671	651	650
	RPP											
PHY	1,603	1,625	1,657	1,707	1,758	1,784	1,872	1,954	2,000	1,983	1,968	
AMS	AMS	255	306	361	55	64	349	92	456	113	104	118
	AMS-X	0	0	0	301	302	289	359	356	367	335	376
	AMS	255	306	361	356	366	638	451	812	480	439	494
EDK	EDK	439	388	503	417	435	421	464	474	454	402	434
	EDK-X	0	0	0	13	13	10	10	10	10	9	11
	EDK	439	388	503	430	448	431	474	484	464	411	445
DME	LA					223	160	209	336	345	346	329
	NR						218	281	267	287	291	283
	DME						378	490	603	622	637	612
CDTM						41	41	52	59	66	68	
MAR						1,617	2,037	2,383	2,603	2,820	2,981	
PMP												
SWP				58	78	126	38	54	48	48	47	
TM											61	
TOTAL							21,405	22,865	24,254	24,635	24,766	25,618

Louisiana Board of Pharmacy
 Credentials Division
 CDS Program

<i>Classification</i>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>06/30/14</u>	<u>06/30/15</u>	<u>06/30/16</u>	<u>06/30/17</u>	<u>02/12/18</u>
AMS Automated Medication Sys	0	0	0	0	0	26	29	22	28	34
AMX Automated Medication Sys - Exempt	0	0	0	0	0	2	1	0	0	2
APN APRN	607	758	889	1,015	1,103	1,479	1,954	2,296	2,343	2,842
DDS Dentist	2,267	2,363	2,027	2,048	1,902	2,123	2,133	2,134	1,929	2,153
DET Drug Detection / Canine	20	22	14	12	10	11	11	9	8	9
DEX Drug Detection / Canine - Exempt						1	1	0	0	
DIS Distributor	363	400	279	288	273	324	319	301	284	290
DPM Podiatrist	161	165	139	136	118	133	142	152	136	154
DVM Veterinarian	1,000	1,065	922	901	852	1,002	1,045	1,085	1,007	1,223
ETC Animal Euthanasia Tech - Cert	44	49	16	7	6	6	5	5	1	3
ETL Animal Euthanasia Tech - Lead	0	0	12	20	21	23	23	22	24	25
HOS Hospital	405	438	280	267	263	272	271	289	278	298
HOX Hospital - Exempt	0	0	12	14	5	6	6	5	5	5
LAB Laboratory	14	15	8	6	7	8	8	8	7	8
LAX Laboratory - Exempt	0	0	4	5	5	5	5	4	4	4
MD Physician	14,599	15,269	12,362	11,727	10,698	11,913	12,124	12,360	11,575	12,646
MFR Manufacturer	52	58	48	50	45	42	42	37	38	46
MP Medical Psychologist	50	58	65	67	69	78	82	86	84	93
OD Optometrist	269	278	275	287	279	309	316	326	297	349
PA Physician Assistant	232	272	294	326	344	449	487	610	667	748
PHX Pharmacy - Exempt	0	0	50	47	41	30	24	21	20	20
PHY Pharmacy	0	0	1,307	1,318	1,329	1,357	1,379	1,367	1,339	1,331
REP Sales Representative	66	88	29	20	7	0	0	0	0	0
RES Researcher	119	156	109	110	98	113	113	108	100	103
ROF Registered Outsourcing Facility	0	0	0	0	0	0	8	14	13	18
SAC Substance Abuse Clinic	14	17	7	9	9	9	9	7	6	6
SAX Subst. Abuse Clinc - Exempt	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	1	0	0	0
Total	20,282	21,471	19,148	18,680	17,484	19,721	20,538	21,268	20,193	22,410

Total Credentials Under Management

Pharmacy	16,601	17,818	18,260	18,625	21,405	22,865	24,254	24,635	24,766	25,618
CDS	<u>20,698</u>	<u>21,916</u>	<u>19,148</u>	<u>18,680</u>	<u>17,745</u>	<u>20,009</u>	<u>20,809</u>	<u>21,316</u>	<u>20,193</u>	<u>22,410</u>
Total	37,299	39,734	37,408	37,305	39,150	42,874	45,063	45,951	44,959	48,028

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>6/30/1996</u>	<u>3/19/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>	<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>	<u>6/30/2006</u>	<u>6/30/2007</u>
Pharmacists												
In-state	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486	4,532	4,460	4,522
Out-of-state	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484	1,686	1,915	1,975
TOTAL	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970	6,218	6,375	6,497
Pharmacy Interns												
In-state											980	1,079
Out-of-state											109	117
TOTAL						957	976	929	995	1,154	1,089	1,196
Pharmacy Technicians												
In-state											4,552	4,587
Out-of-state											163	152
TOTAL						3,216	3,453	3,505	4,114	4,455	4,715	4,739
Pharmacy Technician Candidates												
In-state											1,081	1,389
Out-of-state											32	32
TOTAL						2,896	2,372	1,336	1,069	1,074	1,113	1,421
Pharmacy Permits												
IR	634	636	609	621	585	584	576	573	633	729	681	620
RC	473	471	493	505	520	528	535	541	555	473	430	491
H	174	171	175	172	171	171	174	179	181	181	167	164
IN	45	38	39	19		17	18	19	27	36	35	36
NU	10	10	9	10		12	14	13	13	13	17	16
CH	4	4	7	4		8	9	11	12	12	12	12
PEN												
OS	152	168	175	216	223	262	313	353	339	200	226	240
PE	104	102	120	102			95	94	0			
CO	12	12	12	12		12	13	13	0			
TOTAL	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760	1,644	1,568	1,579
Equipment Permits												
AMS						0	109	136	158	174	173	212
EDK						468	461	474	444	471	428	412

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>	<u>2/12/2018</u>
AMS Automated Medication System	0	0	0	0	0	28	30	22	28	36
APN Advanced Practice Registered Nurse	607	758	889	1,015	1,103	1,479	1,954	2,296	2,343	2,842
DDS Dentist	2,267	2,363	2,027	2,048	1,902	2,123	2,133	2,134	1,929	2,153
DET Drug Detection Canine	20	22	14	12	10	11	12	9	8	9
DIS Distributor	363	400	279	288	273	324	319	301	284	290
DPM Podiatrist	161	165	139	136	118	133	142	152	136	154
DVM Veterinarian	1,000	1,065	922	901	852	1,002	1,045	1,085	1,007	1,223
ETC Animal Euthanasia Tech - Cert	44	49	28	27	27	29	28	27	25	28
HOS Hospital	405	438	292	281	268	278	277	294	283	303
LAB Analytical Laboratory	14	15	12	11	12	13	13	12	11	12
MD Physician	14,599	15,269	12,362	11,727	10,698	11,913	12,124	12,360	11,575	12,646
MFR Manufacturer	52	58	48	50	45	42	42	37	38	46
MP Medical Psychologist	50	58	65	67	69	78	82	86	84	93
OD Optometrist	269	278	275	287	279	309	316	326	297	349
PA Physician's Assistant	232	272	294	326	344	449	487	610	667	748
PHY Pharmacy	0	0	1357	1,365	1,370	1,387	1,403	1,388	1,359	1,351
RES Researcher	119	156	109	110	98	113	113	108	100	103
ROF Registered Outsourcing Facility	0	0	0	0	0	0	8	14	13	18
SAC Substance Abuse Clinic	<u>14</u>	<u>17</u>	<u>7</u>	<u>9</u>	<u>9</u>	<u>9</u>	<u>10</u>	<u>7</u>	<u>6</u>	<u>6</u>
TOTAL	20,202	21,916	19,119	18,660	17,477	20,009	20,809	21,268	20,193	22,410

Total Credentials Under Board Management

Pharmacy Program	16,601	17,818	18,260	18,625	21,405	22,865	24,254	24,635	24,766	25,618
CDS Program	<u>20,698</u>	<u>21,916</u>	<u>19,119</u>	<u>18,660</u>	<u>17,477</u>	<u>20,009</u>	<u>20,809</u>	<u>21,316</u>	<u>20,193</u>	<u>22,410</u>
TOTAL	37,299	39,734	37,379	37,285	38,882	42,874	45,063	45,951	44,959	48,028

New Credentials Issued
FYE 2018 ~ 2st Quarter
October 1, 2017 - December 31, 2017

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	4
AMS	X	Automated Medication System - Exempt	11
Prefix Totals			15
CDS	AMS	CDS License - Automated Medication System	4
CDS	APN	CDS License - APRN	81
CDS	DDS	CDS License - Dentist	19
CDS	DIS	CDS License - Distributor	3
CDS	DPM	CDS License - Podiatrist	2
CDS	DVM	CDS License - Veterinarian	55
CDS	ETL	CDS License - Animal Euthanasia Technician, Lead (AET-L)	3
CDS	HOS	CDS License - Hospital	10
CDS	MD	CDS License - Physician	111
CDS	MP	CDS License - Medical Psychologist	3
CDS	OD	CDS License - Optometrist	4
CDS	PA	CDS License - Physician Assistant	19
CDS	PHX	CDS License - Pharmacy - Exempt	2
CDS	PHY	CDS License - Pharmacy	14
CDS	ROF	CDS License - Registered Outsourcing Facility	1
Prefix Totals			331
CDTM		Collaborative Drug Therapy Management (V)	2
CPT		Certified Pharmacy Technician	130
DME		Durable Medical Equipment (DME) Provider	17
EDK		Emergency Drug Kit	30
MA		Medication Administration (V)	54
PHY	HOS	Pharmacy - Hospital Inpatient	3
PHY	IR	Pharmacy - Community ~ Independent	13
PHY	NR	Pharmacy - Nonresident	13
PHY	RC	Pharmacy - Community ~ Chain	1
Prefix Totals			30
PIC		Pharmacist-in-Charge (V)	1
PMP	CDS	PMP - CDS Credential (V)	767
PMP	PHY	PMP - PHY Dispenser Account (V)	251
PMP	PST	PMP - Pharmacist (V)	37
Prefix Totals			1055
PNT		Pharmacy Intern	167
PST		Pharmacist	61
PTC		Pharmacy Technician Candidate	397
SWP		Special Work Permit	12
TM	CPT	Therapeutic Marijuana Designation - CPT	1
TM	OMO	Therapeutic Marijuana Designation - OMO	5
TM	PST	Therapeutic Marijuana Designation - PST	2
Prefix Totals			8
Grand Totals			2310

Pending Applications

PHARMACY CREDENTIALS

Prefix	Subcat.	CredentialType	08/03/16	11/07/16	01/13/17	05/03/17	8/16/2017	11/7/2017	2/12/2018
AMS		Automated Medication System	3	3	7	11	13	14	5
CPT		Certified Pharmacy Technician	54	53	41	48	30	26	44
DME		Durable Medical Equipment	27	23	23	18	23	20	20
EDK		Emergency Drug Kit					7	3	4
PHY	CH	Pharmacy - Charitable							
PHY	HOS	Pharmacy - Hospital Inpatient	3	6	7	7	9	6	4
PHY	IN	Pharmacy - Institutional		1					
PHY	IR	Pharmacy - Community ~ Independent	16	20	21	21	23	32	32
PHY	NR	Pharmacy - Nonresident	89	89	94	67	92	94	84
PHY	NRN	Pharmacy - Nonresident Nuclear					2	3	2
PHY	NU	Pharmacy - Nuclear							
PHY	PEN	Pharmacy - Penal							3
PHY	RC	Pharmacy - Community ~ Chain	4		3	1		2	176
PHY	RPP	Pharmacy - Remote Processor			1	1			
PHY	SAT	Pharmacy - Hospital Off-Site Satellite							
PHY	TM	Pharmacy - Therapeutic Marijuana						40	34
PIC		Pharmacist-in-Charge	1	1	1				
PNT	FPG	Pharmacy Intern - Foreign Graduate	1	2	3	3	4	1	
PNT		Pharmacy Intern	58	101	89	43	65	66	44
PST		Pharmacist	419	294	272	282	374	316	297
PTC		Pharmacy Technician Candidate	346	480	515	405	502	395	338
Subtotal			1021	1073	1077	907	1144	1018	1087

CDS CREDENTIALS

Prefix	Subcat.	CredentialType	08/03/16	11/07/16	01/13/17	05/03/17	8/16/2017	11/7/2017	2/12/2018
CDS	AMS	CDS - Automated Medication System						2	2
CDS	APN	CDS - APRN	6	7	7	12	12	13	12
CDS	DDS	CDS - Dentist	1			1	1	4	1
CDS	DET	CDS - Drug Detection / Canine			2	2	3	3	4
CDS	DIS	CDS - Distributor	6	10		8	8	4	6
CDS	DPM	CDS - Podiatrist							
CDS	DVM	CDS - Veterinarian		1			2	2	3
CDS	ETC	CDS - Animal Euthanasia Tech, Certified							
CDS	ETL	CDS - Animal Euthanasia Tech, Lead		1	1			2	
CDS	HOS	CDS - Hospital	7	7	11	14	18	14	10
CDS	MD	CDS - Physician	9	10	8	13	19	15	17
CDS	MFR	CDS - Manufacturer		1	1	2	1	1	4
CDS	MP	CDS - Medical Psychologist					1		
CDS	OD	CDS - Optometrist	2	2	2	1	2		
CDS	PA	CDS - Physician Assistant	4	13	6	6	6	4	4
CDS	PHY	CDS - Pharmacy	20	23	25	26	23	30	85
CDS	PHX	CDS - Pharmacy - Exempt						1	
CDS	REP	CDS - Sales Representative							
CDS	RES	CDS - Researcher	6	10	8	8	7	7	9
CDS	ROF	CDS - Registered Outsourcing Facility	3	1	1	1	1	4	1
CDS	SAC	CDS - Substance Abuse Clinic	1						
CDS	TM	CDS - Therapeutic Marijuana						40	34
Subtotal			65	86	72	94	104	146	192

OTHER CREDENTIALS

Prefix	Subcat.	CredentialType	08/03/16	11/07/16	01/13/17	05/03/17	8/16/2017	11/7/2017	2/12/2018
CDTM		Collaborative Drug Therapy Management							
LB		Law Book							
MA		Medication Administration	3	5	10	9	7	4	3
PMP		PMP - CDS Credential	55	34	33	65	266	284	207
PMP		PMP - MIS Credential							
PMP		PMP - PHY Credential						86	
PMP		PMP - PST Credential	7	5	5	70	3	1	4
SWP		Special Work Permit	62	71	52	31	11	10	10
TM	CPT	Therapeutic Marijuana Designation - CPT						3	
TM	OMO	Therapeutic Marijuana Designation - OMO						6	2
TM	PST	Therapeutic Marijuana Designation - PST						18	3
Subtotal			127	115	100	175	287	412	229

TOTAL

1213

1274

1249

1176

1535

1576

1508



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 21, 2018

Agenda Item 11-L: Report of Executive Director

Section 2 – A – 5 ~ Exceptions Report

1. **PIC at Multiple Pharmacies**

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- *(none since last meeting)*

2. **Special Work Permits for military-trained applicants and their spouses**

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- *(none since last meeting)*

3. **Special Work Permits**

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On December 20, 2017, Mr. Aron and Mr. Finalet concurred to grant a request from Cortney Elise Boone. She had previously obtained PTC.021054 which expired on August 19, 2015. She was issued a Special Work Permit for one year to earn 600 hours of practical experience.
- On January 3, 2018, Mr. Aron and Mr. Finalet concurred to grant a request from Christopher Paul Dausat. He had previously obtained PTC.014920 which expired on September 16, 2010. He is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.
- On January 3, 2018, Mr. Aron and Mr. Finalet concurred to grant a request from Laci Jenavet Hudson. She had previously obtained PTC.023885 which expired on October 11, 2017. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.
- On January 15, 2018, Mr. Aron and Mr. Finalet concurred to grant a request from Carla Lawrence Nordquist. She had previously obtained PTC.021233 which expired on September 30, 2015. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.
- On January 16, 2018, Mr. Aron and Mr. Finalet concurred to grant a request from Lan Thuy Le. She had previously obtained PTC.017687 which expired on December 28, 2012. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.
- On January 16, 2018, Mr. Aron and Mr. Finalet concurred to grant a request from Ieshia Rena Coleman. She had previously obtained PTC.024136 which expired on December 13, 2017. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

September 1 – December 31, 2017

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)

February 21, 2018

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the colleges of pharmacy and state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	07
Current Trimester Report for Xavier College of Pharmacy	12
Cumulative Report (since January 2000) for Xavier College of Pharmacy	16



**Multistate Pharmacy Jurisprudence Examination® (MPJE®) School
Summary Report**

University of Louisiana at Monroe

Test Window: September 1, 2017 - December 31, 2017

This MPJE score report provides summary information for first-time examinees from ACPE-accredited schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school, state, and national pass rate information as well as total score means.

MPJE in-state: Examinees taking the MPJE for the same jurisdiction as respective pharmacy program
 MPJE out of state: Examinees testing in different jurisdiction than respective pharmacy program

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
In-state	12	83.33%	78.33	3.65
Out of state	35	97.14%	79.29	2.76
State	124	72.58%	76.88	4.35
National	5424	77.03%	77.52	4.17

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
In-state	29	79.31%	77.17	3.33
Out of state	41	95.12%	79.34	2.98
State	207	70.53%	76.52	3.94
National	8394	74.01%	76.99	4.01

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	62	95
All Candidates	58	95
Scaled Score Range	0	100

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

The following tables and graphs are scaled score frequency distributions for MPJE candidates who tested in-state. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 & Graph 1 School Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 12

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	0	0%
[65,69]	0	0%
[70,74]	2	17%
[75,79]	5	58%
[80,84]	4	92%
[85,89]	1	100%
[90,94]	0	100%
[95,100]	0	100%





Table 5 & Graph 2 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 1171

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	2	0%
[65,69]	46	4%
[70,74]	299	30%
[75,79]	549	77%
[80,84]	254	98%
[85,89]	20	100%
[90,94]	1	100%
[95,100]	0	100%



Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	4	126	87	47	94	30	32	122	39	42	122	56
<i>* testing in same/different state</i>		72 / 54	11 / 34	11 / 36	40 / 54	2 / 28	5 / 27	62 / 60	6 / 33	13 / 29	68 / 54	13 / 43
Mean Scale Score - School *	82.25	82.44/82.70	80.09/79.85	81.45/84.03	82.50/82.59	80.50/82.79	79.40/81.41	81.44/83.32	78.50/81.42	76.85/81.90	81.44/84.13	79.85/83.12
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13	79.81	80.56	80.05
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08	81.32	82.40	80.91
School Pass Rate: *	100.00	97.22/90.74	90.91/85.29	100/97.22	95.00/98.15	100 / 92.86	100 / 85.19	95.16/96.67	83.33/87.88	76.92/93.10	94.12/98.15	84.62/95.35
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69	80.69	88.14	86.55
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50	88.20	93.04	87.78
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	4	124	70	44	93	28	29	119	33	38	120	49
<i>* testing in same/different state</i>		72 / 52	10 / 29	10 / 34	39 / 54	1 / 27	5 / 24	62 / 57	3 / 30	11 / 27	68 / 52	7 / 42
Mean Scaled Score - School *	82.25	82.44/83.02	80.62/79.90	81.80/84.26	82.77/82.59	82.00/83.19	79.40/82.29	81.44/83.58	78.00/81.97	76.91/82.04	81.44/84.40	78.71/83.14
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13	80.63	80.62	80.81
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79	82.14	82.66	81.60
School Pass Rate: *	100.00	97.22/92.31	89.66/90.00	100.00/97.06	97.44/98.15	100 / 96.30	100 / 91.67	95.16/98.25	66.67/90.00	72.73/92.59	94.12/98.08	85.71/95.24
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96	83.61	88.77	91.06
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87	91.72	93.97	90.35

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2016			2017			2018			2019		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	80	143	66	45	147	70						
* <i>testing in same/different state</i>	7 / 73	89 / 54	15 / 51	6 / 39	80 / 67	29 / 41						
Mean Scale Score - School *	80.14/84.04	77.42/79.20	77.67/78.71	74.50/78.67	76.61/80.63	77.17/79.34						
* <i>testing in same/different state</i>												
Mean Scaled Score - State	80.92	77.12	76.91	77.39	76.83	76.52						
Mean Scaled Score - National	81.10	78.08	77.08	77.59	78.16	76.99						
School Pass Rate: *	100 / 98.63	83.15/79.63	73.33/80.39	50.00/94.87	76.25/95.52	79.31/95.12						
* <i>testing in same/different state</i>												
State Pass Rate:	90.23	77.93	75.14	75.57	77.13	70.53						
National Pass Rate:	87.62	82.66	74.77	76.90	83.24	74.01						

ACPE probation eff. 06-24-2017

FIRST-TIME CANDIDATE GROUP

No. of Candidates	76	133	48	40	139	47
* <i>testing in same/different state</i>	7 / 69	84 / 49	6 / 42	4 / 36	73 / 66	12 / 35
Mean Scaled Score - School *	80.14/84.23	77.31/79.41	78.83/79.07	74.75/78.67	76.67/80.65	78.33/79.29
* <i>testing in same/different state</i>						
Mean Scaled Score - State	81.58	77.10	77.33	78.28	77.00	76.88
Mean Scaled Score - National	81.84	78.24	77.61	78.31	78.41	77.52
School Pass Rate: *	100 / 98.55	82.14/77.55	66.67/83.33	50.00/94.44	78.08/95.45	83.33/97.14
* <i>testing in same/different state</i>						
State Pass Rate:	92.79	77.21	77.88	80.85	78.38	72.58
National Pass Rate:	90.71	83.77	78.24	82.10	84.89	77.03



**Multistate Pharmacy Jurisprudence Examination® (MPJE®) School
Summary Report**

Xavier University of Louisiana

Test Window: September 1, 2017 - December 31, 2017

This MPJE score report provides summary information for first-time examinees from ACPE-accredited schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school, state, and national pass rate information as well as total score means.

MPJE in-state: Examinees taking the MPJE for the same jurisdiction as respective pharmacy program
 MPJE out of state: Examinees testing in different jurisdiction than respective pharmacy program

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
In-state	18	66.67%	75.28	3.46
Out of state	61	55.74%	75.41	4.41
State	124	72.58%	76.88	4.35
National	5424	77.03%	77.52	4.17

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
In-state	42	59.52%	75.52	3.07
Out of state	92	53.26%	75.13	4.39
State	207	70.53%	76.52	3.94
National	8394	74.01%	76.99	4.01

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	62	95
All Candidates	58	95
Scaled Score Range	0	100

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

The following tables and graphs are scaled score frequency distributions for MPJE candidates who tested in-state. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 & Graph 1 School Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 18

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	0	0%
[65,69]	1	6%
[70,74]	5	33%
[75,79]	10	89%
[80,84]	2	100%
[85,89]	0	100%
[90,94]	0	100%
[95,100]	0	100%





Table 5 & Graph 2 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 1171

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	2	0%
[65,69]	46	4%
[70,74]	299	30%
[75,79]	549	77%
[80,84]	254	98%
[85,89]	20	100%
[90,94]	1	100%
[95,100]	0	100%



Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	181	87	53	188	115	52	193	128	81	215	103
<i>* testing in same/different state</i>		94 / 87	23 / 65	6 / 47	95 / 93	46 / 69	12 / 40	82 / 111	43 / 85	26 / 55	105 / 110	33 / 70
Mean Scaled Score - School *	79.69	79.27/78.48	76.96/79.95	78.17/79.09	79.46/79.55	77.33/78.72	76 / 79.28	78.35/79.98	77.05/80.62	75.27/79.70	79.39/80.75	78.36/80.64
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13	79.81	80.56	80.05
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08	81.32	82.40	80.91
School Pass Rate: *	84.62	84.04/81.61	60.87/86.15	83.33/76.60	85.26/81.72	71.74/76.81	50 / 82.50	76.83/90.09	65.12/90.59	50.00/72.73	81.90/89.09	78.79/85.71
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69	80.69	88.14	86.55
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50	88.20	93.04	87.78
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	9	163	70	43	171	86	43	176	98	65	193	73
<i>* testing in same/different state</i>		87 / 76	11 / 54	3 / 40	89 / 82	31 / 55	8 / 35	76 / 100	24 / 74	14 / 51	94 / 99	14 / 59
Mean Scaled Score - School *	79.78	79.34/78.70	77.55/80.57	81.33/79.38	79.66/79.94	77.03/78.85	76.63/79.31	78.83/80.23	77.33/80.86	76.29/80.28	79.24/81.07	79.00/81.47
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13	80.63	80.62	80.81
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79	82.14	82.66	81.60
School Pass Rate: *	88.89	83.91/84.24	63.64/87.04	100 / 77.50	87.64/82.93	67.74/74.55	50 / 80	80.26/90.00	62.5 / 91.89	57.14/78.43	80.85/91.92	92.86/91.53
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96	83.61	88.77	91.06
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87	91.72	93.97	90.35

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2016			2017			2018			2019		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	111	182	130	61	187	134						
* <i>testing in same/different state</i>	13 / 98	92 / 90	51 / 79	18 / 43	95 / 92	42 / 92						
Mean Scaled Score - School *	75.15/79.34	75.93/77.13	75.16/76.56	74.00/75.63	76.36/76.23	75.52/75.13						
* <i>testing in same/different state</i>												
Mean Scaled Score - State	80.92	77.12	76.91	77.39	76.83	76.52						
Mean Scaled Score - National	81.10	78.08	77.08	77.59	78.16	76.99						
School Pass Rate: *	53.85/82.65	64.13/74.44	56.86/78.48	44.44/65.12	73.68/67.39	59.52/53.26						
* <i>testing in same/different state</i>												
State Pass Rate:	90.23	77.93	75.14	75.57	77.13	70.53						
National Pass Rate:	87.62	82.66	74.77	76.90	83.24	74.01						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	94	163	77	42	164	79						
* <i>testing in same/different state</i>	10 / 84	83 / 80	16 / 61	6 / 36	86 / 78	18 / 61						
Mean Scaled Score - School *	74.90/79.99	76.04/77.46	73.19/76.64	75.17/75.64	76.66/76.58	75.28/75.41						
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.58	77.10	77.33	78.28	77.00	76.88						
Mean Scaled Score - National	81.84	78.24	77.61	78.31	78.41	77.52						
School Pass Rate: *	50.00/88.10	65.06/76.25	31.25/77.05	50.00/66.67	75.58/70.51	66.67/55.74						
* <i>testing in same/different state</i>												
State Pass Rate:	92.79	77.21	77.88	80.85	78.38	72.58						
National Pass Rate:	90.71	83.77	78.24	82.10	84.39	77.03						



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

September 1 – December 31, 2017

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


February 21, 2018

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the colleges of pharmacy and state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	08
Current Trimester Report for Xavier College of Pharmacy	13
Cumulative Report (since January 2000) for Xavier College of Pharmacy	18



**North American Pharmacist Licensure Examination® (NAPLEX®) School
Summary Report**

University of Louisiana at Monroe

Test Window: September 1, 2017 - December 31, 2017

This NAPLEX score report consists of two levels of scores: aggregated school scores and individual candidate scores. Beginning November 1, 2015, individual (unidentified) scores are reported in the NAPLEX Roster excel file. Summary information is provided separately for first-time examinees from ACPE-accredited schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school, state, and national pass rate information as well as total score means and area score means for each of the two main NAPLEX content domains:

Area 1 - Ensure Safe and Effective Pharmacotherapy and Health Outcomes (67%)

Area 2 - Safe and Accurate Preparation, Compounding, Dispensing and Administration of Medications and Provision of Healthcare Products (33%)

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
School	7	57.14%	78.14	20.72	11.29	1.38	11.71	1.98
State	27	51.85%	74.81	17.91	11.11	1.31	11.26	1.46
National	1691	69.31%	83.79	18.33	11.74	1.21	11.70	1.50

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
School	22	54.55%	78.32	13.31	11.27	0.98	11.91	1.27
State	55	63.64%	77.78	16.24	11.24	1.12	11.65	1.47
National	3484	65.47%	80.89	17.03	11.52	1.15	11.65	1.45

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	26	134
All Candidates	24	134
Scaled Score Range	0	150

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite score and area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into performances in each of the content area domains independent of one another.

There are a total of two area scores, one per main competency area. Area scores are reported on a scale of [6,18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the two content areas.

Table 4 shows the mean area scores for candidates scoring within the designated ranges of NAPLEX total scores. Data in this table includes outcomes from all candidates testing between January 1, 2016 and December 31, 2016.

Comparison Information

<i>Total Scaled Score Range</i>	<i>AREA 1</i>	<i>AREA 2</i>
0 - 24	8	7
25 - 49	9	9
50 - 74	11	11
75 - 99	12	12
100 - 124	13	13
125 - 150	15	15

The following tables and graphs are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 5 & Graph 1 School Frequency Distribution of Scaled Scores

Based on First-Time Candidates N = 7

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	2	29%
[60,64]	1	43%
[65,69]	0	43%
[70,74]	0	43%
[75,79]	1	57%
[80,84]	0	57%
[85,89]	1	71%
[90,94]	0	71%
[95,99]	0	71%
[100,104]	1	86%
[105,109]	1	100%
[110,114]	0	100%
[115,119]	0	100%
[120,124]	0	100%
[125,129]	0	100%
[130,134]	0	100%
[135,139]	0	100%
[140,144]	0	100%
[145,150]	0	100%





Table 6 & Graph 2 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 1691

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	2	0%
[30,34]	5	0%
[35,39]	5	1%
[40,44]	14	2%
[45,49]	33	3%
[50,54]	36	6%
[55,59]	82	10%
[60,64]	81	15%
[65,69]	128	23%
[70,74]	133	31%
[75,79]	188	42%
[80,84]	135	50%
[85,89]	171	60%
[90,94]	149	69%
[95,99]	178	79%
[100,104]	146	88%
[105,109]	80	93%
[110,114]	52	96%
[115,119]	42	98%
[120,124]	21	99%
[125,129]	7	100%
[130,134]	3	100%
[135,139]	0	100%
[140,144]	0	100%
[145,150]	0	100%



North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)


University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u> S+O/N+D
TOTAL CANDIDATE GROUP												
No. of Candidates	6	80	17	3	40	7	1	68	11	4	79	9 / 3
Mean Scaled Score - School	75.33	97.14	85.41	92.00	100.45	88.43	101.00	95.10	82.27	82.00	94.93	83.89/89.67
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88	82.15	95.51	85.60/73.62
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22	83.84	100.46	88.25/73.84
School Pass Rate:	83.33	92.50	82.35	100.00	90.00	100.00	100.00	89.71	63.64	50.00	89.87	77.78/100
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59	69.23	88.24	76.00/46.15
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77	67.06	92.29	77.64/46.27
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	80	9	3	38	4	1	68	3	1	78	5 / 0
Mean Scaled Score - School	49.50	97.14	87.11	92.00	101.68	92.00	101.00	95.10	92.00	74.00	94.62	83.60 / 0
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.34	77.00	96.08	86.50 / 0
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94	94.01	101.53	91.24 / 0
School Pass Rate:	50.00	92.50	77.78	100.00	92.11	100.00	100.00	89.71	66.67	0.00	89.74	80.00 / 0
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68	33.33	89.34	75.00 / 0
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36	84.96	93.86	81.88 / 0

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2016			2017			2018			2019			
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	
TOTAL CANDIDATE GROUP													
No. of Candidates	4	94	18	11	95	22							
Mean Scaled Score - School	60.25	87.35	83.76	87.45	90.85	78.32							
Mean Scaled Score - State	66.88	89.27	77.06	80.50	90.83	77.78							
Mean Scaled Score - National	74.52	84.81	81.48	79.33	95.88	80.89							
School Pass Rate:	0.00	76.6	77.78	81.82	84.21	54.55							
State Pass Rate:	22.22	77.61	54.72	70.59	82.76	63.64							
National Pass Rate:	48.80	85.71	65.32	62.73	88.07	65.47							
				ACPE probation eff. 06-24-2017									
FIRST-TIME CANDIDATE GROUP													
No. of Candidates	1	91	4	2	92	7							
Mean Scaled Score - School	31.00	87.62	79.67	72.50	91.55	78.14							
Mean Scaled Score - State	47.33	89.71	71.05	87.50	91.6	74.81							
Mean Scaled Score - National	78.95	95.9	83.02	86.04	97.19	83.79							
School Pass Rate:	0.00	76.92	50.00	50.00	85.87	57.14							
State Pass Rate:	0.00	78.07	38.10	75.00	84.46	51.85							
National Pass Rate:	57.75	87.78	65.64	76.19	90.22	69.31							



**North American Pharmacist Licensure Examination® (NAPLEX®) School
Summary Report**

Xavier University of Louisiana

Test Window: September 1, 2017 - December 31, 2017

This NAPLEX score report consists of two levels of scores: aggregated school scores and individual candidate scores. Beginning November 1, 2015, individual (unidentified) scores are reported in the NAPLEX Roster excel file. Summary information is provided separately for first-time examinees from ACPE-accredited schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school, state, and national pass rate information as well as total score means and area score means for each of the two main NAPLEX content domains:

Area 1 - Ensure Safe and Effective Pharmacotherapy and Health Outcomes (67%)

Area 2 - Safe and Accurate Preparation, Compounding, Dispensing and Administration of Medications and Provision of Healthcare Products (33%)

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
School	23	39.13%	73.00	19.13	10.91	1.24	11.09	1.56
State	27	51.85%	74.81	17.91	11.11	1.31	11.26	1.46
National	1691	69.31%	83.79	18.33	11.74	1.21	11.70	1.50

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
School	45	55.56%	74.84	17.29	11.02	1.08	11.20	1.53
State	55	63.64%	77.78	16.24	11.24	1.12	11.65	1.47
National	3484	65.47%	80.89	17.03	11.52	1.15	11.65	1.45

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	26	134
All Candidates	24	134
Scaled Score Range	0	150

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite score and area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into performances in each of the content area domains independent of one another.

There are a total of two area scores, one per main competency area. Area scores are reported on a scale of [6,18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the two content areas.

Table 4 shows the mean area scores for candidates scoring within the designated ranges of NAPLEX total scores. Data in this table includes outcomes from all candidates testing between January 1, 2016 and December 31, 2016.

Comparison Information

<i>Total Scaled Score Range</i>	<i>AREA 1</i>	<i>AREA 2</i>
0 - 24	8	7
25 - 49	9	9
50 - 74	11	11
75 - 99	12	12
100 - 124	13	13
125 - 150	15	15

The following tables and graphs are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 5 & Graph 1 School Frequency Distribution of Scaled Scores

Based on First-Time Candidates N = 23

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	1	4%
[35,39]	0	4%
[40,44]	0	4%
[45,49]	2	13%
[50,54]	0	13%
[55,59]	2	22%
[60,64]	4	39%
[65,69]	3	52%
[70,74]	2	61%
[75,79]	0	61%
[80,84]	2	70%
[85,89]	1	74%
[90,94]	3	87%
[95,99]	2	96%
[100,104]	0	96%
[105,109]	1	100%
[110,114]	0	100%
[115,119]	0	100%
[120,124]	0	100%
[125,129]	0	100%
[130,134]	0	100%
[135,139]	0	100%
[140,144]	0	100%
[145,150]	0	100%





Table 6 & Graph 2 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 1691

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	2	0%
[30,34]	5	0%
[35,39]	5	1%
[40,44]	14	2%
[45,49]	33	3%
[50,54]	36	6%
[55,59]	82	10%
[60,64]	81	15%
[65,69]	128	23%
[70,74]	133	31%
[75,79]	188	42%
[80,84]	135	50%
[85,89]	171	60%
[90,94]	149	69%
[95,99]	178	79%
[100,104]	146	88%
[105,109]	80	93%
[110,114]	52	96%
[115,119]	42	98%
[120,124]	21	99%
[125,129]	7	100%
[130,134]	3	100%
[135,139]	0	100%
[140,144]	0	100%
[145,150]	0	100%



North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u> S+O/N+D
TOTAL CANDIDATE GROUP												
No. of Candidates	13	120	21	10	136	43	18	138	27	15	141	22 / 9
Mean Scaled Score - School	76.69	95.13	83.24	68.67	95.13	81.47	70.72	96.29	80.41	72.13	96.03	86.73/59.78
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88	82.15	95.51	85.60/73.62
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22	83.84	100.46	88.25/73.84
School Pass Rate:	46.15	90.00	61.90	40.00	86.03	65.12	50.00	92.75	70.37	53.33	85.11	86.36/22.22
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59	69.23	88.24	76.00/46.15
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77	67.06	92.29	77.64/46.27
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	111	12	1	131	29	3	131	18	4	137	10 / 1
Mean Scaled Score - School	84.67	97.71	95.58	47.00	96.65	82.76	61.00	97.15	82.33	84.75	97.31	89.60/27.00
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.84	77.00	96.08	86.50/73.67
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94	94.01	101.53	91.24/81.00
School Pass Rate:	66.67	93.69	91.67	0.00	89.31	68.97	66.67	93.89	72.22	75.00	87.59	80.00 / 0
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68	33.33	89.34	75.00/33.33
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36	84.96	93.86	81.88/58.74

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2016			2017			2018			2019		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	16	123	43	25	127	45						
Mean Scaled Score - School	61.87	89.84	75.2	77.68	90.03	74.84						
Mean Scaled Score - State	66.88	89.27	77.06	80.50	90.83	77.78						
Mean Scaled Score - National	74.52	94.81	81.48	79.33	95.88	80.89						
School Pass Rate:	25.00	78.05	51.16	64.00	80.31	55.56						
State Pass Rate:	22.22	77.61	54.72	70.59	82.76	63.64						
National Pass Rate:	48.80	85.71	65.32	62.73	88.07	65.47						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	4	114	22	1	121	23						
Mean Scaled Score - School	63.67	91.1	74.81	111.00	90.57	73						
Mean Scaled Score - State	47.33	89.71	81.05	87.50	91.60	74.81						
Mean Scaled Score - National	78.95	95.9	83.02	86.04	97.19	83.79						
School Pass Rate:	25.00	80.7	50.00	100.00	81.82	39.13						
State Pass Rate:	0.00	78.07	38.10	75.00	84.46	51.85						
National Pass Rate:	57.75	87.78	65.64	76.19	90.22	69.31						



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Initial Legislative Report

2018-0217 @ 1200

Regular Session of the 2018 Louisiana Legislature
Convenes 2018-0312 @ 1200 – Adjourns 2018-0604 @ 1800

Last Items Reviewed									
HB	82	HR	0	HCR	2	HSR	0	HCSR	0
SB	31	SR	0	SCR	0	SSR	0	SCSR	0
Total = 115								Items on Watch List = 7	

House of Representatives

Bills

HB 45 Connick Health & Welfare
Requires third-party logistics providers to obtain controlled dangerous substance licenses.
01-31-2018 Prefiled and referred to committee.

This measure amends the Controlled Dangerous Substance Law to require third-party logistics providers to obtain controlled dangerous substance licenses, and establishes the licensure fee at \$50, the same amount paid by distributors. If successful, this measure will require an update to the law book.

HB 53 Talbot House & Governmental Affairs
Prohibits public servants in state government from engaging in certain activities with public funds and assets.
02-02-2018 Prefiled and referred to committee.

This measure would prohibit a public servant (elected official or public employee, including members of boards and commissions) in a state agency from using or obligating the funds or assets of his governmental agency to urge the passage or defeat of any matter pending before the legislature or any local governing authority. Current penalties for violations of ethics laws (\$10,000 fine) would be applicable to violations of this measure.

Resolutions

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions

Senate

Bills

SB 24 Mills Health & Welfare
Provides relative to social work practice.
02-15-2018 Prefiled and referred to committee.

This measure seeks to exempt social workers serving as faculty at accredited institutions of higher learning from the definition of 'social work practice.' The measure includes a provision prohibiting social workers from having any prescriptive authority or dispensing authority which is proposed for relocation in the same law. Will monitor for any change in that provision.

SB 26 Mills Health & Welfare
Provides relative to disposal of controlled substances by hospice providers.
02-15-2018 Prefiled and referred to committee.

This measure creates a new section in the Hospice Licensing Law to establish procedures for the disposal of controlled substances by hospice providers following the death of the hospice patient.

SB 27 Mills Health & Welfare
Provides relative to the Medicaid Pharmaceutical & Therapeutics Committee.
02-15-2018 Prefiled and referred to committee.

This measure seeks to revise the composition of the committee.

SB 28 Mills Health & Welfare
Provides relative to veterinarians.
02-15-2018 Prefiled and referred to committee.

This measure seeks to specifically exempt veterinary products from the drug price disclosure program, as well as veterinarians from the requirement for prescribers to access the state prescription monitoring program and the requirement for prescribers of controlled substances to obtain continuing education relative to the proper use of controlled substances.

SB 29 Mills Health & Welfare
Provides relative to a single uniform prescription drug prior authorization form.
02-15-2018 Prefiled and referred to committee.

This measure requires the Board of Pharmacy and the Board of Medical Examiners to jointly develop a single uniform prescription drug prior authorization form for use by all payers in the state, no later than January 1, 2019.

Resolutions

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions



NABP
National Association of
Boards of Pharmacy
www.nabp.pharmacy

1600 Feehanville Drive
Mount Prospect, IL 60056
T) 847/391-4406
F) 847/375-1114

TO: EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY
FROM: Carmen A. Catizone, Executive Director/Secretary
DATE: February 8, 2018
RE: Proposed Resolutions, NABP 114th Annual Meeting, May 5-8, 2018, Denver, CO

Attached you will find a copy of the resolutions that NABP has received since the 113th Annual Meeting through February 2, 2018. We hope that you will have the opportunity to discuss the resolutions with your board so as to assist your voting delegate during the consideration of the resolutions at the 114th Annual Meeting in Denver, CO.

Although we encourage you to share these resolutions with your board members, we strongly ask that these resolutions **not** be released to the press or any third parties at this time. Please remember that the NABP Committee on Resolutions has not yet reviewed the resolutions. The resolutions are presented exactly as we received them at the NABP office. The resolutions do **not** represent any official position of the Association or position advocated by NABP. The language and subject matter contained in the resolutions is solely the product of the entities that submitted them.

As you may know, any active member board, district, or committee of the Association may submit resolutions. All resolutions submitted in writing to the Association at least 20 days prior to the date of the Annual Meeting (April 16, 2018) shall be presented at the Annual Meeting for consideration. Resolutions not presented within such time limitations may be presented to the NABP Registration/Information Desk during the Annual Meeting by 8 AM on Sunday, May 6, 2018, and will be considered for adoption by the Association upon the affirmative vote of three-fourths of those Association members present and constituting a quorum.

The Committee on Resolutions will meet the morning of Sunday, May 6, 2018, during the Annual Meeting to review the resolutions. At that time, and with the consent of the submitter, changes may be made to ensure that the resolutions do not conflict with the purposes of NABP or create any adverse legal consequences. Each revised resolution will be presented to the membership for discussion and consideration at the 114th Annual Meeting.

If you have any questions, please feel free to contact us at ExecOffice@nabp.pharmacy.

Attachment

Resolutions passed at 2017 District Meetings

District 1

Resolution #1: Implementation and Regulation to Technology in Pharmacy Practice

Whereas, technology is a critical complement to and support for the provision of pharmacy and patient care services; and

Whereas, state boards of pharmacy are responsible for regulating the practice of pharmacy, and consequently the utilization of technology in practice; and

Whereas, effectively regulating the use of technology is complicated because of the ever-changing nature and rapid development of technology that it often outpaces the development and adoption of state laws and rules to regulate the use of technology; and

Whereas, the *Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy* includes broad and effective language addressing the implementation and regulation of the use of technology in pharmacy practice.

Therefore, be it resolved, that NABP communicate to states the NABP Model Language for the implementation and regulation of technology to encourage states to remove prescriptive and outdated existing statutes and regulations and replace that language with the NABP Model Language to the extent applicable.

Resolution #2: Safety Standards for the Compounding and Dispensing of Compounded Products

Whereas, the compounding of products for patients may involve materials that are deemed hazardous by the appropriate state or federal agency or are active product ingredients that require black box warnings; and

Whereas, the handling of those materials in the preparation of such compounded products or the dispensing of those products to the patient or caregiver could endanger the health of the compounding pharmacist, technician, and patient or caregiver receiving the compounded product.

Therefore, be it resolved that NABP work with USP and other stakeholders to provide information concerning USP Chapter <800> and its applicability to pharmacies and related information concerning hazardous materials and the appropriate handling of these materials in the pharmacy and when dispensed to the patient or caregiver.

Resolution #3: Electronic Transmission of Prescriptions (Co-support by District 4)

Whereas, the electronic transmission of prescriptions from prescribers to pharmacists provides a more effective means of transmission in comparison to a handwritten prescription or verbal order; and

Whereas, there is evidence that the mandating of electronic transmission for all prescriptions has been proven to be more effective when implemented, for example, the mandating of electronic prescriptions in the State of New York.

Therefore, be it resolved that NABP convene a task force of appropriate stakeholders including, but not limited to, the DEA, CMS, and electronic prescribing experts, to examine the feasibility of encouraging member boards to require that all prescriptions be transmitted electronically.

Resolution #4: Veterinary Pharmacy Education

WHEREAS, pharmacists are recognized as the only healthcare professionals expected by society and legally permitted by regulatory authorities to provide pharmaceutical care for all species; and

WHEREAS, evolving pharmacist practice includes providing medication therapy for both human and veterinary patients; and

WHEREAS, a substantial need exists for increasing veterinary pharmacist care and education in pharmacy practice;

THEREFORE, BE IT RESOLVED that NABP recommend the development and availability of veterinary pharmacy education at colleges and schools of pharmacy in collaboration with schools of veterinary medicine and critical veterinary hospitals.

BE IT FURTHER RESOLVED that pharmacists dispensing medications for veterinary patients possess the competence and have access to resources necessary to appropriately dispense and provide care.

District 4

Resolution #1: Task Force on changes to the Model Act adopted by ACPE/ASHP Technician Standards

Whereas, ASHP/ACPE have established the Pharmacy Technician Accreditation Board and;

Whereas, The PTAC is in the process of revising its standard and;

Whereas, the time line for revision of the standards is likely to occur in June 2018;

Therefore, be it resolved NABP establish a Task Force to consider changes to the Model Act incorporating changes adopted by the ACPE/ASHP Technician Standards.

District 5

Resolution #1: Improvement in the NABP Resolution Submission and Action Process

WHEREAS, District members take seriously the resolution process by focusing on timely issues important to District members; and

WHEREAS, District members wish to encourage the District membership actively participate in the resolution development process for the benefit of the public they intend to serve; and

WHEREAS, Past resolution submissions have not consistently followed the established resolution process; and

WHEREAS, District resolutions submitted after due consideration and passage at the District meeting must be considered by the NABP resolutions committee in accordance with Article IV Section 6 of the NABP Constitution,

THEREFORE, BE IT RESOLVED, Consideration of resolutions submitted by districts to the NABP resolutions committee should result only in form and style changes being made and/or recommendations of Do Pass, Do Not Pass or No Recommendation be appended along with the reasons for that recommendation, such as, conflict with NABP Constitution and Bylaws, duplication with previous resolutions, or request for actions that are already underway at the behest of the Executive Committee; and

THEREFORE, BE IT FURTHER RESOLVED, Resolutions passed at the annual meeting be considered by the Executive Committee for implementation and that action or lack of action be reported to the Districts by the Executive Committee along with an explanation for the decision reached.

District 7

Resolution #1: Task Force to Develop Standard of Care based Regulation (Co-support from District 6, District 8, & District 4)

WHEREAS the practice of pharmacy continues to evolve toward direct patient care;

WHEREAS in some settings pharmacists are currently prescribing drugs and devices, ordering and interpreting drug therapy-related tests, and administering drugs;

WHEREAS technology continues to develop and lead to advancements within the pharmacy profession;

WHEREAS the medical and nursing professions regulate according to a standard of care that has allowed flexibility in their professional scope of practice while maintaining the ability of their respective regulatory boards to maintain patient safety;

THEREFORE, BE IT RESOLVED that NABP form an inter-disciplinary task force to explore considerations for transitioning from prescriptive rule-based regulations to a "standard of care" process, and highlight

tools Boards of Pharmacy may need to make this transition (e.g., peer review committees, different enforcement tools, etc.)

District 8

Resolution #1: Cooperative Inter State Investigations & Actions (Co-support by District 6 & District 7)

WHEREAS, state boards of pharmacy are charged with protecting the public health as it relates to patient safety, patient health, and patient services provided by pharmacies and pharmacists; and

WHEREAS, the practice of pharmacy has expanded to embrace dispensing models wherein a single dispensing transaction may extend across state boundaries; and

WHEREAS, states do not always require individual pharmacists who participate in interstate dispensing models to obtain a pharmacist license in each state into which the pharmacist will participate in dispensing medication; and

WHEREAS, errors occur in such interstate transactions where the pharmacist who committed the error is beyond the jurisdiction of the state in which the patient is harmed or potentially harmed.

WHEREAS, the board of pharmacy in the patient's state cannot meet its charge to protect the public because it lacks jurisdiction to pursue a remedial action and/or discipline against the offending pharmacist.

THEREFORE, BE IT RESOLVED that NABP, through its staff, will contact each state board of pharmacy to request a letter of assurance stating that if a licensee of one state commits a serious dispensing error that actually or potentially harms a patient in another state in which the pharmacist is not licensed, the board of pharmacy in the state in which the error occurred will accept a complaint from the offended state. The board of pharmacy in the state in which the error occurred will further assure that it will investigate the matter, and, where appropriate, initiate a disciplinary action under the laws and regulations of the state in which the error occurred.

Resolution #2: Cannabidiol Medications

WHEREAS, there is a Cannabidiol (CBD) prescription medication that has been submitted to the Food and Drug Administration (FDA) and will be rescheduled by the Drug Enforcement Administration (DEA) to treat the devastating childhood onset epilepsies of Dravet Syndrome and Lennox Gastaut Syndrome (LGS); and

WHEREAS, healthcare professionals including pharmacists who care for patients with these difficult-to-control epilepsies have a significant need for education that focuses on understanding the pharmacology of CBD and other cannabinoids and the translation of data from clinical trials; and

WHEREAS, the federal ban in the USA on marijuana in the past has resulted in a patchwork of state regulatory strategies governing unapproved cannabis products and such control measures are not consistent with those that govern a prescription medication that has been approved by the FDA

WHEREAS a CBD prescription medication should be controlled by state and federal regulatory provisions that govern other prescription-only products, such as dispensing through pharmacies, rather than by these various state laws applicable to unapproved cannabis products; and

WHEREAS, state boards of pharmacy are drug regulatory experts and have the responsibility to provide regulatory guidance and oversee the training and practice of pharmacists in the interest of the patient health and safety;

THEREFORE, BE IT RESOLVED that pharmacists dispensing medications to patients with difficult-to-treat, difficult-to-control types of childhood onset intractable epilepsies, should possess the competence and have access to resources necessary to provide good patient care.

BE IT FURTHER RESOLVED that FDA approved CBD and other cannabinoid products should be subject to the state laws that govern prescription medications, rather than by state laws that govern unapproved cannabis products;

BE IT FURTHER RESOLVED that NABP collaborate with interested stakeholders to encourage and assist in the development of adequate resources related to the use of CBD prescription medications in the treatment of seizures with CBD for intractable epilepsy.

Resolution #3: Compounding for Research Purposes

WHEREAS, the extemporaneous preparation of clinical trial materials has long been integral to the drug development process, and

WHEREAS, many State Board of Pharmacy include in their definition of compounding: “For the purpose of, or incident to, research ...” and

WHEREAS, a number of State Board of Pharmacy prohibit non-patient specific, or “office use” compounding.

THEREFORE, BE IT RESOLVED THAT consistent with NABP Model Pharmacy Act language, the extemporaneous preparation of compounds for FDA, NIH or other approved research studies is not “office use” compounding.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Announcements

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 21, 2018

Agenda Item 12: Announcements

Mar. 6-8	MPJE Item Development Workshop – Mount Prospect, IL
Mar. 12	Regular Session of 2018 Legislature convenes
Mar. 16-19	APhA Annual Meeting – Nashville, TN
Mar. 19	La. Pharmacy Congress
Mar. 21-22	Violations Committee Informal Conference
Mar. 27-28	Special Board Meeting (Marijuana Pharmacy Permits)
Mar. 31	Good Friday – <i>Board office closed</i>
April 11	PMP Advisory Council
May 5-8	NABP Annual Meeting – Denver, CO
May 19-20	World Health Professions Regulation Conference – Geneva, CH
May 22	Reinstatement, Impairment, & Executive Committees
May 23	Reciprocity Committee & Board Meeting
May 24	Administrative Hearing
May 24-26	LSHP Annual Meeting – New Orleans, LA
May 28	Memorial Day – <i>Board office closed</i>
May 30-June 3	APhA Institute on Alcoholism & Drug Dependencies

Late Additions to Meeting Binder from Committee Deliberations



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Impairment Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Roster of Approved Addictionists

Richard P. Amar, MD
Talbot Recovery Center
5448 Yorktowne Drive
Atlanta, GA 30349
Telephone (844) 225-3097

La. License No. 049558
Issued: 12-08-2000 Expires: 04-30-2019
Status: Active and unrestricted
Certification: ABPN No. 002041
Issued: 10-12-2010 Expires: 10-12-2020

Daniel S. Aronow, MD
Podiatry Institute of Southern California
9808 Venice Blvd Ste 600
Culver City, CA 90232
Telephone (310) 204-2300

Cal. License No. A63273
Issued: 08/15/1997 Expires: 10/31/2018
Status: Active and unrestricted
Certification: ABAM No. 2012025
Issued: 12-15-2012 Expires: 12-15-2022

Roy D. Ary, Jr., MD
BioBehavioral Medicine, Inc.
4933 Wabash Street
Metairie, LA 70001
Telephone (504) 780-2766

La. License No. MD.09977R
Issued: 07-29-1993 Expires: 08-31-2017
Status: Active and unrestricted
Certification: ABAM No. 000870
Issued: 03-12-2009 Expires: 12-31-2019

Navjyot S. Bedi, MD
Talbot Recovery Center
5448 Yorktowne Drive
Atlanta, GA 30349
Telephone (844) 225-3097

Ga. License No. 055658
Issued: 12-03-2004 Expires: 04-30-2019
Status: Active and unrestricted
Certification: ABAM No. 002509
Issued: 05-02-2009 Expires: 12-31-2019

Joan E. Brunson, MD
Edgefield Recovery Center
10631 Hwy. 71 North
Cheneyville, LA 71325
Telephone (888) 327-2673

La. License No. MD.017125
Issued: 06-16-1983 Expires: 09-30-2017
Status: Active and unrestricted (D)
Certification: ABAM No. 000999
Issued: 03-12-2008 Expires: 12-31-2018

José Calderón-Abbo, MD
The Mind-Body Center of Louisiana
3439 Magazine Street
New Orleans, LA 70115
Telephone (504) 891-8808

La. License No. MD.14816R
Issued: 10-22-2002 Expires: 01-31-2018
Status: Active and unrestricted
Certification: ABAM No. 000881
Issued: 03-12-2009 Expires: 03-12-2019

Louis Cataldie, MD
3535 Brentwood Drive
Baton Rouge, LA 70806
Telephone (225)
Facsimile

La. License No. MD.012613
Issued: 06-13-1974 Expires: 08-31-2017
Status: Active and unrestricted (D)
Certification: ABAM No. 003000
Issued: 05-02-2009 Expires: 05-02-2019

Revised: 02-21-2018

John R. Colaluca, DO
Palmetto Recovery Center
86 Palmetto Road
Rayville, LA 71269
Telephone (318) 728-2970

La. License No. DO.021805
Issued: 07-01-1993 Expires: 09-30-2017
Status: Active and unrestricted (D)
Certification: ABAM No. 000886
Issued: 03-12-2009 Expires: 03-12-2019

J. David Hammond, Jr., MD
Palmetto Recovery Center
86 Palmetto Road
Rayville, LA 71269
Telephone (318) 728-2970

La. License No. MD.022970
Issued: 07-01-1996 Expires: 07-31-2017
Status: Active and unrestricted
Certification: ABAM No. 2014243
Issued: 11-15-2014 Expires: 11-15-2024

Dean A. Hickman, MD
Ochsner Medical Center
1514 Jefferson Highway, BH-4
New Orleans, LA 70121
Telephone (504) 842-3842

La. License No. MD.020992
Issued: 08-06-1990 Expires: 01-31-2018
Status: Active and unrestricted
Certification: ABPN No. 001163
Issued: 04-08-1997 Expires: 12-31-2018

Oksana V. Kershteyn, MD
Talbot Recovery Center
5448 Yorktowne Drive
Atlanta, GA 30349
Telephone (844) 225-3097

Ga. License No. 065470
Issued: 01-07-2011 Expires: 03-31-2018
Status: Active and unrestricted
Certification: ABPN No. 064327
Issued: 05-18-2012 Expires: 05-18-2022

Edward C. LaFleur, MD
Victory Addiction Recovery Center
111 Liberty Avenue
Lafayette, LA 70508
Telephone (888) 991-2237

La. License No. MD.025580
Issued: 09-01-2002 Expires: 03-31-2018
Status: Active and unrestricted
Certification: ABAM No. 2014630
Issued: 11-15-2014 Expires: 11-15-2024

Scott D. Mayers, MD
Victory Addiction Recovery Center
111 Liberty Avenue
Lafayette, LA 70508
Telephone (888) 991-2237

La. License No. MD.202066
Issued: 06-16-2008 Expires: 11-30-2017
Status: Active and unrestricted
Certification: ABAM No. 2014362
Issued: 11-15-2014 Expires: 11-15-2024

Jay L. Piland, Sr., MD
Palmetto Recovery Center
86 Palmetto Road
Rayville, LA 71269
Telephone (318) 728-2970

La. License No. MD.022337
Issued: 08-23-1995 Expires: 03-31-2018
Status: Active and unrestricted (D)
Certification: ABAM No. 2010367
Issued: 12-11-2010 Expires: 12-11-2020

Arwen L. Podesta, MD
4322 Canal Street, No. 9
New Orleans, LA 70119
Telephone (504) 252-0026
Facsimile (504) 322-3856

La. License No. MD.200907
Issued: 06-01-2006 Expires: 09-30-2018
Status: Active and unrestricted
Certification: ABPN No. 006208
Issued: 06-03-2011 Expires: 06-03-2021

Alphonse K. Roy, III, MD
BioBehavioral Medicine, Inc.
4933 Wabash Street
Metairie, Louisiana 70001
Telephone (504) 780-2766

La. License No. MD.012078
Issued: 06-15-1972 Expires: 09-30-2017
Status: Active and unrestricted (D)
Certification: ABAM No. 000088
Issued: 1986 (Issues prior to 1998 do not expire)

Kelly A. Scheinberg, MD
Talbot Recovery Center
5448 Yorktowne Drive
Atlanta, GA 30349
Telephone (844) 225-3097

Ga. License No. 067608
Issued: 03-29-2012 Expires: 05-31-2017
Status: Active and unrestricted
Certification: ABPN No. 002323
Issued: 09-29-2014 Expires: 09-29-2024

Ronald V. Taravella, MD
7777 Hennessy Boulevard, Suite 302
Baton Rouge, LA 70808
Telephone (225) 767-4668
Facsimile (225) 765-3430

La. License No. MD.016298
Issued: 08-16-1981 Expires: 08-31-2017
Status: Active and unrestricted (D)
Certification: ABPN No. 039750
Issued: 06-30-1994 (Issues prior to 1998 do not expire)

Jennifer R. Velandar, MD
Ochsner Medical Center
1514 Jefferson Hwy.
New Orleans, LA 70121
Telephone (504) 842-4025

La. License No. MD.300460
Issued: 11-04-2015 Expires: 11-30-2017
Status: Active and unrestricted
Certification: ABPN No. 002346
Issued: 09-29-2014 Expires: 09-29-2024

Jay A. Weiss, MD
Palmetto Recovery Center
86 Palmetto Road
Rayville, LA 71269
Telephone (318) 728-2970

La. License No. MD.12286R
Issued: 06-18-1997 Expires: 09-30-2017
Status: Active and unrestricted
Certification: ABAM No. 000853
Issued: 03-12-2009 Expires: 12-31-2019

Bob Winston, MD
2020 W. Pinhook Rd., Ste 504
Lafayette, LA 70508
Telephone (337) 593-0830
Facsimile (337) 593-0122

La. License No. MD.11569R
Issued: 12-07-1995 Expires: 04-30-2018
Status: Active and unrestricted
Certifications: ABPN No. 029746
Issued: 11-30-1987 (Issues prior to 1998 do not expire)



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Executive Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



RESOLUTION

The following Motion and Resolution was offered by Mr. Morris Rabb who moved for its adoption, and seconded by Mr. Marty McKay at the February 21, 2018 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as the Board's prosecutor, and further, there is a need for an attorney experienced in administrative law to provide prosecutorial services during its administrative hearings, and further, to provide additional representation when the Board's decisions are appealed to the judiciary, and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law; and

WHEREAS, the Board has worked with **Celia R. Cangelosi** in the same capacity for over fifteen years, providing the experience as prosecuting attorney, with additional experience in representing the Board's interests in the 19th Judicial District Court, the First Circuit Court of Appeals; and the Louisiana Supreme Court; and

WHEREAS, the Board's proposed contract with **Celia R. Cangelosi** specifies an hourly rate of two hundred twenty five dollars (\$225) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed one hundred thousand dollars (\$100,000) for Fiscal Year 2018-2019; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect on July 1, 2018.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **Celia R. Cangelosi** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS:	16
NAYS:	0
ABSENT:	0
NOT VOTING:	Carl W. Aron (Chair)

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 21st day of February 2018.

I, Carl W. Aron, President of the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held February 21, 2018, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 21st day of February, 2018.

Carl W. Aron



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



RESOLUTION

The following Motion and Resolution was offered by Mr. Morris Rabb who moved for its adoption, and seconded by Mr. Marty McKay at the February 21, 2018 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as an advisor to the Board's Hearing Officer, and further, there is a need for an attorney experienced in administrative law to provide advisory services to the Board's Hearing Officer during its administrative hearings, or to serve as the Hearing Officer; and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law, as well as other professional legal services as may be requested by the Board from time to time; and

WHEREAS, the Board has worked with **Shows, Cali & Walsh, LLP** in the same capacity for over ten years, where they have provided advisory services to the Board's Hearing Officer as well as serving as the Hearing Officer from time to time; and further, represented the Board and its staff during a suit against the Board in 2013; and

WHEREAS, the Board's proposed contract with **Shows, Cali & Walsh, LLP** specifies an hourly rate of two hundred twenty-five (\$225) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed fifty thousand dollars (\$50,000) for Fiscal Year 2018-2019; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect on July 1, 2018.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **Shows, Cali & Walsh, LLP** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS: 16
NAYS: 0
NOT VOTING: Carl W. Aron (Chair)

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 21st day of February, 2018.

I, Carl W. Aron, President of the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held February 21, 2018, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 21st day of February, 2018.

Carl W. Aron

2
3 *Title:* Authorized Drivers

Policy No. II.A

4
5 Approved: 05-05-2010

Revised: 05-10-2017

6
7
8 1. Authorized drivers shall include board members as well as employees who hold the
9 following positions with the Board:

10 ~~1.~~ a. Executive Director / Chief Executive Officer (Appointing Authority)

11 ~~2.~~ b. General Counsel

12 ~~3.~~ c. Office Manager

13 ~~4.~~ d. PMP Manager / Chief Operating Officer

14 ~~5.~~ e. PMP Assistant

15 ~~6.~~ f. Administrative Coordinator & Administrative Assistant – Administrative
16 Division

17 ~~7.~~ g. Compliance Officer / Chief Compliance Officer

18
19 2. Employees holding a position not listed herein shall not be authorized to drive on
20 state business.

21
22 3. Employees classified as “high-risk” shall not be authorized to drive vehicles on state
23 business from the date of discovery for a minimum of twelve months. High-risk
24 drivers are those individuals:

25 ~~1.~~ a. Having three or more convictions, guilty pleas, and/or *nolo contendere* pleas
26 for moving violations within the previous twelve month period; or

27 ~~2.~~ b. Having a single conviction, guilty plea, or *nolo contendere* plea for operating a
28 vehicle while intoxicated, hit and run driving, vehicular negligent injury,
29 reckless operation of a vehicle, or similar violation within the previous twelve
30 month period.

31
32 4. When used in the context of these policies and procedures, a ‘state vehicle’ shall
33 include the following:

34 a. A vehicle owned by the board or another state agency; or

35 b. A vehicle rented or leased by the board or another state agency.

36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Louisiana Board of Pharmacy**

51

52 *Title:* Authorized Drivers

53

54 Approved: 05-05-2010

55

Loss Prevention

Policy No. II.A

Revised: 05-10-2017



56

57 *Revision History*

58

59

60 05-27-2015

Added definition of 'state vehicle'.

61

62 05-10-2017

Added Administrative Assistants in the Administrative Division in the list of authorized drivers.

63

64

65

66

67

68

69

70

DRAFT

1 **Louisiana Board of Pharmacy**

Loss Prevention

2
3 *Title:* Initial Authorization Process

Policy No. II.B

4
5 Approved: 05-05-2010

Revised: 05-29-2013

- 6
7
- 8 1. Board member and employee shall complete and sign the Authorization and
9 Driving History Form (DA-2054) and return the completed form to the Office
10 Manager.
 - 11 2. Board member and employee shall provide proof that he has a valid driver's
12 license.
 - 13 3. Board member and employee shall provide proof of automobile insurance.
 - 14 4. Board member and employee shall complete an ORM-recognized defensive
15 driving course within 30 days of hire (or 30 days after commissioning for board
16 members) and once every three years.
 - 17 5. The Office Manager shall obtain official driving records (ODRs) annually and
18 ensure that board members and employees meet all program requirements to be
19 authorized to drive.
 - 20 6. The Appointing Authority or designee shall review the Official Driving Record to
21 ensure the board member or employee does not meet the high-risk driver
22 definition.
- 23
24

DRAFT

2
3 *Title:* Annual Re-Authorization Process

Policy No. II.C

4
5 Approved: 05-05-2010

Revised: 05-29-2013

- 6
7
8 1. Board member and employee shall complete and sign the Authorization and
9 Driving History Form (DA-2054) attesting that they currently carry at least the
10 required minimum vehicle insurance annually on or before January 1st in order to
11 be authorized for the new calendar year.
- 12 2. The Office Manager shall obtain official driving records (ODRs) annually and
13 ensure that board members and employees meet all program requirements to be
14 authorized to drive on state business.
- 15 3. The Appointing Authority or designee shall review the Official Driving Record to
16 ensure the board member or employee does not meet the high-risk driver
17 definition.
- 18 4. Board members and employees who meet requirements will be authorized to
19 drive on state business until the end of the calendar year.
- 20 5. Receipt of evidence that places a driver in the high-risk category shall cause the
21 board member's or employee's driving privileges to be revoked immediately. An
22 employee whose job responsibilities require driving shall be dismissed. In the
23 event a board member's driving privileges are revoked, the member shall not be
24 authorized to drive on state business nor receive mileage reimbursement.
25

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Louisiana Board of Pharmacy

Loss Prevention

Title: Supervisor's Responsibility

Policy No. II.D

Approved: 05-05-2010

Revised:



1. The supervisor shall provide time for each authorized employee to complete an approved Defensive Driving Course.
2. The supervisor shall allow only authorized board members and employees to drive on state business.
3. The supervisor shall ensure that all accidents or incidents are properly reported and said records are maintained.

DRAFT

2
3 *Title:* Employee's Responsibility

Policy No. II.E

4
5 Approved: 05-05-2010

Revised: 05-29-2013

- 6
7
8 1. Board members and employees may only operate those vehicles for which they
9 are licensed and insured.
- 10 2. The board member and employee shall be required to demonstrate proof of
11 insurance on an annual basis.
- 12 3. The board member and employee shall immediately report any revocation of
13 their driver's license or any moving violations received to his supervisor, but no
14 later than their next scheduled workday. Said reporting applies whether on state
15 or personal/private business and whether in a state or personal/private vehicle.
- 16 4. The board member and employee shall complete a refresher course at least
17 once every three years.
- 18 5. Drivers who have convictions on their motor vehicle records shall be required to
19 retake a recognized driving course within ninety days of notification of a
20 conviction.
- 21 6. Board members and employees shall not use a Wireless Telecommunications
22 Device while driving in a state-owned, leased, or private vehicle that is being
23 driven on state business. This includes writing, sending, or reading a text based
24 communication and engaging in a call. Use of a Wireless Telecommunications
25 Device is permissible for passengers in such vehicles. The following situations
26 shall constitute exceptions to this policy:
- 27 A. Report a traffic crash, medical emergency, or serious road hazard.
 - 28 B. Report a situation in which the person believes his personal safety
29 is in jeopardy.
 - 30 C. Report or avert the perpetration or potential perpetration of a
31 criminal act against the driver or another person.
 - 32 D. Engage in a call or write, send or read a text-based communication
33 while the motor vehicle is lawfully parked.
- 34
35

2
3 *Title:* Accident Reporting

Policy No. II.F

4
5 Approved: 05-29-2013

Revised: 05-27-2015

6
7
8
9 A vehicular accident is defined as any incident in which the vehicle comes in contact with
10 another vehicle, person, object, or animal that results in death, personal injury, or property
11 damage, regardless of who was injured, what was damaged or to what extent, where it occurred
12 or who was responsible.

- 13 1. All accidents shall be reported to the employee's immediate supervisor and Office
14 Manager by the driver of the state vehicle (or other vehicle driven on state business) on
15 the day of the accident. If the driver is not able to complete the Louisiana State Driver's
16 Accident Report Form (DA 2041), then the driver's supervisor will complete the report to
17 the best of his ability for the employee. The supervisor may enter identifying information
18 and attach the police report. The DA 2041 shall be completed within 48 hours after any
19 vehicle accident while on state business and forwarded to the ORM Claims Unit. The DA
20 2041 form can be downloaded from: <http://www.doa.la.gov/orm/formsCR.htm>. The Office
21 Manager shall retain proof of the submission of the DA 2041 form to the ORM Claims
22 Unit within the 48-hour time limit.

23
24 *(Note: When an accident occurs in a board member's or an employee's personal vehicle
25 or a rental vehicle while he/she is on state business, complete the DA 2041 and note
26 whether or not the vehicle is rented or personal. In addition, in ALL cases the board
27 member's or employee's liability insurer is the primary insurer of the accident. ORM's
28 coverage is excess over any other collectible insurance).*

29
30 A copy of the Uniform Motor Vehicle Traffic Accident Report (police report) shall
31 accompany the DA 2041 or should be sent to the ORM Claims Unit as soon as it is
32 received by the agency. Do NOT delay submission of the DA 2041 waiting on the police
33 report.

- 34
35 2. Failure of an authorized driver to report any vehicular accident may be cause for
36 suspension of Driver Authorization. Accidents by board members or employees in their
37 personal vehicle after hours need not be reported unless the employee was ticketed.
38
39 3. The supervisor of the authorized driver involved in an accident shall review the accident
40 report within two working days of the accident for completeness of information.
41 Incomplete reports shall be returned for completion or corrected information. The
42 supervisor may assist the individual in completing the report. All accidents require
43 completion of the Vehicle Accident Report (DA 2041).
44
45 4. The supervisor may consider what corrective action(s) may be necessary for accidents.
46
47 5. The executive director or designee shall review the Accident Report Form, the Uniform
48 Motor Vehicle Traffic Accident Report (police report – if one was completed), and the
49 Authorization and Driving History Form (DA 2054).
50
51
52
53



60
61 Revision History

62
63
64 05-29-2013 Added the exclusion of accidents by employees in their personal
65 vehicles after office hours unless they were ticketed to Section 2.

66
67
68 05-27-2015 Added requirement for Office Manager to retain proof of timely
69 submission of report in Section 1.
70

DRAFT

1 **Louisiana Board of Pharmacy**

Loss Prevention

2
3 *Title:* Safety Audits and Recordkeeping

Policy No. II.H

4
5 Approved: 05-29-2013

Revised:

- 6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1. Driver Safety Program records shall be maintained at the Board office for review until at least the next audit or compliance review.
2. The following specific records shall be retained for the period of time indicated here:
- A. Official Driving Records (ODR) and High-Risk Driver documentation, e.g., re-training records, letters) – maintain for one year.
 - B. Driver training (initial, refresher) documentation – maintain for 3 years.
 - C. DA 2054 forms – maintain indefinitely or until form information is updated.
3. The Board office shall maintain a list of board members and employees who have been authorized to drive or in the alternative, a list of board members and employees not authorized to drive.

-
1. This policy covers the Travel card program (T-card) and establishes minimum standards possession and use. Travel Card is a tool used to assist in the management of purchasing, payment, and accounting. Travel Card is a Visa card issued by Bank of America for the State of Louisiana. This card will enable employees to purchase items with the convenience of a credit card, while providing management with a means of maintaining control over those purchases. The use of this card will improve efficiency and effectiveness by reducing costs associated with processing purchases and payments and will allow for the receipt of goods on a timely basis.
 2. The Louisiana Board of Pharmacy allows a maximum Single Purchase Limit (SPL) of up to \$5,000. Multiple purchases may be made with the T-Card for contract purchases, each day, up to but not exceeding \$5,000 per contract. The board has safeguards in place to ensure that purchases from contract vendors are for each contract's specific approved contract items.
 3. Purchases should never be artificially divided to avoid the Travel Card policy limits or placed on different cards within the Section/Unit.
 4. Current Purchasing Policies, Rules and Regulations, Louisiana Statutes, Executive Orders and/or State Travel Card Policy, as well as the Board's Travel Policy must always be followed during the use of the Travel Card. Copies of State of Louisiana Travel Card Purchasing Card Policy, Rules and Regulations, LA Statutes and Executive Orders may be viewed/obtained from the State Purchasing Website at www.doa.louisiana.gov/ops/traveloffice.htm.
 5. All program participants, i.e. program administrators, cardholder, CBA, administrators and cardholder approvers are required to complete an online certification class, annually, receiving a passing grade of at least 90 in order to receive a new t-card, a renewal t-card, remain as CBA administrator or remain as a cardholder approver. These certifications will be developed and updated, as necessary, by the Office of State Purchasing and Travel and the agency will be notified as soon as they are approved. All program participants will be given ample time to obtain this certification once notified. Note: The certification class for the CBA administrator would be the same as a cardholder's certification.

A cardholder's approver must be a supervisor of the cardholder which would be at least one level higher than the cardholder. The approver must be the most logical supervisor which would be most familiar with the business case and appropriate business needs for the cardholder's transactions.

To allow for proper and complete program audits, all program participants, including public post secondary, will be mandated to implement WORKS Workflow, which is an

online system through Bank of America. The system captures transactions; Workflow requires both cardholders and cardholder approver's electronic signatures, along with the ability to maintain receipts and backup supporting documentation in one central location through the scanning feature which is also being mandated, therefore, assisting with audits and reviews. The system allows for an additional level of approvals, beyond the cardholder and approver. Another function of Workflow allows accounting information to be coded by the cardholder for each transaction. The accounting function is mandated for ISIS/LaGov interfaced agencies which would ultimately be interfaced to the ISIS and LaGov systems. For all other agencies/post secondary/board/commissions, which are not ISIS/LaGov, interfaced agencies, although it is still mandated for the agency to utilize Workflow including scanning capabilities, the agency will not be required to interface with any accounting system.

Agency program participation requires annual review of the agency's program conducted by the agency's internal audit section.

All receipt and supporting documentation must be scanned and tied to the applicable transaction and not as one image for all transactions.

6. The Department Head will be responsible for designating Agency T-Card/CBA Program Administrators and for notifying the Office of State Purchasing and Travel of any changes.

DECLARED EMERGENCY USE

In the event the Governor declares a state of emergency, the T-Card may be changed to allow higher limits and opening of certain MCC codes for essential employees who are cardholders that would be active during an emergency situation and not for ALL cardholders. An emergency profile must be created in WORKS which shall not exceed the following limits, without prior approval from Office of State Purchasing and Travel: SPL (single purchase limit) \$25,000, Travel and Rest MCC Groups may be removed if determined to be necessary for group accommodations however, the Cash MCC Group must remain attached to the profile at all times, as the use of cash is never allowed, even during emergency situations.

Higher limits do NOT eliminate the need to follow emergency procurement rules, policies, procedures and/or executive orders.

DEFINITIONS

1. Approver - individual within the agency who is responsible for verifying that all charges against the cardholder's account are authorized and supported by adequate documentation. This may or may not be the cardholder's direct supervisor.
2. CBA (Controlled Billed Account) – a credit account issued in an agency's name (no plastic cards issued). These accounts are direct liabilities of the State and are paid by each agency. CBA Accounts are controlled through an authorized approver(s) to provide means to purchase any allowed transactions/services allowed in the current State Liability Travel Card and CBA Policy. Please realize that although other travel related charges are now allowed on the CBA account, the traveler needs to ensure that the actual "plastic" is not necessary, as there is no plastic issued for a CBA Account.
3. Cardholder - employee whose name appears on the card and who is accountable for all charges made with the card.
4. Cardholder Agreement Form - an agreement signed by the cardholder, prior to being issued a Travel Card, which verifies that the cardholder has read and understands the policies and procedures of the Louisiana Board of Pharmacy, and agrees to comply with them.
5. Cardholder Enrollment Form - a form containing pertinent information on a cardholder necessary for statement and information mailing purposes, contact information, daily/monthly spending limits and budgetary controls. The form must be submitted by the cardholder to the Program Administrator for completion and approval.
6. Credit Card - a Visa card issued by Bank of America for State of Louisiana for the purpose of making authorized purchases on behalf of the Louisiana Board of Pharmacy.
7. Cycle – the period of time between billings. For example the State of LA t-Card closing period ends at midnight the 8th of each month.
8. Cycle Limit – maximum spending (dollar) limit a T-Card/CBA is authorized to charge in a cycle. These limits should reflect the individual's purchasing patterns. These are preventative controls and, as such, should be used judiciously.
9. Denied Item - a purchase that has been determined by the Supervisor/Reviewer as a non work related purchase and not acceptable for payment. This item must be returned for a credit memo or must if not returnable, employee must reimburse the Department. Continued purchases of this type will result in disciplinary action.
10. Disputed Item – any transaction that was double charged; charged an inaccurate amount, or charged without corresponding good or services by the individual cardholder.
11. Electronic Fund Transfer (EFT) – an electronic exchange or transfer of money from one amount to another, either within the same financial institution or across multiple institutions.
12. Electronic Signature – an electronic sound, symbol or process attached to or logically associated with a record or executed or adopted by a person with the intent to sign the record.
13. Fraud – any transaction, intentionally made that was not authorized by the cardholder or not for Official State Business.
14. Incidental Expense – if travel expenses have been approved, these are expenses incurred while traveling on official state business which are not allowed on the state liability purchasing card. Incidentals include but are not limited to, meals; fees and tips to porters, baggage carriers, bellhops, hotel maids; transportation between places of lodging/airport such as taxi; phone calls and any other expense not allowed in the State Liability Travel Card and CBA Policy.

DEFINITIONS (continued)

15. INTELLILINK – Visa’s web-based auditing tool which is used to assist with monitoring and managing the agency’s card program usage to ensure that card use conforms to all policies and procedures.
16. ISIS – State of Louisiana’s integrated system used for accounting, financing, purchasing, and contracting functions.
17. LaGov – State of Louisiana’s newest integrated system used for accounting, financing, logistics, human resources, travel and data warehouse storage and reporting.
18. MCC Code (Merchant Category Code) – a standard code the credit card industry used to categorize merchants based on the type of goods or services provided by the merchant. A merchant is assigned an MCC by the acquiring bank.
19. Merchant Category Code Group (MCCG) – a defined group of merchant category codes. MCCGs are used to control whether or not cardholders can make purchases from particular types of merchants.
20. Merchant – a business or other organization that may provide goods or services to a customer.
21. Billing Statement of Account - a listing of all transactions charged to the cardholder’s account through the end of the monthly billing cycle. This statement is sent by the bank, directly to the cardholder, on a monthly basis for reconciliation purposes. This is not a bill. The cardholder must reconcile this statement upon receipt and forward it to the Approver to accompany transaction documentation at the time of review and approval.
22. Monthly Spending Limit - a dollar limit assigned to the cardholder for the total of all charges made during the monthly billing cycle.
23. PPM 49 (Policy Procedure Memorandum 49) – the state’s general travel regulations. These regulations apply to all state departments, boards and commissions created by the legislature or executive order and operating from funds appropriated, dedicated, or self sustaining; federal funds, or funds generated from any other source.
<http://doa.louisiana.gov/osp/travel/travelpolicy/2013-2014travelguide.pdf>
24. Program Administrator - liaison between the cardholder, Agency Travel Card Administrator, State Program Administrator and Bank of America. Provides support and assistance to all agencies, processes new card applications and changes to cardholder information, provides training and maintains policies and procedures. Maintains user login id and passwords for all agency users. Maintains hierarchal structure for all agency roles.
25. Single Purchase Limit (SPL) – the maximum spending (dollar) limit a T-Card is authorized to charge in a single transaction. The SPL limit may be up to \$5,000; however, this limit should reflect the individual’s purchasing patterns. These are preventative controls and, as such, should be used judiciously. Purchases shall not be split with the intent of and for the purpose of evading the T-Card single purchase limit set for cardholders.
26. T-Card – a credit card account issued in an employee’s name. This account is a direct liability of the State and is paid by each agency.
27. Billing Cycle Purchase Log - Printed from WORKS to document the online reconciliation process for purchases/services charged during the billing cycle. The Billing Cycle Purchase Log is printed and filed with the billing statement and the transaction documentation obtained from the merchant.
28. Transaction – a single purchase. A credit also constitutes a transaction.

DEFINITIONS (continued)

29. Transaction Documentation – all documents pertaining to a transaction, both paper and electronic. The documentation is also used for reconciliation at the end of the billing cycle and is to be retained with the monthly reconciliation documentation for review and audit purposes. Examples of transaction documentation include, but are not limited to: itemized purchase receipts/invoices (with complete item descriptions, not generic such as “general merchandise), receiving documents, credits, disputes, and written approvals. If travel has been approved, documentation should also contain airline exceptions, justifications, approvals, travel authorization, travel expense, etc.
30. WORKS – Bank of America’s web-based system used for program maintenance, card/CBA issuing/suspension/cancellation and reporting.
31. WORKS Workflow – Bank of America’s online system that includes user profiles and transaction workflow. For ISIS and LaGov interfaced agencies, transactions are coded and interfaced to the ISIS/LaGov systems for payment monthly.

Rescinded

Cardholder Enrollment

1. A Cardholder Enrollment Form must be completed and signed by the Executive Director for each prospective cardholder. The Executive Director is responsible for assigning cardholder's spending limits per transaction and per monthly cycle which limits the number of transactions allowed for the cardholder. The form should be sent to:
Executive Director
Louisiana Board of Pharmacy
3388 Brentwood
Baton Rouge, LA 70809
mbroussard@pharmacy.la.gov
2. When the Program Administrator receives the new card from the bank, the cardholder will be contacted for training. The prospective cardholder must attend a training session before receiving and using the credit card.
3. Credit cards are not transferable. Use by anyone other than the cardholder is prohibited. The only person authorized to use the card is the person whose name appears on the face of the card. A transaction can only be signed by the cardholder. A receipt may be signed by someone other than the cardholder if it is being used as a delivery receipt for a phone order. In this case the receipt should be signed "Received By" followed by the employee's name accepting the delivery.
4. The Program Administrator must be notified immediately of a cardholder's termination. The cardholder is responsible for return of the credit card to the Program Administrator upon termination of employment. Cardholders who transfer to a new position in the same agency and require the use of the card as part of their new duties must complete a Cardholder Enrollment Form and submit the form to the Program Administrator indicating "Change" on the form.
5. If the card is lost, stolen, or damaged, the cardholder must immediately notify Bank of America at 1-888-449-2273 and the Program Administrator at (225) 925-6498 after reporting the incident to the bank. If the card is located after reported lost or stolen, it must be destroyed.
6. Whenever any information contained on the Cardholder Enrollment Form changes, the changes must be submitted to the Program Administrator on the form with "Change" checked on the form.
7. The cardholder shall submit through their chain of command a Cardholder Enrollment Form indicating "Change" if use of the card has changed and lower or higher limits are necessary.

Supervisor/Approver Responsibilities

1. Obtain annual approver certification through the State's online certification training program in which a passing grade of at least 90 must be obtained.
2. Obtain agency program training and sign an Approver Agreement Form, annually, with originals given to agency program administrator along with approver receiving a copy.
3. Obtain, review and understand the state and agency policies and all applicable rules, regulations, policies, procedures, guidelines, statutes, executive orders and PPM49, if applicable.
4. Keep well informed of program updates as sent from agency program administrators or anyone associated with the State Liability T-Card Program.
5. Ensure that a log is completed by each cardholder, that the log corresponds with the monthly billing statement and that the log and statement are signed by both approver and the cardholder.
6. Always submit approvals with all necessary documentation including complete line item descriptions where generic description is on receipts such as "general merchandise" (both paper and electronic) in a timely manner.
7. Ensure that supporting documentation, including the signed log or approved electronic log and signed statement, by both approver and the cardholder, along with any findings and justifications are sent to the agency's fiscal office for review, where the documentation will be maintained in one central location, in accordance with the state's requirements and the agency's policy.
8. Immediately report any fraud or misuse, whether actual, suspected or personal charges to the agency program administrator, as well as, agency head and other personnel/agencies as required. An approver will participate in any disciplinary actions which may be deemed appropriate, if necessary.
9. Notify an agency program administrator, immediately, upon separation, change in department/section or during extended leave for any cardholders in which you are the approver.
10. Complete an exit review, with the cardholder, of the cardholder's transactions, supporting documentation and receipts, as well as, obtaining necessary signatures prior to departure.
11. Ensure that the T-Card is obtained from the employee upon separation or change in department/section and return card to agency program administrator. Ensure that agency program administrator makes necessary changes to cancel the card and to remove approver as the employee's approver and/or employee from the list of cardholders for which approver is responsible.
12. Ensure that either approver or the cardholder notifies the agency program administrator if card is lost, stolen or has fraudulent charges. Ensure the cardholder immediately notifies the bank as well.
13. Review, at a minimum annually, all cardholders which approver is designated as an approver along with profile limits to ensure appropriate utilization of the card and program intent. This will ensure that all cardholders limits, MCC Codes, etc., are working properly for the cardholder. If limits or codes are not allowing the cardholder to perform his duties, then approver should contact the agency program administrator to make necessary adjustments.
14. Ensure that cardholder is never a final approver of his own monthly transactions.
15. Ensure each transaction, to the best of approver's knowledge:

- Has an appropriate business purpose, fits the cardholder's business needs, and is audited including a review of all supporting documentation.
 - Is in compliance with all current purchasing rules and regulations, statutes, executive orders, policies and PPM49, if applicable.
 - Is in compliance with the board's policy and the State Liability Travel Card and CBA Policy, if applicable.
 - Does not include state tax, as this program is state tax exempt.
 - Includes all required and complete documentation, including a detailed receipt, supporting the transaction and all documentation is scanned into Workflow and tied to the appropriate transactions.
 - Is not a duplication of personal request and/or reimbursements, if for travel related expenses.
 - Has been verified to ensure that each transaction has a receipt and the receipt's date, supporting documentation and documentation dates, along with the log dates, correspond with known business needs or trip allowances and dates, if applicable and travel has been approved, along with program cycle dates (which begin the 8th of one month and ends the 9th of the following month).
 - Has been coded properly for payments as outlined in the agency policy and procedures and as required in Workflow for ISIS and LaGov interfaced agencies.
16. Secure all assigned WORKS application User IDs and passwords. Never share User ID and passwords and/or leave the work area while logged into the system or leave log-in information lying in an unsecure area.
17. Ensure Ebay, Paypal, Amazon, etc are tied to business accounts and are legitimate state business related purchases.
18. Understand that failure to properly fulfill responsibilities as a T-Card approver could result, at a minimum, in the following:
- Written counseling which would be placed in employee file for a minimum of 12 months.
 - Consultation with agency program administrators, and possibly head of agency and internal audit section.
 - Disciplinary actions, up to and including termination of employment.
 - Legal actions, as allowed by the fullest extent of the law.

Audit Reports

State Purchasing has created a list of reports created for agencies to use for monthly audit requirements of this program through WORKS and Intellilink. Some reports are required to be generated and reviewed at least once a month, while others have been created and designed as added value to assist in policy compliance. Although all of the reports are not required monthly, agencies are strongly encouraged to determine which of the reports are of the most value to them and should consider rotating them, at a minimum every other month.

When running these reports, it is the agency's responsibility to not only review the data gathered, but to make certain that transactions are for a business purpose and have a legitimate business need for the cardholder. In the event that a transaction is being investigated, the cardholder must explain and justify the transaction being questioned. Based on the cardholder's explanation, the agency should address the situation accordingly.

Supervisor/Approver Responsibilities (continued)

All documentation/findings/replies, resulting from the monthly audit of T-card transactions, are to be centrally located and readily available for any internal or external audits that may occur. Most reports are available through VISA Intellilink. Intellilink's data is available for a 27 rotating month period. If an agency requires documentation retention for more than 27 months, it is the responsibility of the agency to obtain and archive the transaction data accordingly.

Monthly certification that the above procedures have been conducted must be submitted to the Office of State Travel. The certification will indicate that agency personnel administering the T-card program have generated the required reports, all requirements listed in the policy have been completed, and necessary findings have been investigated, documented and handled appropriately.

In addition, reports shall be used as a tool to assist the agency program administrator / agency with determining which cardholders may need a refresher training course, re-certification of the state's online training, counseling, cancellation of card, due to inaccuracies, etc., as well as, to determine possible changes to cardholder's limits, profiles, and MCC groups.

When WORKS Workflow implementation has been completed, a Billing Cycle Purchase Log report will be available for print. It is an un-editable, PDF, formatted report. The WORKS Workflow system data is generated at the time of report request with the most current signoff information with the date and time stamp of the approval captured in the audit tracking along with all documentation which has been scanned to support T-Card transactions and tied to the appropriate transaction. Always ensure that the correct cycle period/dates are entered when printing the log report. Cycle dates for the program begin on the 8th of one month and ends on the 9th of the following month.

Once an agency has implemented WORKS Workflow, there are additional reports that can be created to give cardholder approvers, accountants, agency program administrators, auditors, and management information to monitor the compliance of their cardholders and staff. Data is available electronically within WORKS Workflow for up to 3 years. If an agency requires documentation retention for more than 3 years, it is the responsibility of the agency to obtain and archive the transaction data annually.

Cardholder Responsibilities

1. Use T-Card for official state business only. No personal use. T-Card is limited to the person whose name is embossed on the card. The T-Card shall not be used to pay for another or loaned to another person to pay for official or non-official business expenses.
2. Attend required agency training and sign a State Corporate Liability Cardholder Agreement Form, annually, acknowledging cardholder's responsibilities prior to receiving the card.
3. Obtain annual cardholder certification through the State's online certification training program receiving a passing grade of at least 90 to possess or continue to possess a State of Louisiana T-Card.
4. Never include the full T-Card account number in emails, fax, reports, memos, etc. If an account number is necessary, only the use of the last four or eight digits of the account number is allowed.
5. Secure assigned WORKS application User IDs. Never share User ID and password and/or leave work area while logged into the system or leave log-in information lying in an unsecure area.
6. Recognize that the T-Card is the property of the State of Louisiana and the cardholder is responsible for the physical security and control of the T-Card and its appropriate use. The Cardholder is also responsible for maintaining the security of card data such as the account number, the expiration date, and the card verification value (CVV), the 3-digit security code located on the back of the card.
7. Never send a copy of the T-Card if requested by a merchant. If this is required for payment, then the cardholder must use another form of payment other than the State Liability T-Card.
8. Never use an individual T-Card for personal, non-business expenses for any reason.
9. Never pay taxes on purchases with this card, since it is a state liability. See Section 6.
10. Never, under any circumstances, use the T-Card to access or attempt to access cash.
11. Never accept cash in lieu of a credit to the T-Card account.
12. Never use T-Card for gift cards/gift certificates, without prior approval from the Office of State Purchasing and Travel, as they are considered cash and taxable.
13. Never use T-Cards to avoid procurement or payment procedures.
14. Never use the T-Card for the purchase of alcohol, food, travel expense transactions or entertainment services. The only exceptions are vehicle rentals.
15. Never use T-Card for fuel or vehicle maintenance if agency is part of the Fuel Card and Maintenance Program.
16. Submit all required transaction documentation (both paper and un-editable electronic format), special approvals, etc., timely. Remember, every transaction must have a receipt with a full description, not a generic description such as "general merchandise" or item should be fully documented/described elsewhere (both paper and un-editable electronic format). Failure to do so should result in cancellation of T-Card. All paper supporting documentation, including the signed log or approved electronic log and signed memo statement, along with any findings and justifications is to be scanned into Workflow and tied to each applicable transaction. All mentioned above, will be sent to the supervisor/approver for required audit and signatures, and forwarded to the agency's fiscal office for review and file maintenance.

Cardholder Responsibilities (continued)

17. **NEVER MAKE A PAYMENT DIRECTLY TO THE BANK** in the event that an unauthorized charge is placed on the individual's state corporate liability T-Card. Making a payment directly to the bank will cause the monthly statement billing file to be out of balance, and the agency will have to determine the cause. Ultimately, it will be determined that a personal payment was made. In order to avoid this situation, report any unauthorized charges to the agency's program administrator immediately, along with decision on how the funds will be reimbursed back to the agency.
18. Notify the agency's program administrator if fraudulent charges are noticed, as the card may need to be cancelled and another card issued.
19. Notify the agency's program administrator if use of a card has changed and lower or higher limits are necessary.
20. Responsible for requesting additional training if the use of the online Works system proves to be difficult to master
21. Agrees to reimbursement of unauthorized charges by personal check or payroll deduction.
22. Makes purchases for which the cardholder has been authorized to spend and does not exceed their single transaction limit.
23. Card declines due to exceeding monthly or single transaction limit may result in cancellation of the card. (See Card Misuse section).
24. Online accounts such as Ebay, Paypal, Amazon, etc must have a standalone business account or registration and must not be combined with an individual's personal account.
25. Cardholder's business email address must match the cardholder's name.

Making a Purchase

Merchants Category Codes (MCC) have been developed and built into the card. These codes authorize the types of goods and/or services for which individual cards may be used (i.e. office supplies). A list of Merchants Category Codes is furnished to cardholders. Included in the list are prohibited and restricted codes. Cardholders are prohibited from attempting to purchase from the prohibited or restricted merchants unless the Department has obtained prior approval from the Office of State Purchasing and Travel.

LBP – Louisiana Board of Pharmacy purchasing procedures will remain the same. Procedures for making card purchases:

1. Obtain necessary approvals to purchase through proper chain of command.
2. When making purchases in person, the cardholder must sign the charge receipt and retain the customer copy or proper documentation of the purchase. Cardholder should be certain that the total amount of the purchase (including shipping, handling, postage, freight, etc.) does not exceed the card's single transaction dollar limit.
3. State sales tax should not be charged on card purchases.
4. When making a purchase other than in person (e.g. via telephone, computer, mail order, etc.), the cardholder should give the vendor the account number and tax exempt number (both of which are embossed on the card) and direct the vendor to include the following on the shipping label or packing slip.
 - Cardholder name and telephone number
 - Department name
 - Complete delivery address
 - VISA purchase
5. For items such as subscriptions and registrations, where the vendor does not normally generate a receipt or packing slip, a copy of the ordering document may be used. Acceptable documentation must include a line description and line item pricing for the purchase or the item will not be reimbursed.
6. The cardholder must maintain a file of transactions including document purchase type (telephone, computer, mail order, etc.) to facilitate monthly reconciliation. The cardholder will be solely responsible for reconciling his statement with the database.
7. In the event the Central Warehouse receives a shipment on behalf of the cardholder, Central Warehouse personnel will notify the cardholder of receipt. The cardholder will be responsible for retaining all documentation (shipping labels, packing slips, etc.) related to the purchase.
8. The cardholder will maintain a permanent file of all supporting documentation for card purchases, in accordance with state laws. The documentation is subject to review by LBP, the Legislative Auditor and other duly authorized auditors. The file must be maintained for a period of 3 years. If the purchase is for a grant funded project, the cardholder is responsible for ensuring the documentation is maintained for the appropriate required retention schedule.

Making a Purchase (continued)

Merchandise Returns & Exchanges

1. The cardholder is responsible for contacting the merchant when merchandise purchased with the card is not acceptable (incorrect, damaged, defective, etc.) and arranging for the return for credit or exchange.
2. If the merchandise is to be exchanged, the cardholder is responsible for returning the merchandise to the merchant and obtaining a replacement as soon as possible. Documentation of the resolution of the exchange is to be retained with the support documentation of that purchase.
3. If the merchandise is returned in person, the cardholder is responsible for obtaining a credit receipt from the merchant and retaining the receipt with the support documentation. If the merchandise is shipped back to the supplier, prepare the package according to supplier instructions and retain shipping documents until supplier issues a credit or exchanges merchandise. Supplier must issue credit to the card. Receiving cash or checks to resolve a credit is prohibited.

State Corporate Business Account (CBA) Requirements/Guidelines

1. All CBA transactions must be in accordance with PPM49 guidelines, State Liability Travel Card and CBA Policy, Purchasing Policies, Rules and Regulations, Board policy, Louisiana Statutes and/or Executive Orders.
2. The purpose of a CBA is to provide a tool for agencies to purchase airfare, conference registrations and assist with payment of high dollar travel expenses only, as per current State Liability Travel Card and CBA Policy. Please realize that although other travel related charges are now allowed on the CBA account, the traveler should be aware that there is no plastic issued for a CBA to ensure that this will not impair his travel plans.
3. The account(s) are issued in the name of the agency and the agency program administrator is the primary point of contact for administering the accounts. The agency may designate an administrator/authorizer per account. Each administrator has the same duties, obligations and responsibilities as a cardholder. The contract travel agency must be notified of authorizers for each CBA account.
4. CBA account(s) shall have an overall card cycle limit determined by the agency. These limits should reflect the agency's travel patterns. Therefore, these limits must be judiciously established by the agency and adhered to accordingly. The agency Program Administrator may establish a new or additional CBA account through Bank of America's on-line system, WORKS.
5. The CBA accounts are the direct liability of the State. Each agency is responsible for ensuring all accounts are paid timely and in full each month with ONE electronic funds transfer (EFT) to Bank of America.
6. CBA accounts do not allow issuance of a plastic card. These are referred to as ghost accounts. If it is determined that personal or other unauthorized charges are occurring on the CBA account, appropriate steps, up to and including dismissal, shall be taken to resolve the misuse/abuse of the account.

7. The full CBA account number shall never be included in emails, fax, reports, memos, etc. If an account number is necessary, only the use of the last four or eight digits of the account number is allowed.
8. All persons with approval for use of travel on their T-Card shall follow the Statewide Travel card policy and procedures and PPM49.

Reconciliation

Agency procedures and controls are in place for prompt payment, reconciliation and cost distribution of charges and credits. Post audits of cardholder transactions will be performed to monitor the number and dollar amount of purchases made; vendor used, and detailed transaction information to properly allocate the cost.

1. The paper billing statements from Bank of America will be mailed directly to each cardholder at the business address. The cardholder must reconcile purchases made during the billing cycle by matching the billing statement to the online transaction log in WORKS, along with the cardholder's supporting documentation (receipts). The documentation (receipts) will be reviewed and certified by the cardholder as received OR reported as a disputed item if the receipt does not match the transaction online information. The cardholder shall allocate the expense to the appropriate budget categories and sign off electronically in WORKS on each transaction by the 8th of the month. This information will be queued for supervisory review and approval.
 - If a charge or credit does not appear on the statement within 60 days after the original charge or credit was made, the cardholder must notify the Program Administrator.
 - Incorrect charges are disputed online in the WORKS system.
2. The Approver must review the information in WORKS, along with the documentation submitted by the cardholder. Approver must verify that acceptable documentation exists (including line item description, price and coding) to support each purchase and/or credit, verify that purchases are for official state business, and that purchases comply with appropriate rules and regulations. The Approver shall approve the log by signing off in WORKS to certify his review and approval. A cardholder shall not, and cannot, approve his own monthly purchasing log in WORKS. The WORKS transaction log must be reviewed and approved (signed off) by the Approver for the previous billing cycle by the 11th of the month.

Once approved and returned to the cardholder, the cardholder shall print a copy of the Billing Cycle Purchase Log to file with the billing statement and transaction documentation. This log will document the electronic approvals and coding in addition to the electronic approvals tracked within WORKS online system.

Note: If the Approver determines that personal or unauthorized charges are made on the card, the transaction is "flagged" in WORKS, which returns it to the cardholder, with a comment, for resolution. If repeated issues occur, appropriate steps shall be taken to resolve the misuse/abuse of the card. When an unapproved item was purchased and it is discovered during review, the item should be returned for a credit memo. If the item is nonrefundable, the employee must reimburse the Department for this purchase.

Reconciliation (continued)

3. If a cardholder's transactions are not signed off timely, the card balance will not be fully refreshed to the full monthly credit limit until all transactions are completed (signed-off) for all previous cycles.
4. All supporting documentation, including the signed log or approved electronic log and signed memo statement, by both cardholder and approver, along with any findings and justifications, must then be forwarded to the agency's fiscal office for review and maintenance of the file. Once all approvals and audits by cardholder approvers have been obtained and forwarded to the agency's fiscal office, the agency's fiscal office must review receipts in the program journal vouchers to correct any necessary coding changes.

Rescinded

Card Misuse

1. **Fraud Purchase** – any use of the T-card/CBA which is determined to be an intentional attempt to defraud the state for personal gain or for the personal gain of others.

An employee suspected of having misused the T-Card/CBA with the intent to defraud the state will be subjected to an investigation. Should the investigation result in findings which show that the actions of the employee have caused impairment to state service, and should those findings be sufficient to support such action, the employee will be subject to disciplinary action. The nature of the disciplinary action will be at the discretion of the Entity's Appointing Authority and will be based on the investigation findings and the record of the employee. Any such investigation and ensuing action shall be reported to the Legislative Auditor, the Office of Inspector General and the Director of the Office of State Purchasing and Travel.

2. **Non-Approved Purchase** – a purchase made by a State cardholder for whom payment by the state is unapproved. A non-approved purchase differs from a fraud purchase in that it is a non-intentional misuse of the T-card/CBA with no intent to deceive that agency for personal gain or for the personal gain of others.

A non-approved purchase is generally the result of a miscommunication between a supervisor and the cardholder. A non-approved purchase could occur when the cardholder mistakenly uses the T-card/CBA rather than a personal card.

When a non-approved purchase occurs, the cardholder should be counseled to use more care in handling of the T-card/CBA. The counseling should be in writing and maintained in the employee's file for no longer than one year unless another incident occurs. The employee shall pay for the item purchased inappropriately. Should another incident of a non-approved purchase occur within a twelve (12) month period, the appointing authority should consider revocation of the T-card/CBA.

3. **Same Vendor/Same Day (Split Purchasing)** – A split purchase occurs when a cardholder purchases like commodities within a limited time frame, while exceeding the single purchase limit set for cardholder. Purchases shall not be artificially divided to avoid the single purchase limit (SPL) or procurement procedures.
4. **Merchant Forced Transaction**-Commercial cards are accepted by a variety of merchants that process transactions only if approved by the issuing bank thereby abiding by the card controls in place. Merchant transactions are processed using one of the 2 steps as follows:
 1. Merchants process transactions against card controls (MCC, limits, expiration date, etc.) and, if approved, receive an authorization number.
 2. Merchants submit the transactions for payment from the bank.
 3. In rare instances, merchants will circumvent the authorization process and only perform step 2. This means that the merchant didn't process the transaction against the card controls and therefore did not receive an authorization number.
 4. If this happens, the merchant has forfeited all dispute rights and the transaction can be disputed and unless the merchant can provide a valid authorization number, the dispute will be resolved in the cardholders favor.

Card Misuse (continued)

5. Card and WORKS User ID/Password Security

Each cardholder, CBA administrator, agency program administrator, auditor, cardholder approver, etc is responsible for the security of their card, User ID(s) and password(s), and therefore should:

- Never display their card account number, WORKS and WORKS Workflow User ID numbers and passwords around their work area
- Never share User IDs and passwords and/or leave work area while logged into the system or leave log-in information lying in an unsecure area
- Never give his or her card account number, User IDs or passwords to someone else
- Never email the full account numbers or User IDs numbers or passwords under any circumstances

Consequences of Card Misuse

- Suspension/cancellation of card
- Written counseling which would be placed in employee file for a minimum of 12 months
- Consultation with agency program administrators, and possibly head of agency and internal audit section
- Disciplinary actions, up to and including termination of employment.
- Legal actions, as allowed by the fullest extent of the law.

Sales Tax

1. LA state sales tax should not be charged on card purchases.
2. In the event state sales tax is charged and a credit is warranted, it will be the cardholder's responsibility to have the vendor (not Bank of America) issue a credit to the cardholder's account.
3. It is State Policy not to pay LA sales tax; however, the Agencies may exempt cardholders from obtaining a credit from the vendor for the state sales tax charges of \$25.00 or less. If a cardholder continually allows taxes of \$ 25.00 or less to be charged to the card, corrective measures must be taken. It is the Agency's responsibility to monitor these sales tax transactions to ensure corrective action is taken against repeat offenders.
4. See current State Liability Travel card and CBA Policy for travel exemptions

Documentation

1. Ensure that documentation is adequate and sufficient to adhere to current purchasing policies, rules, regulations, statutes, executive orders, State Travel Card and CBA Policy, for recording of expenditures in the State/Agency accounting system and the State Liability Travel card and CBA Policy and PPM49, if applicable. The agency must ensure that all supporting documentation along with receipts are scanned and attached to each corresponding transaction. Agencies should ensure that immediate supervisors/approvers are verifying and ensuring that these controls are being met and that transactions are appropriate, accurate, have a business case and business need for the purchase, all receipt dates and other supporting documentation dates are applicable with known need or business travel, if applicable, and approved. Documentation of approval must be accomplished electronically online by signing off on the transaction. Approval by the approver certifies that the documentation is acceptable for each transaction, that it was for official state business, that it is in compliance with appropriate rules and regulations, etc., as mentioned above and that it has been reviewed and is approved.
2. Documentation is required for all purchases and credits. For items purchased over the counter, the cardholder should obtain the customer copy of the receipt. When ordering by telephone, fax, or computer, the cardholder must obtain a packing list or similar document. For items such as registrations, where the vendor does not normally generate a receipt or packing slip, a copy of the ordering document may be used. Acceptable documentation must include a line description, with full description not a generic “general merchandise” description, and line item pricing for the purchase. Electronic receipts are allowed if they are un-editable and are maintained in compliance with the agency retention policy.
3. For internet purchases, the print out of the order confirmation showing the details, or the printout of the order details, or the shipping document if it shows what was purchased, the quantity and the price paid suffice for the itemized receipts.
4. The agency cardholder approvers will forward all supporting documentation along with invoices, receipts and signed paper or approved electronic log, by both cardholder and approver, and signed statement, by both cardholder and approver, and any findings and justifications to the agency’s fiscal office for review and for maintenance of the files in accordance with record retention laws. This file must be centrally located in the agency’s fiscal office and will be subject to review by the Office of State Purchasing and Travel, the Louisiana Legislative Auditors Office and any other duly authorized auditor.
5. All system entries and scanned supporting documentation, when utilizing Workflow and electronic approvals are maintained electronically within the WORKS Workflow online system for up to 3 years. If an agency requires documentation retention for more than 3 years, it is the responsibility of the agency to obtain and archive the transaction data annually. If the purchase is for a grant funded project, the cardholder is responsible for ensuring the documentation is maintained for the appropriate, required retention schedule.

Dispute Resolution

The cardholder's first recourse is to contact the merchant to try and resolve problems regarding disputed items, charges or quality.

1. If the merchant agrees the error has been made, he will credit the cardholder's account. The credit will appear on the next monthly billing statement. The cardholder should check the next statement for the credit.
2. If the problem with the vendor is not resolved, notice of the dispute must be communicated to bank within 60 days from the billing close date (5th of each month) to:

Bank of America-Commercial Card Service Operation
P.O. Box 53142
Phoenix, AZ 85072-3142
Phone (800) 352-4027 Fax (888) 678-6046

A copy of the dispute form should be faxed to the Program Administrator at (225) 925-6498.
3. The transaction will be paid; therefore, it is important for the cardholder to mark the online WORKS transaction as "DISPUTED." The cardholder should retain a copy of the disputed documentation and verify receipt of the credit on future statements.
4. All disputes will be resolved by Bank of America within 180 days.

Fraudulent Charge

In the event of a fraudulent charge, the cardholder shall complete the following steps:

- Contact the Bank of America's Security Division at (877) 451-4602. Sign and return the affidavit provided by Bank of America. Notify the Travel Card Program Administrator (225) 925-6498 of the fraudulent charge. Submit a copy of the fraudulent charge affidavit to the Travel Card Program Administrator. Indicate the fraudulent charge in the comment section of the transaction during online reconciliation in WORKS.

2
3 Title: Application for New Pharmacy Permit (in-state)

Policy No. IV.B.6

4
5 Approved: 11-15-2017

Revised:

6
7
8 1. The statutory authority requiring pharmacies to be licensed by the Board prior to
9 dispensing medications to Louisiana residents is found at La. R.S. 37:1221.A,
10 and further amplified at La. R.S. 37:1222.

11
12 2. The regulatory authority for the regulation of pharmacies is found at LAC 46:LIII.
13 Chapters 13-31.

14
15 3. The Executive Director shall develop and maintain an application form to be used
16 by applicants for nonresident pharmacy permits. The form shall be uniquely
17 identified and bear the date of its creation or revision. The application form shall
18 collect sufficient information necessary to:

- 19 a. Establish the identity of the applicant;
- 20 b. Describe the direct and indirect ownership profile of the applicant;
 - 21 ➤ *Direct* ownership refers to the natural person(s) or legal person(s)
 - 22 [organizations] seeking and holding the permit.
 - 23 ➤ *Indirect* ownership refers to the natural person(s) or legal person(s)
 - 24 holding ownership interests in the direct owner ~~or other indirect~~
 - 25 ~~owners. There may be more than one level of indirect owners; if so,~~
 - 26 ~~all levels of indirect owners must be declared in the application.~~
 - 27 i. by collecting specific information for every *natural* person with any
 - 28 direct or indirect ownership interest in the pharmacy, specifically:
 - 29 (a) Full legal name, date of birth, and Social Security number;
 - 30 (b) Mailing address and telephone number;
 - 31 (c) Percentage of ownership or fraction thereof;
 - 32 (d) Evidence of any professional license or other credential
 - 33 issued by any state government agency (either legible copy
 - 34 or website verification thereof), and further, whether or not
 - 35 the credential has ever been sanctioned or disciplined by
 - 36 any state licensing agency or by any local, state, or federal
 - 37 government agency, or by any local, state, or federal court.
 - 38 In the event of any such sanction or discipline, or in the
 - 39 event an application for such credential has ever been
 - 40 denied or refused by any jurisdiction, a copy of the board,
 - 41 agency, or court decision document shall be provided.
 - 42 ~~This requirement shall not be applicable to a natural person~~
 - 43 ~~holding no direct ownership, no first level indirect ownership,~~
 - 44 ~~and less than 5% ownership in any indirect level ownership~~
 - 45 ~~beyond the first level.~~
 - 46 ii. by collecting specific information for every *legal* person
 - 47 (organization) with any direct or indirect ownership interest in the
 - 48 pharmacy, specifically:

50
51 Title: Application for New Pharmacy Permit (in-state)

Policy No. IV.B.6

52
53 Approved: 11-15-2017

Revised:

54
55
56 3.b.ii (cont.)

- 57 (a) Full legal name and Federal Employment Identification
- 58 Number, as evidenced by a copy of the Internal Revenue
- 59 Service (IRS) letter assigning that number, or in the
- 60 alternative, a signed W-9 form;
- 61 (b) Mailing address and telephone number;
- 62 (c) Percentage of ownership or fraction thereof; and
- 63 (d) An accounting of 100% of the ownership thereof, ~~and further,~~
- 64 ~~where there are multiple levels of ownership, an~~
- 65 ~~organizational chart clearly identifying the corporate~~
- 66 ~~relationships.~~
- 67 ~~Where the legal person is a publicly traded firm or an~~
- 68 ~~institutional investor, the accounting of its ownership shall~~
- 69 ~~identify any natural person holding 5% or more ownership~~
- 70 ~~interest in that organization.~~

- 71 c. Describe the pharmacy's location and credentials issued by other
- 72 agencies;
- 73 ~~d. Identify the pharmacy owner's registered agent for the service of process;~~
- 74 e. Identify the special professional services intended for Louisiana residents;
- 75 ~~and~~
- 76 f. Identify the ~~Owner's Managing Officer and Pharmacist-in-Charge, and~~
- 77 ~~further, assist in the determination of their his fitness for practice in these~~
- 78 ~~capacities that capacity; and~~
- 79 g. Confirm the owner's consent for the Pharmacist-in-Charge to submit the
- 80 application for the pharmacy permit on behalf of the owner.

- 81
- 82 4. The application form shall instruct the applicant to cause the following persons
- 83 identified in their application to submit to a criminal background check (CBC):
- 84 a. ~~Owner's Managing Officer;~~
- 85 b. Pharmacist-in-Charge; and
- 86 c. Any natural person holding 20% or more ownership interest at the direct or
- 87 ~~first-level~~ indirect level; provided, however, that this requirement may be
- 88 waived in the event that person has already submitted to such CBC for the
- 89 Board and that CBC report was received less than five years prior to the
- 90 date of the application for the permit.

- 91
- 92 5. The application package should also contain additional guidance information for
- 93 the applicant as well as a summary checklist designed to ensure the submission
- 94 of all additional required documents.
- 95
- 96



104 6. All applications shall be referred to the Credentials Division staff for processing.

105 a. In the event the staff determines there are deficiencies in the application
106 or supporting materials, the staff shall communicate with the applicant to
107 assist them in compiling a complete application.

108 b. In the event the staff determines there is information (e.g., prior
109 disciplinary or legal action) impacting qualifications or fitness for practice,
110 staff shall refer the completed application to an administrative officer, for a
111 determination as to whether a referral to a Board committee is warranted.

112 i. In the event the administrative officer determines no committee
113 referral is warranted, the administrative officer shall annotate the
114 application form and return it to licensing staff for final
115 administrative review and issuance of the permit.

116 ii. In the event the administrative officer determines a referral to a
117 Board committee is warranted, he shall assign a case number to
118 the application, schedule a hearing before the appropriate
119 committee, and notify the applicant of the hearing, ensuring
120 compliance with due process requirements.

121 c. In the event staff determines the applicant does not meet all of the
122 licensing criteria and the applicant wishes to appeal that staff
123 determination, staff shall direct the applicant to submit a written appeal to
124 the Executive Director. The Executive Director shall present the appeal
125 and relevant information from the applicant's file to the Board President.
126 The Board President shall have the authority to review such appeals and
127 determine whether to grant such requests, either in part or in full. The
128 Executive Director shall notify the applicant and the licensing staff of the
129 President's decision.

131 7. When the licensing staff has completed the processing of the application, the
132 staff may issue the permit if they have been delegated the authority to issue it, or
133 in the alternative, shall refer the application to the licensing manager, for final
134 review and issuance of the permit.

2
3 Title: Application for New Nonresident Pharmacy Permit

Policy No. IV.B.7

4
5 Approved: 11-15-2017

Revised:

- 6
7
8 1. The statutory authority requiring nonresident pharmacies (located outside the
9 state) to be licensed by the Board prior to dispensing medications to Louisiana
10 residents is found at La. R.S. 37:1221.B and C, and further amplified at La. R.S.
11 37:1222.
12
- 13 2. The regulatory authority for the regulation of nonresident pharmacies is found at
14 LAC 46:LIII.Chapter 23.
15
- 16 3. The Executive Director shall develop and maintain an application form to be used
17 by applicants for nonresident pharmacy permits. The form shall be uniquely
18 identified and bear the date of its creation or revision. The application form shall
19 collect sufficient information necessary to:
20 a. Establish the identity of the applicant;
21 b. Describe the direct and indirect ownership profile of the applicant;
22 ➤ *Direct* ownership refers to the natural person(s) or legal person(s)
23 [organizations] seeking and holding the permit.
24 ➤ *Indirect* ownership refers to the natural person(s) or legal person(s)
25 holding ownership interests in the direct owner ~~or other indirect~~
26 ~~owners. There may be more than one level of indirect owners; if so,~~
27 ~~all levels of indirect owners must be declared in the application.~~
28 i. by collecting specific information for every *natural* person with any
29 direct or indirect ownership interest in the pharmacy, specifically:
30 (a) Full legal name, date of birth, and Social Security number;
31 (b) Mailing address and telephone number;
32 (c) Percentage of ownership or fraction thereof;
33 (d) Evidence of any professional license or other credential
34 issued by any state government agency (either legible copy
35 or website verification thereof), and further, whether or not
36 the credential has ever been sanctioned or disciplined by
37 any state licensing agency or by any local, state, or federal
38 government agency, or by any local, state, or federal court.
39 In the event of any such sanction or discipline, or in the
40 event an application for such credential has ever been
41 denied or refused by any jurisdiction, a copy of the board,
42 agency, or court decision document shall be provided.
43 ~~This requirement shall not be applicable to a natural person~~
44 ~~holding no direct ownership, no first-level indirect ownership,~~
45 ~~and less than 5% ownership in any indirect level ownership~~
46 ~~beyond the first level.~~
47
48

50
51 Title: Application for New Nonresident Pharmacy Permit

Policy No. IV.B.7

52
53 Approved: 11-15-2017

Revised:

54
55
56 3.b (cont.)

- 57 ii. by collecting specific information for every *legal* person
- 58 (organization) with any direct or indirect ownership interest in the
- 59 pharmacy, specifically:
 - 60 (a) Full legal name and Federal Employment Identification
 - 61 Number, as evidenced by a copy of the Internal Revenue
 - 62 Service (IRS) letter assigning that number, or in the
 - 63 alternative, a signed W-9 form;
 - 64 (b) Mailing address and telephone number;
 - 65 (c) Percentage of ownership or fraction thereof; and
 - 66 (d) An accounting of 100% of the ownership thereof, ~~and further,~~
 - 67 ~~where there are multiple levels of ownership, an~~
 - 68 ~~organizational chart clearly identifying the corporate~~
 - 69 ~~relationships.~~
 - 70 ~~Where the legal person is a publicly traded firm or an~~
 - 71 ~~institutional investor, the accounting of its ownership shall~~
 - 72 ~~identify any natural person holding 5% or more ownership~~
 - 73 ~~interest in that organization.~~
- 74 c. Describe the pharmacy's location and credentials issued by other
- 75 agencies;
- 76 d. ~~Identify the pharmacy owner's registered agent for the service of process;~~
- 77 e. Identify the special professional services intended for Louisiana residents;
- 78 ~~and~~
- 79 f. ~~Identify the Owner's Managing Officer and Pharmacist-in-Charge, and~~
- 80 ~~further, assist in the determination of their his fitness for practice in these~~
- 81 ~~that capacities capacity; and~~
- 82 g. Confirm the owner's consent for the Pharmacist-in-Charge to submit the
- 83 application for the pharmacy permit on behalf of the owner.

- 84
- 85 4. The application form shall instruct the applicant to cause the following persons
- 86 identified in their application to submit to a criminal background check (CBC):
 - 87 a. ~~Owner's Managing Officer;~~
 - 88 b. Pharmacist-in-Charge; and
 - 89 c. Any natural person holding 20% or more ownership interest at the direct or
 - 90 ~~first-level~~ indirect level; provided, however, that this requirement may be
 - 91 waived in the event that person has already submitted to such CBC for the
 - 92 Board and that CBC report was received less than five years prior to the
 - 93 date of the application for the permit.

5. The application package should also contain additional guidance information for the applicant as well as a summary checklist designed to ensure the submission of all additional required documents.

6. All applications shall be referred to the Credentials Division staff for processing.
a. In the event the staff determines there are deficiencies in the application or supporting materials, the staff shall communicate with the applicant to assist them in compiling a complete application.

b. In the event the staff determines there is information (e.g., prior disciplinary or legal action) impacting qualifications or fitness for practice, staff shall refer the completed application to an administrative officer, for a determination as to whether a referral to a Board committee is warranted.

i. In the event the administrative officer determines no committee referral is warranted, the administrative officer shall annotate the application form and return it to licensing staff for final administrative review and issuance of the permit.

ii. In the event the administrative officer determines a referral to a Board committee is warranted, he shall assign a case number to the application, schedule a hearing before the appropriate committee, and notify the applicant of the hearing, ensuring compliance with due process requirements.

c. In the event staff determines the applicant does not meet all of the licensing criteria and the applicant wishes to appeal that staff determination, staff shall direct the applicant to submit a written appeal to the Executive Director. The Executive Director shall present the appeal and relevant information from the applicant's file to the Board President. The Board President shall have the authority to review such appeals and determine whether to grant such requests, either in part or in full. The Executive Director shall notify the applicant and the licensing staff of the President's decision.

7. When the licensing staff has completed the processing of the application, the staff may issue the permit if they have been delegated the authority to issue it, or in the alternative, shall refer the application to the licensing manager, for final review and issuance of the permit.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	1995-1999									
<u>National Data</u>	<u>Data</u>	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
Louisiana Data										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
<hr/>										
	2000-2002									
<u>National Data</u>	<u>Data</u>	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
Louisiana Data										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2005 Data	<u>3/11/2006</u>	<u>7/22/2006</u>	<u>9/9/2006</u>	<u>11/18/2006</u>	2000-2006 Data	<u>2/5/2007</u> <u>3/9/2007</u>	<u>4/24/2007</u> <u>5/25/2007</u>	<u>8/27/2007</u> <u>9/28/2007</u>	<u>11/26/2007</u> <u>12/31/2007</u>
<u>National Data</u>										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
Louisiana Data										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
<hr/>										
	2000-2007 Data	<u>2/4/2008</u> <u>3/14/2008</u>	<u>4/28/2008</u> <u>6/20/2008</u>	<u>8/18/2008</u> <u>10/10/2008</u>	<u>11/10/2008</u> <u>12/19/2008</u>	2000-2008 Data	<u>1/1/2009</u> <u>3/31/2009</u>	<u>4/1/2009</u> <u>6/30/2009</u>	<u>7/1/2009</u> <u>9/30/2009</u>	<u>10/1/2009</u> <u>12/31/2009</u>
<u>National Data</u>										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
Louisiana Data										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2009 Data	1/1/2010 3/31/2010	4/1/2010 6/30/2010	7/1/2010 9/30/2010	10/1/2010 12/31/2010	2000-2010 Data	1/1/2011 3/31/2011	4/1/2011 6/30/2011	7/1/2011 9/30/2011	10/1/2011 12/31/2011
National Data										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
Louisiana Data										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
<hr/>										
	2000-2011 Data	1/1/2012 3/31/2012	4/1/2012 6/30/2012	7/1/2012 9/30/2012	10/1/2012 12/31/2012	2000-2012 Data	Changed to semi-annual reports			
National Data							1/1/2013 to 6/30/2013		7/1/2013 to 12/31/2013	
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448		28,797	
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581		21,745	
Pass Rate	75%	78%	77%	76%	76%	75%	77%		76%	
Louisiana Data										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622		537	
No. of Candidates Passing	8,298	158	269	226	168	9,119	412		351	
Pass Rate	68%	64%	73%	69%	70%	68%	66%		65%	

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2013 Data	1/1/2014 to 6/30/2014	7/1/2014 to 12/31/2014	2000-2014 Data	1/1/2015 to 06/30/2015	7/1/2015 to 12/31/2015
National Data						
No. of Candidates Attempting	628,957	26,423	27,085	682,465	22,197	36,167
No. of Candidates Passing	470,680	15,233	15,125	501,038	13,280	21,643
Pass Rate	74.8%	57.7%	55.8%	73.4%	59.8%	59.8%
Louisiana Data						
No. of Candidates Attempting	11,002	630	568	12,200	480	632
No. of Candidates Passing	7,451	287	265	8,003	255	304
Pass Rate	67.7%	45.6%	46.7%	65.6%	53.1%	48.1%
<hr/>						
	2000-2015 Data	1/1/2016 to 12/31/2016		2000-2016 Data	1/1/2017 to 6/30/2017	7/1/2017 to 12/31/2017
National Data						
No. of Candidates Attempting	740,829	53,277		794,106		23,494
No. of Candidates Passing	535,961	30,835		566,796		13,377
Pass Rate	72.3%	57.8%		71.4%		57.0%
Louisiana Data						
No. of Candidates Attempting	13,314	1,329		14,643	595	414
No. of Candidates Passing	8,562	592		9,154	271	186
Pass Rate	64.3%	44.5%		62.5%	45.5%	44.9%